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EXECUTIVE SUMMARY 
Background: Polycystic ovary syndrome (PCOS) is associated with increased 
metabolic risk and hypertension, which may relate to enhanced sympathetic nervous 
system (SNS) activation. The cerebral pathways involved in this process are not 
known.  
Aims: (1) To compare blood pressure and SNS activation in response to isometric 
forearm contraction (IFC) between PCOS and control groups. (2) To identify and 
compare the neuronal signatures of this response. (3) To investigate metabolic and 
anthropometric correlates of SNS activation.    
Methods: 20 PCOS (age 29.8 yrs, BMI 26.1 kg/ m²) and 20 matched controls (age 
29.7 yrs, BMI 26.1 kg/ m²; p=NS) were studied. Out-of-scanner tests: measurement of 
mean blood pressure (MAP) and heart rate (HR) responses to 30% IFC for 180 
seconds; baseline and post-task catecholamines, and microneurography (MSNA) in a 
subgroup of 8 PCOS and 8 controls.  In-scanner: Blood oxygen level dependent 
(BOLD) fMRI using an identical block paradigm design for IFC, BOLD signal 
correlating to MAP responses (threshold Z>2.3, corrected cluster threshold p=0.05).  
 
Results: IFC elicited an increase in HR and MAP in PCOS and controls but these did 
not differ between groups (p=0.16[HR] and p=0.06[MAP]). Adrenaline increased 
significantly post-IFC in PCOS (0.68 to 1.23ng/mL p<0.001) but not in controls (0.77 
to 0.99ng/mL p=0.14). MSNA burst frequency increased by 68% in the PCOS group 
compared to 11.9% in controls (p=0.002). Brain activation indexed by the BOLD signal 
in response to IFC was significantly greater in the PCOS group compared to the control 
group in the right orbitofrontal cortex (p<0.0001), left angular gyrus and lateral occipital 
cortex (p=0.04). When the BOLD signal was separately corrected for insulin sensitivity, 
BOLD signal in the right orbitofrontal cortex was no longer significant. 
 
Conclusions: PCOS is associated with enhanced SNS activation and increased 
regional brain activation in response to IFC. The right orbitofrontal cortex BOLD signal 
change in the PCOS group is associated with insulin sensitivity. 
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1.1 PCOS INTRODUCTION 
 
1.1.1  Overview 
 
Polycystic ovary syndrome (PCOS) is characterised by oligo/anovulation, 
hyperandrogenism and altered ovarian morphology, encompassing a broad range of 
phenotypes depending on the definition of the syndrome. PCOS is associated with 
increased metabolic risk and hypertension as well as its reproductive consequences 
[Erhmann 1995, Dunaif 1997] and there is the suggestion that it is the hyperandrogenic 
phenotype which presents with a worse cardiometabolic profile [Daan 2014]. There is 
evidence that activity of sympathetic nervous system (SNS) is enhanced in metabolic 
disease, including obesity, insulin resistance, non-alcoholic fatty liver disease 
(NAFLD) and obstructive sleep apnoea (OSA) [Alvarez 2002, Thorp 2015, Sabath 
2015, Drager 2015]. Since these conditions are prevalent in PCOS, it has been both 
hypothesised and demonstrated that sympathetic overactivity is present in PCOS and 
may be related to its pathogenesis and natural history [Sverisdottir 2008, Lambert 
2015]. In addition higher centres have been implicated relating to increased 
sympathetic outflow but these have never been studied in patients with PCOS [Kramer 
2014, Critchley 2000(a)].  This study therefore aimed to compared blood pressure and 
SNS activation responses between PCOS and control groups, to identify any higher 
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centres involved in these responses and to investigate metabolic and anthropometric 
correlates of the SNS activation.    
 
1.1.2   Historical aspects 
 
Hipppocrates (460 BC- 377 BC) noted that: “But those women whose menstruation is 
less than three days or is meagre, are robust, with a healthy complexion and a 
masculine appearance; yet they are not concerned about bearing children nor do they 
become pregnant.” [Hansen AE 1975]. Likewise Soranus of Ephesus (c. 98-138 AD) 
made note that: “[s]ometimes it is also natural not to menstruate at all…It is natural too 
in persons whose bodies are of a masculine type…we observe that the majority of 
those not menstruating are rather robust, like mannish and sterile women” [Temkin 
1991]. PCOS does not seem to be a newly recognised entity. 
 
In more recent centuries, the renaissance surgeon and obstetrician, Ambroise Pare 
(1510-1590 AD) observed: “Many women, when their flowers or tearmes be stopped, 
degenerate after a manner into a certaine manly nature, whence they are called 
Viragines, that is to say stout, or manly women; therefore their voice is loude and 
bigge, like unto a mans, and they become bearded.” [Paré A, 1634]. 
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At the beginning of the 20th century, Bullock and Sequeira described the association 
between masculinisation and endocrine pathology linking the adrenals and gonads 
[Bullock 1905]. This had followed reports over the centuries that virilisation was 
associated with specific organs.  
 
It was only in 1935, however, that the syndrome of ovarian dysmorphology, 
hyperandrogenism and menstrual irregularity was first fully described by American 
gynaecologists Irving F Stein, Sr and Michael L Leventhal. In their landmark paper, 
they noted of the clinical characteristics of seven women: ‘The breasts were usually 
normal. In some patients, there was a distinct tendency toward masculinizing changes. 
A typical rhomboid hairy escutcheon, hair on the face, arms and legs and coarse skin 
was noted. No voice changes were observed. The external genitalia were normal, but 
in some, the labia minora was markedly hypertrophied. Libido is apparently not 
affected by the changes noted in the ovaries.’ Surgical exploration of these women 
often revealed ovaries that were enlarged to two to four times their original size and 
full of tiny fluid filled cysts. Some of the ovaries were flat and they called them “oyster 
ovaries” due to their shape and greyish colour. A description of ovaries with sago-like 
grains or a polycystic appearance was put forth in the earliest descriptions. [Stein and 
Leventhal 1935]. A number of years after this first description, the eponymous 
syndrome was named Stein-Leventhal Syndrome. 
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1.1.3   Definitions 
 
In more recent years, the term polycystic ovary syndrome has replaced this and 
several diagnostic criteria have been reported to aid in its diagnosis. Both the National 
Institute of Health (NIH) 1990 consensus and Androgen Excess and Polycystic Ovary 
Syndrome Society (AEPCOS) 2009 task force report identify the importance of 
androgen excess, with the need for both hyperandrogenism and ovarian dysfunction 
/oligo-anovulation to make a diagnosis of PCOS [Zawadzki 1992, Azziz R 2009]. The 
Rotterdam criteria, however, encompasses a wider PCOS phenotype, with only two 
out of three of hyperandrogenism, oligo-anovulation and polycystic ovaries on 
ultrasound scan required to define the syndrome [Rotterdam Group 2004]. Although 
these three different criteria have been established, the Task Force for the Endocrine 
Society in 2013 recommended using the Rotterdam criteria for the diagnosis of PCOS 
in their guidance [Legro RS 2013]. 
 
1.1.4   Clinical manifestations 
 
Clinical manifestations of PCOS are therefore diverse, with a broad spectrum of 
clinical presentations possible. Using the current Rotterdam criteria, four different 
phenotypes are possible (Figure 1.1): (1) hyperandrogenism (clinical or biochemical) 
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and chronic anolvulation; (2) hyperandrogenism and polycystic ovaries on ultrasound 
but with ovulatory cycles; (3) chronic anovulation and polycystic ovaries without 
hyperandrogenism; (4) hyperandrogenism, chronic anovulation and polycystic 
ovaries. The prevalence of PCOS is therefore variable depending on the criteria 
applied, ranging from 6-25% in the pre-menopausal population [Livadas 2013, 
Conway G 2014].  
 
 
Figure 1.1 
The different phenotypes in PCOS  
 
 
 
7 
 
1.1.5  Cardiometabolic risk by PCOS definition 
 
How PCOS is defined is important since it is becoming more apparent that the different 
definitions in use have differences with respect to cardiometabolic risk. There is 
increasing evidence that insulin resistance and features of the metabolic syndrome 
are more prevalent in the classic, hyperandrogenic PCOS phenotype, as defined by 
the NIH criteria [Moran 2015, Fauser BC 2012, Ehrmann D 2005]. In contrast, the 
prevalence of metabolic syndrome in the milder phenotype (oligo-anovulatory patients 
with polycystic ovaries on ultrasound scan but without hyperandrogenism) are closer 
to control subjects than to the other phenotypes [Gambineri 2009]. The PCOS 
phenotype could therefore be a predictor of cardiovascular and metabolic risk but 
longterm studies are needed to show this.  
 
1.2  LONG-TERM SEQUELAE 
 
1.2.1  Infertility and cancer risk 
 
Infertility affects 40% of women with PCOS, which is the commonest cause of 
anovulatory infertility [Teede 2010]. Approximately 90%–95% of anovulatory women 
presenting to infertility clinics have PCOS, accounting for a major cause of infertility 
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that requires treatment for ovulation induction or assisted reproductive techniques 
[Balen 2002]. In addition, spontaneous abortion occurs more frequently in PCOS with 
incidences ranging from 42%–73% [Gluek 2001, Jakubowicz DJ 2002]. Even following 
successful conception, pregnancy in PCOS carries complications, with a 3-4 fold 
increased risk of pregnancy-induced hypertension and pre-eclampsia, a 3-fold 
increased risk of gestational diabetes and a 2-fold higher chance of premature 
delivery. It is thought that features of hyperandrogenism, insulin resistance and obesity 
may contribute to these adverse outcomes [Palomba 2015]. More recently a 
retrospective observational study by Rees et al of over 9000 women with PCOS 
confirmed reduced fertility rates, increased miscarriage, pre-eclampsia, gestational 
diabetes and premature delivery in PCOS compared with controls. Of PCOS births, 
significantly more (27.7%) were by Caesarean section compared with 23.7% of 
controls. Infants born to mothers with PCOS also had an increased risk of neonatal 
jaundice and respiratory complications [Rees DA 2016]. 
 
A recent systematic review and meta-analysis of observational studies assessed the 
risk of gynaecological cancers in women with PCOS compared to controls. There was 
an increased risk of endometrial cancer, but the risk of breast and ovarian cancer was 
not increased in women of all ages. It did, however, find that when women with PCOS 
below age 54 alone were considered, the risk of endometrial cancer increased further, 
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and the risk became significantly increased for ovarian cancer [Barry 2014]. 
Conversely, Morgan et al found no increase in gynaecological cancer in those with 
PCOS versus matched controls in their retrospective observational study [Morgan CL 
2012]. 
 
1.2.2  Cardiometabolic consequences 
 
PCOS is strongly associated with obesity and metabolic consequences. Studies 
performed to date make it difficult to establish the direction of association between 
PCOS and obesity, [Pasquali 2006], but it appears that abdominal visceral adiposity 
worsens the metabolic and reproductive features of PCOS [Lim 2013]. Conversely, it 
is also possible that androgen excess favours abdominal adiposity from early ages, 
facilitating insulin resistance [Welt 2013]. Certainly there is evidence of impaired 
insulin secretion and insulin action [Ehrmann 1995, Dunaiff 1997] leading to an 
increased risk of metabolic syndrome, glucose dysregulation and T2DM.  Longitudinal 
studies demonstrate that there is a risk intrinsic to PCOS in developing T2DM, that 
this risk increases steadily with BMI and is particularly high for BMI over 30kg/m² 
[Moran 2010, Morgan 2012, Pasquali 2013]. 
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Obstructive sleep apnoea (OSA) is an established risk factor for cardiovascular 
disease and is associated with a greater risk of insulin resistance and T2DM. 
Compared with age- and weight-matched controls, women with PCOS have an 
increased risk of OSA, which occurs in 44-70% of obese patients with the syndrome 
[Fogel 2001, Vgontzas 2001, Gopal 2002]. OSA correlates significantly with insulin 
resistance and glucose intolerance in patients with PCOS [Tasali 2008]. 
 
In addition, women with PCOS have an increased prevalence of subclinical markers 
of premature cardiovascular disease.Many studies have suggested that measures of 
cardiovascular risk are increased in young or middle-aged women with PCOS, 
including endothelial dysfunction [Paradisi et al., 2001], carotid intima-media thickness 
[Talbott et al., 2000], arterial stiffness [Meyer et al., 2005] and myocardial dysfunction 
[Orio et al., 2004], but it is difficult to establish how much of this risk is due to PCOS 
per se and how much to obesity. Rees et al, in a cross-sectional study, comprising 84 
young women with PCOS and 95 volunteers, showed central arterial stiffness and 
diastolic dysfunction were associated with both insulin resistance and abdominal 
obesity, but PCOS itself did not confer increased risk [Rees E 2014]. The long-term 
effects of such subclinical changes in PCOS on cardiovascular morbidity and mortality 
remain uncertain, although evidence to date has failed to demonstrate an increased 
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incidence of cardiovascular events in pre- or post-menopausal women with PCOS 
[Wild 2000, Schmidt 2011, Morgan 2012]. 
 
Furthermore, PCOS has been associated with dyslipidaemia, with elevated LDL 
cholesterol and triglycerides, and significantly lower HDL cholesterol compared with 
healthy volunteers [Kim 2013]. The correlation between PCOS and hypertension 
remains unclear, with conflicting results from studies [Zimmermann 1992, Holte 1996, 
Meyer 2005], although a recent large longitudinal Australian study of over 8000 women 
found that in those with PCOS, the prevalence of hypertension was higher, and that 
this was independent of BMI [Joham AE 2015]. Table 1.1 outlines a number of key 
studies investigating blood pressure and hypertension in PCOS. It is clear that a 
potentially important confounder in the interpretation of these studies is obesity, which 
is itself a significant risk factor for hypertension. This variable was not consistently 
controlled for across the studies. However, in those studies which did adjust the 
analyses for BMI,  the association between hypertension and PCOS is still not always 
clear. It is also apparent that other factors, including ethnicity and the use of 
medications such as the oral contraceptive pill, are further confounders which may 
affect blood pressure regulation and the development of hypertension [Lo 2006, 
Joham 2015, Chang 2016]. Interestingly, Chen et al studied the effect of 
hyperandrogenism on blood pressure and noted that total testosterone was  
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independently related to systolic and diastolic blood pressure, and hyperandrogenism 
in women with PCOS associated with hypertension (p=0.029) [Chen 2007]. This 
strengthens the emerging concept that it is the hyperandrogenic phenotype of PCOS 
that is more associated with metabolic dysfunction, and also raises the question of 
what role androgens may play in blood pressure regulation in PCOS. 
 
In addition, PCOS has been associated with the increased risk of developing non-
alcoholic fatty liver disease (NAFLD) [Kelley 2014]. A rmeta-analysis showed NAFLD 
was diagnosed three to four times more often in PCOS compared to controls, which 
can progress from simple steatosis to alcoholic steatohepatitis, liver fibrosis, cirrhosis 
and eventually hepatocellular carcinoma [Ramezani-Binabaj M 2014]. Several cross-
sectional and case-control studies have demonstrated that the prevalence of NAFLD 
is increased in young women with PCOS and that this is independent of obesity and 
other coexisting metabolic syndrome features [Targher G 2016]. Interestingly, it has 
been shown that those women with the hyperandrogenic PCOS phenotype have 
significantly higher liver fat than those with normal androgen phenotype, independent 
of insulin resistance and obesity, sitting with the known evidence that the 
hyperandrogenic form of PCOS is associated with increased cardiometabolic 
problems [Jones H 2010]. Furthermore PCOS women are more likely to have the more 
severe forms of NAFLD, including advanced fibrosis, and cirrhosis. It is also 
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Table 1.1 Key studies investigating blood pressure and hypertension in PCOS 
Author Year Number studied Blood pressure measures Main findings 
Zimmermann S et al 1992 14 PCOS, 18 controls 24-hr ambulatory systolic & diastolic BP 
Left ventricular mass by 
echocardiography 
No difference in systolic, diastolic BP or in 
left ventricular mass between groups 
Conway GS et al 1992 102 PCOS, 19 controls Automatic recumbent blood pressure Obese women with PCOS had higher 
systolic blood pressure than lean women 
with PCOS and controls 
Holte J et al 1996 17 PCOS, 16 controls 24-hr ambulatory systolic & diastolic BP PCOS group had higher daytime systolic 
BP and mean arterial BP compared to 
controls 
No difference between groups in daytime 
diastolic BP or night-time recordings 
Wild S et al 2000 319 PCOS, 1060 controls Data collected from medical records 
124 women attended a clinical 
examination 
Higher levels of hypertension in PCOS 
group (p=0.04) 
Adjustment for BMI, OR 3.2 (1.7-6.0) 
Elting MW et al 2001 346 PCOS Telephone questionnaire asking for 
presence of hypertension 
Hypertension present in 9% 
Hypertension also occurred significantly 
more in the younger (35–44 years) PCOS 
group compared with Dutch female 
population but the group was significantly 
more obese 
Vrbíková J et al 2003 50 PCOS, 335 controls Mean of two resting blood pressure 
recordings 
(Hypertension defined as on 
antihypertensive treatment or BP ≥ 
140/90mmHg) 
PCOS women had higher blood pressure 
than controls 
Arterial hypertension was more prevalent 
in PCOS compared to controls 
Meyer C et al 2005 100 PCOS, 20 controls 24-hr ambulatory BP monitoring No difference in total systolic & diastolic 
BP between groups 
Lo JC et al 2006 11,035 PCOS, 55,175 controls Resting blood pressure measured on 2 
outpatient visits 
(Hypertension defined as systolic BP 
≥140mmHg and/or diastolic BP 
≥90mmHg) 
PCOS associated with hypertension (OR 
1.41, 1.31-1.51) 
In PCOS, blacks were more likely and 
Hispanics less likely to have hypertension 
Chen MJ et al 2007 151 PCOS Mean of 2 readings after resting for >30 
minutes 
Free androgen index (FAI) and total 
testosterone independently related to 
systolic and diastolic blood pressure 
Higher FAI in women with PCOS 
increased the risk of elevated blood 
pressure (SBP ≥130 mm Hg and/or DBP 
≥85 mm Hg) (p=0.029) 
Joham AE et al 2015 8612 subjects (5.8% PCOS) Women asked if they had been treated for 
hypertension (outside pregnancy) in the 
last 3 years 
Hypertension reported by 5.5% with 
PCOS compared to 2.0% in controls 
(p<0.001) 
Higher prevalence of hypertension in 
PCOS in those taking the oral 
contraceptive pill (OCP) 
Chang AY et al 2016 117 PCOS, 204 controls Resting BP measured and asked if on 
antihypertensive medication 
(Hypertension defined average systolic 
BP ≥140mmHg, diastolic BP ≥90mmHg) 
PCOS increased the risk of hypertension 
across racial /ethnic groups. Black women 
with PCOS had significantly higher 
systolic blood pressure than white women 
with PCOS 
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hypothesised that NAFLD can also exacerbate hepatic and systemic insulin resistance 
and may therefore play a role in the pathophysiology of PCOS [Targher G 2016].  
 
1.2.3  Pro-inflammatory state and cardiometabolic risk 
 
There is increasing evidence that the long-term cardiometabolic consequences in 
PCOS are linked to a low-grade chronic inflammatory state. As inflammation underpins 
insulin resistance in obesity and type 2 diabetes, it is thought to also be the cause of 
insulin resistance when present in PCOS, which in turn may be related to excess 
abdominal adiposity. Independent of excess adiposity and insulin resistance, 
hyperandrogenism activates circulating mononuclear cells in the fasting state to 
increase their sensitivity to nutrients, and is a potential mechanism for initiating 
inflammation in PCOS. This may in turn promote atherogenesis [González F 2015]. It 
is thought that the triad of hyperinsulinemia, hyperandrogenism, and low-grade 
inflammation may therefore act together in the pathophysiology of PCOS. 
Dysregulation of the sympathetic nervous system may also act as an important 
component, in addition to these, all contributing to the pathophysiology of PCOS 
[Shorakae S 2015].  
 
 
15 
 
1.3  HYPERTENSION 
 
1.3.1   Pathogenesis 
 
Hypertension is viewed as a multifactorial disease which arises due to an interaction 
between several genetic and environmental factors, including psychological stressors, 
obesity and increased sodium intake [Korner 1982]. Individually each factor is likely to 
account for a small proportion of variation in blood pressure but together they have an 
additive effect [Carretero 2000]. Blood pressure has been shown to increase with 
ageing, which may in part be due to a loss of homeostatic control of blood pressure 
regulation [Miall and Chinn 1973, Korner 2007].  
 
The sympathetic nervous system had initially been considered to be involved in the 
pathogenesis of essential hypertension but the observation that sympathetic afferent 
denervation in dogs did not alter long-term control of mean arterial pressure 
subsequently led to the conclusion that neuronal influences were not important in 
longer-term blood pressure control [Cowley et al 1973]. However, it subsequently 
became recognised that the efferent arm of the SNS can function independently of the 
baroreceptor reflex and therefore its role may be more significant than first thought 
[Thresher 2007]. 
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1.3.2   Sympathetic Nervous System (SNS) 
 
The autonomic nervous system comprises of the sympathetic and parasympathetic 
nervous systems. The sympathetic nervous system has a role in regulating the ‘fight 
or flight’ response under conditions of stress, and also regulates various tissue 
functions including chronotropic and inotropic control of the heart, vascular tone, 
pupillary diameter and urinary output (Figure 1.2). It is the neurotransmitter 
noradrenaline into the synaptic cleft and subsequent activation of alpha and beta 
adrenergic receptors that mediates these actions. In the normal physiological state, a 
fine balance exists between parasympathetic and sympathetic activity to maintain 
homeostasis. 
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Figure 1.2 
 
The autonomic nervous system and its target organs 
[Adapted from Lansdown A et al 2012] 
 
1.3.3  Sympathetic Nervous System in Hypertension 
 
In hypertensives, both systemic and regional noradrenaline turnover is increased 
[Goldstein 1983, Esler et al 1989], as well as increased cardiac, renal and muscular 
sympathetic drive [Julius and Majahalme 2000]. Thus primary hypertension has now 
become viewed as a hyperadrenergic state [Grassi and Mancia 2004]. It seems that 
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increased sympathetic activity may play a causative role in the natural history of the 
disease, with increased plasma noradrenaline levels preceding the onset of 
hypertension in adults [Julius 1991]. Furthermore, sympathetic activity is related to the 
severity of hypertension [Grassi 2007], the risk of cardiovascular disease [Minami 
1999] and is a predictor of future systolic blood pressure [Flaa 2008a]. 
 
The sympathetic nervous system influences short- and, probably long-term control of 
blood pressure. Blood pressure varies over a 24-hour period, with around 25% of this 
variation attributed to the baroreceptor arch, suggesting that central SNS efferent 
activity is responsible for a significant proportion of blood pressure variability by 
affecting cardiac output and peripheral vascular resistance [Grassi et al 2010]. 
 
1.3.4   Central drivers of SNS activation in hypertension  
 
The brainstem appears to be involved in the regulation of blood pressure. In animal 
models, selective lesion and direct stimulation experiments have identified three 
medullary regions that form a cardiovascular regulatory centre [Colombari 2001]. In 
addition, electrical stimulation of the rostral ventrolateral medulla (RVLM) in humans 
produced tachycardia and a pressor response [Ozer et al 2005]. More recently, 
Coulson et al used blood oxygen level-dependent (BOLD) functional magnetic 
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resonance imaging (fMRI) in 12 healthy young adults to identify the neural response 
to blood pressure changes following isometric forearm contraction (IFC), a recognised 
stimulator of the sympathetic nervous system. Mean Arterial Pressure (MAP) 
increased from 85±6 mm Hg to 108 ±15 mm Hg (P=0.0001). The brainstem BOLD 
signal change associated with this rise was localised to the ventrolateral medulla, 
suggesting a possible role for this neural centre in MAP control [Coulson JM 2015]. 
 
Other studies have suggested a role of the brainstem and other areas of the cerebral 
cortex in blood pressure control in humans. In a positron emission tomography (PET) 
study, muscle sympathetic nerve activity (MSNA) during baroreflex unloading was 
associated with increased activation in the left orbitofrontal cortex and the rostral 
ventrolateral medulla, suggesting a role of these regions in the baroreflex-mediated 
control of sympathetic activity [Kramer 2014]. Critchley et al also used PET imaging to 
correlate the rise in MAP from mental stressor tasks and physical exercise to areas of 
localised increased cerebral blood flow. They found that these areas included the 
dominant anterior cingulate, postcentral gyrus, cerebellum, insular cortex and 
orbitofrontal cortex [Critchley et al 2000(a)]. Higher centres are therefore emerging as 
playing a key role in sympathetic drive and blood pressure control in humans. 
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In humans, there have been historical challenges in studying these higher centres in 
sympathetic activation and blood pressure changes, chiefly due to technical difficulties 
in accessing such brain regions, and also a lack of robust functional imaging tools 
available. However, with the emergence of various modalities during recent years, 
such as the aforementioned fMRI and PET, identification of such regions has vastly 
improved and developed. As these tools continue to improve, such as the availability 
of higher strength MRI scanners with enhanced signal and spatial resolution, so such 
regions can be more easily and accurately defined. 
 
1.4   MEASUREMENT OF SNS ACTIVITY 
 
Various methods exist in order to measure the regional sympathetic activity of target 
organs, including heart rate and blood pressure variability [Axelrod 1981], 
microneurography [Hagbarth 1968, Sundlof 1977] and estimation of noradrenaline 
spillover by isotope dilution [Esler 1984a, Esler 1984b, Esler 2003] (Figure 1.3). 
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Figure 1.3 
Methods for measuring SNS activity [Adapted from Lansdown A et al 2012] 
 
The beat-to-beat variation in heart rate (heart rate variability, HRV) is an indirect 
method of measuring autonomic tone, with contributions from both the sympathetic 
and parasympathetic nervous systems. The high frequency component (HF: 0.15 to 
0.4Hz) reflects vagal control and both the low frequency component (LF: 0.04 to 
0.15Hz) and the LF:HF ratio reflect sympathetic activity, which can both be measured 
with power spectrum analysis. While both measures are influenced by autonomic 
mechanisms, their specificity as markers of sympathetic activation alone is limited 
[Hirsch 2003, Grassi 2008].  
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A more direct measure of sympathetic nerve activity is microneurography, which was 
first described by Hagbarth and Vallbo in 1968 [Hagbarth 1968]. Fine electrodes are 
used to record ‘bursts’ of activity from multiple or single afferent and efferent nerve 
axons in the skin and muscle. The easily accessible common peroneal nerve is 
typically chosen for this method and measures the efferent postganglionic muscle 
sympathetic nerve activity (MSNA) [Vallbo 1979, Macefield 1994]. MSNA has been 
shown to correlate well with sensory, somatomotor and autonomic effector (e.g. blood 
pressure, heart rate) responses [Vallbo 1979]. Microneurography can provide 
instantaneous data on sympathetic neural output but it is invasive so can only be used 
to measure activity in superficial nerves. 
 
Measurement of regional plasma noradrenaline spillover can provide information on 
sympathetic activity in individual organs, such as the heart and kidneys. Following 
nerve depolarisation, any remaining noradrenaline in the synapse, the “spillover”, is 
washed out into the plasma and the plasma concentration is therefore directly related 
to the rate of sympathetic neuronal discharge [Brown 1957]. By infusing tritiated 
noradrenaline, outward flow of endogenous noradrenaline can be measured by 
isotope dilution [Esler 1984a, Esler 1984b]. Plasma noradrenaline concentrations can 
also be measured from subjects without the use of radiolabelled noradrenaline but this 
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offers limited sensitivity, is not reproducible and is unable to distinguish between 
increased central catecholamine production and decreased clearance [Grassi 1999].  
 
These methods should be used in combination to measure sympathetic tone as none 
is considered ‘gold-standard’. 
 
1.5  EXPERIMENTAL STIMULI TO ACTIVATE THE SNS 
 
The sympathetic nervous system (SNS) can be activated using different experimental 
stimuli, broadly divided into non-exercise and exercise SNS stimuli. Non-exercise 
stimuli include the cold pressor test, mental stress, apnoea and drugs, while exercise 
stimuli include isometric forearm contraction (IFC) and orthostatic exercise. 
 
The cold pressor test is one such non-exercise stimulus that can evoke a pressor 
response and increased generalised sympathetic tone. It involves immersing the 
subject’s hand in ice water for 2 minutes with the subject avoiding isometric 
contraction, the Valsalva manouevre or held expiration during that period. The painful 
cold stress results in sympathetic discharge of noradrenaline with arteriolar 
constriction, increased heart rate, and increased cardiac contractility. These 
responses combine to increase blood pressure - a pressor response. The cold pressor 
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test is a useful method of stimulating generalised sympathetic tone but not in 
assessing the SNS response to exercise and can be less practical in certain 
circumstances, such as its use in an MRI environment [Victor 1987]. Emotional or 
mental stress can also evoke a pressor response, and mental arithmetic or displaying 
of emotionally charged images have been used to cause sympathoexcitation 
[Macefield 2013, Fonkoue 2015]. Apnoea can also result in large increases in MSNA 
and the use of end-expiratory breath-holds, for example, have been used in 
experiments to generate increased sympathetic outflow [Kimmerly 2013]. Mental 
stress and breath-holding exercises both have the advantage of being easily used in 
any environment but reproducibility and duration of task can be variable. Αlpha-
adrenergic agonists (such as phenylephrine and clonidine) have been used in study 
settings to induce sympathoexciation, vasoconstriction and a pressor response 
[Limberg 2014(a)], although their use is more technically challenging and requires 
close supervision. 
 
An exercise-SNS stimulus that is well-validated is Isometric forearm contraction (IFC). 
IFC has been shown to generate a haemodynamic response, characterised by a rise 
in arterial blood pressure, heart rate and SNS activation. It represents a complex 
interaction between central command, parasympathetic and sympathetic influences, 
arterial and cardiopulmonary baroreflex control, and the exercise pressor reflex 
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[Kaufman MP 2002, McCloskey 1972]. It has been widely used in studies and is easily 
reproducible, although depending on the task strength and duration, may be 
uncomfortable for the subject. Orthostatic stress is another potent adrenergic stressor 
method where heart rate and blood pressure are regulated by the baroreceptor reflex 
in an effort to maintain systemic blood pressure. Both passive upright tilt and active 
standing have been used experimentally to induce sympathoexcitation [Cao 2014]. A 
significant disadvantage is that there are limitations of where it can be used. For 
example, such an approach would be impractical in the MRI environment when 
studying higher centres involved in sympathoexcitation.  
 
A number of stimuli can therefore be used, each with different strengths and 
weaknesses. 
 
1.6   SYMPATHETIC NERVOUS SYSTEM IN METABOLIC DISEASE 
 
1.6.1   Sympathetic activity in obesity 
 
Abdominal visceral obesity is most associated with increased sympathetic activity, with 
resting MSNA firing greater than 50% more compared to those with subcutaneous 
obesity [Alvarez 2002, Grassi 2004, Sivenius 2003]. It has been proposed that chronic 
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sympathetic activity in obesity is a physiological response to stimulate thermogenesis 
and stabilise body weight during periods of overeating [Landsberg 2001].  
 
In addition, leptin may play an important role in sympathetic activity and obesity. Leptin 
has been shown to be elevated in obesity and can act directly on skeletal muscle to 
impair glucose transporter-4 translocation, resulting in hyperinsulinemia and activation 
of the sympathetic nervous system [Maffei 1995]. Leptin can also act centrally in the 
hypothalamus and brainstem to increase sympathetic activity and may also act at the 
level of the nucleus tractus solitarius to affect neurons involved in baroreflex sensitivity 
[da Silva 2013, Ciriello J 2013]. In obesity, it has been suggested that leptin-expressing 
neurons in the ventromedial hypothalamic nucleus become resistant to the 
hyperleptinaemia found in obesity, reducing its appetite-reducing effects but enabling 
sympathetic activation [Myers 2008, Thorp 2015].  
 
1.6.2  Insulin and sympathetic activity 
 
The effect of insulin upon the sympathetic nervous system has been demonstrated in 
various ways. Animal studies have shown that intracerebroventricular injection of 
insulin increases sympathetic activation acting via the arcuate nucleus [Rahmouni 
2004, Cassaglilia 2011, Thorp 2015]. In humans, it has been shown that systemic 
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infusion of insulin results in increased MSNA outflow [Vollenwieder 1993, Young 2010] 
but this effect may be blunted in obesity and the metabolic syndrome [Vollenweider 
1994, Straznicky 2009]. It was Landsberg who hypothesised that central insulin 
resistance may therefore contribute to sympathetic activation by increasing insulin-
mediated glucose metabolism in hypothalamic neurons and causing suppression of 
the inhibitory pathway between the hypothalamus and sympathetic centres in the 
brainstem [Landsberg 1986]. 
 
Conversely, it has been suggested that increased sympathetic activity may cause 
insulin resistance [Thorp 2015, Moreira 2015]. Observations from a perfused human 
forearm model which showed that increased sympathetic excitation causes acute 
insulin resistance [Jamerson 1993] and it has been shown that noradrenaline 
responses to a cold pressor test independently predicted insulin resistance after 18 
years [Flaa 2008]. In patients with type 2 diabetes, MSNA has been shown to be 
significantly elevated at rest compared to those with prediabetes [Straznicky 2012].  
 
1.6.3  SNS and NAFLD 
 
The circadian pattern has been shown to be key in liver lipid accumulation, with the 
subsequent development of steatosis, and this has been shown to be regulated by the 
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autonomic nervous system and the feeding-fasting cycle. It has been suggested that 
an imbalance in sympathetic and parasympathetic tone between organs might 
therefore be a pathophysiological driver that leads to the development of NAFLD 
[Sabath E 2015]. 
 
1.6.4  SNS in arterial stiffness 
 
The sympathetic nervous system may also play a role in arterial stiffness and 
subclinical cardiovascular disease.  
 
In animal models, recombinant leptin was administered to mice every other day for 1 
week, and mesenteric arteriole myography revealed that the treatment caused 
significant impairment of endothelium-dependent vasorelaxation. Leptin treatment 
also augmented the blood pressure response to angiotensin II, effects which 
neutralised following sympathetic denervation to the mesenteric vasculature. These 
findings suggested that the effects of leptin are mediated by sympathetic nervous 
system activation and may contribute to vascular stiffness and hypertension in obesity 
[Wang J 2013]. 
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In human subjects, investigation has shown an independent relationship between 
carotid-femoral pulse wave velocity (PWV), a measure of arterial stiffness, and resting 
MSNA that is independent of age, BMI, waist circumference, waist-to-hip ratio, heart 
rate, pulse pressure or blood pressure [Swierblewska E 2010]. A further study has 
shown sex differences in the relationship between MSNA and aortic wave reflections, 
with a positive correlation between sympathetic activity and augmentation index in 
young men but a strongly inverse relationship in young women [Casey DP 2011]. This 
correlation is lost in older women, with postmenopausal women with higher MSNA 
having higher aortic pressures and indices of aortic wave reflection, which may relate 
to their increased risk of cardiovascular disease [Hart EC 2013]. In addition, short-term 
sympathetic activation (via a cold pressor test) decreases muscular artery compliance 
in normotensive young humans [Boutouyrie P 1994]. Whether sympathetic activity 
plays a major role in modulating the elastic properties of central arteries or the tone of 
peripheral muscular arteries remains unknown. 
 
Therefore the SNS appears to play a role in arterial stiffness, but it is not known yet 
whether this correlates with clinically significant disease. 
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1.6.5  SNS in obstructive sleep apnoea 
 
It has been suggested that the hypoxic stress associated with OSA can cause a range 
of pathological systemic events including sympathetic activation and systemic 
inflammation, which in turn may be contributors in the development of cardiovascular 
disease and metabolic dysfunction [Drager LF 2015]. Indeed, OSA has been shown 
to be associated with increased MSNA and this is independent of body weight [Grassi 
2005b]. Cardiac sympathetic drive is also increased in subjects with OSA, even when 
established cardiovascular disease is not present [Narkiewicz 1998]. Interestingly, a 
systematic review of randomised studies using continuous positive airways pressure 
(CPAP) intervention versus sham CPAP have consistently shown a reduction in 
sympathetic activation and this occurs rapidly in response to the therapy [Jullian-
Desayes I 2015, Hedner 1995]  
 
1.7  THE SYMPATHETIC NERVOUS SYSTEM IN PCOS 
 
As PCOS is associated with obesity, insulin resistance, NAFLD, arterial stiffness and 
obstructive sleep apnoea, it has been supposed that the syndrome itself may be 
associated with heightened sympathetic nerve activity. Both animal models and 
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human studies have examined this correlation, and to determine how it may be related 
to the pathogenesis and metabolic disturbances found in PCOS. 
 
1.7.1  Ovarian sympathetic tone 
 
Bernuci et al showed that rats exposed to single or repeated cold stress over 4 weeks 
resulted in increased expression of ovarian norepinephrine terminals, derranged 
follicular development and PCO morphology, suggesting a role of the sympathetic 
nervous system in its development [Bernuci 2013]. Similarly, a further study 
performing unilateral or bilateral vagotomy in PCO rats restored ovulation in both 
ovaries [Linares 2013]. A study in which nerve growth factor-producing cells were 
injected into the ovaries of rodents showed subsequent development of other features 
of PCOS, including increased visceral versus subcutaneous fat, glucose intolerance, 
hyperinsulinaemia, as well as increased sympathetic outflow [Wilson JL 2014].  
 
In women with PCOS, a higher density of ovarian catecholaminergic fibres were found 
compared with controls [Heider 2001] and a human further study showed ovarian 
nerve growth factor production was enhanced in women with PCOS [Dissen 2009].  
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These studies may imply a role of sympathetic activation in the pathogenesis and 
natural history of PCOS. 
 
1.7.2  Generalised sympathetic tone 
 
A number of studies have shown a generalised increase in sympathetic nerve activity 
in women with PCOS, as outlined in table 1.2. 
 
One early study compared plasma and urinary catecholamine levels in 14 PCOS 
adolescent patients with age and BMI-matched controls [Garcia-Rudaz 1998]. Serum 
free plasma adrenaline and noradrenaline levels at rest were similar in patients and 
controls. However, patients with PCOS had significantly higher urinary excretion of 
normetanephrine and lower levels of dihydroxyphenylglycol (DHPG), which led to the 
notion that there may be an alteration of noradrenaline reuptake into the presynaptic 
nerve or deamination to DHPG in PCOS. 
 
Furthermore, several studies have compared heart rate variability (HRV) and heart 
rate recovery (HRR) post-exercise in subjects with and without PCOS [Yildirir 2006, 
Tekin 2008, Giallauria 2008, Di Domenico 2012, Saranya K 2014].
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Table 1.2 Studies investigating SNS activity in PCOS
Study 
 
Subjects Measure of SNS activity Results 
Garcia-Rudaz C et al (1998) 14 PCOS, 9 controls (adolescents) Serum free adrenaline and noradrenaline and 
urinary catecholamines at rest 
Plasma free adrenaline and noradrenaline 
similar in both groups 
PCOS patients had a higher urinary excretion 
of normetanephrine than controls 
Yildirir A et al (2006) 30 PCOS, 30 controls Heart Rate Variability (HRV) analysis at rest Low-frequency /High-frequency ratio 
significantly higher in PCOS, indicating 
increased SNS activity 
Tekin G et al (2008) 
 
 
26 PCOS, 24 controls (age, BMI and physical 
activity matched) 
Heart rate Recovery (HRR) post-exercise 
tolerance test, and systolic blood pressure 
(SBP) changes 
PCOS HRR significantly lower at 1 minute 
compared to controls 
Exaggerated SBP response to exercise 
Giallauria F et al (2008) 75 PCOS, 75 controls (age and BMI matched) HRR post-exercise test PCOS showed a significantly reduced HRR 
compared to controls 
 
Sverrisdóttir YB et al (2008) 
 
 
 
20 PCOS, 18 controls (age and BMI matched) 
 
MSNA at rest 
MSNA increased in PCOS women compared 
with controls 
MSNA in PCOS positively correlated to 
testosterone and cholesterol 
 
Stener-Victorin E et al (2009) 
 
20 PCOS 
MSNA at rest pre- and post- 16 weeks low-
frequency electroacupuncture (EA) or 
exercise or no intervention 
Low-frequency EA and physical exercise 
significantly decreased MSNA burst frequency 
compared with untreated group 
 
 
Tasali E et al (2011) 
 
 
19 PCOS 
 
 
24-h plasma noradenaline levels pre- and 
post 8 weeks of CPAP 
Only 9 women were compliant with CPAP and 
completed the study 
25% reduction in mean 24-hr plasma 
noradrenaline levels 
Magnitude of decrease strongly associated 
with hours of CPAP use 
 
 
Schlaich MP et al (2011) 
 
 
2 PCOS (obese, hypertensive) 
 
 
MSNA and noradrenaline spillover at baseline 
and 3 months post-renal denervation 
2.5- 3-fold increase in MSNA and 
norepinephrine spillover compared with 
normotensive controls (previously reported) 
Decrease in MSNA and norepinephrine 
spillover post-procedure 
Jedel E et al (2011) 72 PCOS MSNA at rest in Montgomery Åsberg 
Depression Rating Scale (MADR-S) score 
<11 versus ≥11 
42 patients recorded. MSNA not statistically 
significantly different between two groups 
Di Domenico K (2012) 30 classic anovulatory PCOS, 16 ovulatory 
PCOS, 23 controls (age matched) 
HRV at rest and after a mental stress test During mental stress, classic PCOS showed 
lower HRV response compared with control 
group. PCOS testosterone levels inversely 
associated with low frequency component, 
low frequency/high frequency ratio 
Saranya K (2014) 31 PCOS, 30 controls (age-matched) HRV at rest and HRV, heart rate and blood 
pressure response to standing, deep 
breathing and isometric hand grip 
Low-frequency/High frequency HRV was 
increased in PCOS. Heart rate and blood 
pressure changes were greater in response to 
standing and handgrip in PCOS, less in 
response to deep breathing in PCOS  
Lambert EA (2015) 19 PCOS, 21 control (age and BMI matched) MSNA and HRV at rest Women with PCOS had elevated multiunit 
MSNA compared with controls. 
HRV did not differ between groups 
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One initial study compared resting HRV in 30 PCOS patients and 30 healthy controls, 
showing that PCOS patients had higher low frequency (LF) component, lower high 
frequency (HF) component and higher LF:HF ratio compared with controls [Yidirir 
2006]. This suggested an increased sympathetic and decreased parasympathetic 
component of HRV in the PCOS group. Di Domenico et al assessed HRV in response 
to mental stress in different phenotypes of PCOS, showing that women with PCOS 
appear to have impaired autonomic modulation in response to sympathetic 
stimulation. Patients with classic anovulatory PCOS showed lower HRV response 
when compared to the control group, and this remained even after adjustment for age 
and BMI. When patients with classic and ovulatory PCOS were considered together, 
total testosterone levels were inversely associated with the LF component, LF:HF 
ratio, and the difference between HF response at rest and after the stress test, 
suggesting that androgens may account for the blunted autonomic response in this 
group [Di Domenico 2012]. Saranya K et al compared HRV at rest and HRV, heart 
rate and blood pressure responses to standing, deep breathing and isometric handgrip 
in 31 women with PCOS and 30 age-matched controls. They found that LF:HF ratio 
was increased in PCOS, that heart rate and blood pressure changes were greater in 
response to standing and handgrip in PCOS, and less in response to deep breathing, 
concluding that PCOS patients have altered autonomic modulation in the form of 
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increased sympathetic and decreased parasympathetic reactivity and HRV [Saranya 
2014].  
 
Two other groups studied HRR post-exercise in patients with PCOS and controls 
[Tekin 2008, Giallauria 2008]. One study compared 26 women with PCOS and 24 
matched controls undergoing a modified Bruce protocol exercise tolerance test, with 
measurements of both HRR and recovery [Tekin 2008]. The PCOS group had an 
exaggerated systolic blood pressure response to exercise and a delayed recovery 
systolic blood pressure, implying sympathetic stimulation that persisted into recovery. 
The reduction in HRR suggested lower vagal parasympathetic activity in women with 
PCOS. Giallauria et al compared HRR after a cardiopulmonary exercise test in 75 
overweight women with PCOS with 75 age/BMI-matched healthy volunteers 
[Giallauria 2008]. Similarly the PCOS group showed a reduction in HRR compared to 
healthy controls, and in addition this correlated inversely with BMI and insulin 
sensitivity but not with testosterone.  
 
Only two studies have assessed sympathetic nerve activity in PCOS in comparison to 
matched controls by the use of MSNA. The first of these examined a group of 20 
women with PCOS matched by age and BMI to 18 healthy controls with a normal BMI. 
It was found that both resting burst frequency and burst incidence (both markers of 
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sympathetic activity) were increased in the PCOS group as compared with controls 
Figure 1.4 shows the resting burst frequency for both groups. MSNA correlated 
positively with total and free testosterone, and but less with cholesterol levels in the 
PCOS group. No correlation was found between MSNA and insulin resistance or 
central obesity. Given the relationship between MSNA and testosterone, it was 
suggested that the relationship between MSNA and testosterone may indicate that the 
degree of sympathoexcitation relates to the severity of the syndrome (or the degree of 
hyperandrogenism). [Sverrisdottir 2008]. This, is turn, may lead to a hypothesis that 
the classic hyperandrogenic PCOS phenotype, which is more associated with 
metabolic dysfunction, as defined by the NIH criteria [Moran 2015, Fauser BC 2012, 
Ehrmann D 2005] could have the sympathetic nervous system as a key driver of these 
consequences. It may strengthen evidence that it is PCOS, rather than visceral 
adiposity and obesity, that itself may be associated with increased SNS activation. 
 
More recently, Lambert et al examined multiunit and single-unit muscle SNS activity 
by microneurography and HRV in 19 overweight/obese women with PCOS compared 
with 21 control overweight/obese women presenting a similar metabolic profile. 
Women with PCOS had elevated multiunit muscle SNS activity (41 ± 2 vs 33 ± 3 bursts 
per 100 heartbeats, P < 0.05). In contrast to Sverrisdóttir’s study, there was no 
37 
 
relationship between MSNA and testosterone, countering the hypothesis that 
hyperandrogenaemia is related to elevated sympathetic tone. There was a strong 
 
 
Figure 1.4 
 
Muscle sympathetic nerve activity (MSNA) expressed as burst frequency 
(burst/min) in women with polycystic ovary syndrome (PCOS) and in healthy 
matched controls (p=0.0003). [Sverisdottir 2008] 
 
relationship between MSNA and plasma glucose and insulin concentration as well as 
with HOMA-IR, which remained after controlling for the presence of PCOS. This 
suggested that while insulin resistance is linked to sympathetic tone in 
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overweight/obese women, in women with PCOS sympathetic activation may not be 
adequately explained by obesity or insulin resistance alone. [Lambert 2015]. This sits 
against the hypothesis, therefore, that the more hyperandrogenic PCOS phenotype 
(with greater metabolic dysfunction) may be related to increased sympathetic tone. 
 
1.8  INTERVENTIONS TO REDUCE SNS ACTIVITY IN PCOS  
 
Some evidence exists to suggest that interventions may reduce the SNS activity in 
PCOS, which in turn may have an effect on the cardiometabolic consequences. 
 
1.8.1  Lifestyle measures 
 
In obese subjects with the metabolic syndrome, Straznicky et al showed that MSNA 
and whole body noradrenaline spillover rate were reduced during active weight loss 
[Straznicky 2011]. The noradrenaline spillover was maintained during the 
maintenance phase of the study but MSNA increased, suggesting regional changes 
may occur in SNS activity in response to weight loss [Straznicky 2011]. Interestingly, 
the addition of moderate intensity aerobic exercise training to a weight loss programme 
in subjects with the metabolic syndrome did not result in additional beneficial 
reductions in sympathetic activity beyond weight loss alone [Straznicky 2010]. 
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In contrast, however, an interventional study followed on from the HRR in 
cardiopulmonary exercise testing work by Giallauria et al. 124 subjects with PCOS 
were assigned to a 3-month exercise programme versus no intervention. The group 
with intervention showed significant improvements in HRR post-exercise compared to 
no significant changes in the control group [Giallauria 2008b], suggesting a vital role 
of exercise training in reducing sympathetic tone in PCOS.  
 
1.8.2  Pharmacological 
 
Insulin sensitisers have been used to try and modulate sympathetic activity, given that 
insulin resistance may important in its overactivity. Metformin given intravenously to 
hypertensive rats led to reductions in heart rate, blood pressure and efferent renal 
sympathetic nerve activity and these were thought to be mediated by a direct action in 
the central nervous system [Petersen 1996]. However, metformin did not affect MSNA, 
renal and total body noradrenaline spillover, blood pressure or insulin sensitivity in a 
double blinded, randomised cross over study conducted in 6 obese insulin resistant 
hypertensive men [Gudbjornsdottir 1994]. As thiazolidinediones also improve insulin 
sensitivity, one study randomised 30 patients with type 2 diabetes to either 
pioglitazone or no pioglitazone 4 weeks after a myocardial infarction. In the 
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pioglitazone group MSNA decreased significantly and arterial baroceptor sensitivity 
increased significantly, with there being a significant relationship between change in 
MSAN and insulin sensitivity (HOMA-IR) [Yokoe 2012].  
 
Centrally acting imidazoline receptor-1 agonists, such as moxonidine, have been 
studied with regards to their effects on the SNS and insulin resistance, given their 
sympatholytic effects. In a multicentre study, 98 postmenopausal hypertensive women 
were randomised to either atenolol or moxonidine. Both agents led to a significant 
reduction in diastolic blood pressure but only in the moxonidine group was there a 
significant improvement in insulin sensitivity (p=0.019) [Kaaja 2007]. This may suggest 
a role of such sympatholytic agents in improving metabolic profile through inhibition of 
the SNS.  
 
1.8.3  Electroacupuncture 
 
A number of studies have shown that electroacupuncture (EA) can improve insulin 
resistance and metabolic dysfunction, and this may be through the mechanism of 
altered inflammation and /or sympathetic nervous system activation [Martinez 2016]. 
Furthermore, specific EA studies in PCOS have shown an improvement in symptoms 
which is thought to be due to both spinal and central mechanisms [Stener-Victorin 
41 
 
2013]. Specifically there may be a role of neuropeptides mechanistically in the altered 
sympathetic drive as low-frequency EA has been shown to cause the release of 
serotonin, dopamine, endogenous opioids and oxytocin in the central nervous system 
[Andersson S 1995]. 
 
One study randomly assigned 20 overweight patients with PCOS to either low-
frequency EA, physical exercise or no intervention. They found that both low-
frequency EA and exercise significantly decreased MSNA burst frequency compared 
to the untreated group. These changes were accompanied by improvements in body 
composition in both treated groups, but not in blood pressure, insulin sensitivity or lipid 
profile [Stener-Victorin 2009].  
 
 A subsequent larger randomised trial of 74 women with PCOS showed that low-
frequency EA and physical exercise improved hyperandrogenism and menstrual 
frequency without affecting BMI compared with untreated controls, with the EA group 
showing greater improvements in menstrual regularity and testosterone levels than 
the exercise group [Jedel 2011(b)]. No measures of sympathetic activity were 
undertaken in this study but the findings, taken with the results of their earlier trial, may 
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suggest that these benefits are mediated at least in part by a reduction in sympathetic 
activity. 
 
1.8.4  Continuous positive airways pressure (CPAP) 
 
As discussed, continuous positive airways pressure (CPAP) intervention CPAP has 
consistently shown a rapid reduction in sympathetic activation in obstructive sleep 
apnoea [Jullian-Desayes I 2015]. 
 
Given the prevalence of obstructive sleep apnoea in PCOS, one study has specifically 
looked at the effect of CPAP on SNS activation in this group.  The study used both 
HRV and 24 hour plasma catecholamine profiles as measures of SNS activity, in 
addition to measuring insulin sensitivity and blood pressure in 9 obese women with 
PCOS. Measurements were made at baseline and following 8 weeks of nightly CPAP 
[Tasali 2011]. It was found that daytime and night-time noradrenaline fell significantly 
and this strongly correlated with increasing hours of CPAP use. There was also a 
reduction in LF and an increase in HF components of HRV, suggesting reduced SNS 
activity. The use of CPAP also improved insulin sensitivity and reduced diastolic blood 
pressure. Although the study was small and only examined short-term outcomes, it 
supports the use of CPAP as an intervention to reduce SNS activity in PCOS. 
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1.8.5  Renal denervation 
 
Percutaneous catheter-based radiofrequency ablation of the renal sympathetic nerves 
has been used as a method of reducing SNS activation in recent years. Particularly, 
the Symplicity-1 and Symplicity-2 trials targeted patients with resistant hypertension 
and demonstrated that denervation of the renal nerve resulted in sustained 
improvements blood pressure, reduced renal and total body noradrenaline spillover 
[Schlaich 2009, Krum 2009]. Simplicity-3, however, failed to demonstrate an 
improvement in ambulatory blood pressure in either the 24-hour or day and night 
periods [Bakris GL 2014]. Although questions have since arisen regarding screening 
at entry into the trial, frequent medication changes during the study and the ablation 
technique used, enthusiasm for renal denervation as a treatment for resistant 
hypertension has abated [Epstein M 2015]. Based on these initial observations, 
Maranon et al examined the effects of renal denervation in hyperandrogenaemic 
female rats and found that it resulted in a reduction in mean arterial pressure as 
compared to controls [Maranon 2015]. Taking this approach one-step further, Schlaich 
et al examined the effects of renal denervation on SNS activation, blood pressure and 
insulin resistance in two obese PCOS subjects with hypertension [Schlaich 2011]. 
Both patients had elevated MSNA and total body noradrenaline spillover at baseline, 
compared with normotensive controls. Following renal denervation, MSNA, 
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noradrenaline spillover, blood pressure and insulin resistance were reduced in both 
patients (Figure 1.5). These findings support the role of increased sympathetic tone in 
the pathogenesis of PCOS and may suggest a place for this intervention in improving 
cardiometabolic outcomes.  
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Figure 1.5 
Changes in systolic blood pressure (a) and MSNA (b) in the two patients at 12 
weeks after bilateral renal denervation and (c) whole body norepinephrine 
spillover at baseline and directly after renal denervation. NE, norepinephrine 
[Adapted from Schlaich et al 2011] 
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1.9   STUDY HYPOTHESIS AND AIMS 
 
Previous studies have shown that PCOS is associated with sympathoexcitation but 
the central regulatory pathways are unknown. Advanced MRI has the potential for the 
first time to illuminate some of the cerebral control pathways implicated in this 
activation, as has been discussed, and to establish if there are central differences in 
neural responses to sympathoexcitation between subjects with PCOS and controls, 
which may underly susceptibility to hypertension. 
 
I hypothesise that increased SNS activation in women with PCOS is associated with 
increased BOLD fMRI activity within the brainstem and higher brain structures in 
response to SNS-mediated pressor responses to IFC. Potential mediators of this 
activation may include central obesity, androgens and insulin resistance. This novel 
approach of using functional neuroimaging will improve our understanding of the 
contribution of adiposity and insulin resistance to the neuronal control of blood 
pressure and may inform subsequent clinical trials which seek to target insulin 
sensitivity (e.g. metformin), OSA (CPAP), and weight reduction (e.g. lifestyle or 
pharmacological intervention), leading to improved vascular outcomes for patients 
with PCOS and other metabolic disorders associated with altered insulin sensitivity. 
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The aims of this thesis are: 
 
1. To determine whether blood pressure and SNS responses to IFC are increased in 
women with PCOS compared with age- and BMI-matched controls. 
 
2. To compare BOLD fMRI signal activity in the brainstem and higher brain structures 
associated with increased SNS activity in women with PCOS compared with age- and 
BMI-matched controls.  
 
3. To investigate the metabolic and anthropometric correlates of SNS activity in young 
women with PCOS and age- and BMI-matched controls. 
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CHAPTER 2 
 
 MATERIALS AND 
METHODS 
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2.1  STUDY APPROVAL 
 
The study was approved by Cardiff University (Study Sponsor), Cardiff and Vale 
University Health Board, and the South East Wales Research and Ethics Committee 
in October 2012 (REC reference: 12/WA/0239). A copy of the REC approval can be 
found in Appendix 1, the Patient information sheet and consent form in Appendix 2 
and Volunteer information sheet and consent form in Appendix 3. 
 
2.2  SUBJECTS 
 
2.2.1  Patients 
 
Patients were recruited from the Endocrine and Gynaecology clinics at the University 
Hospital of Wales, Cardiff, the Endocrine clinic at Morriston Hospital, Swansea, 
Morlais Medical Practice, Merthyr Tydfil, and via a PCOS database held at the Centre 
for Endocrine and Diabetes Sciences, Institute for Molecular and Experimental 
Medicine, Cardiff University School of Medicine. Recruitment took place between May 
2013 and June 2014. All patients gave written, informed consent. 
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The diagnosis of PCOS was based on the consensus Rotterdam criteria i.e. at least 2 
out of 3 of the following [Rotterdam 2004]:  
• Androgen excess (clinical symptoms of hyperandrogenism and/or elevated 
testosterone/androstenedione), 
• Ovulatory dysfunction (fewer than 6 menstrual cycles per year) 
• Polycystic ovaries on ultrasound scan (one or both ovaries with 12 or more 
follicles measuring between 2 and 9mm and /or an ovarian volume > 10cm³ 
 
Androgen-secreting neoplasms, Cushing's syndrome, Congenital adrenal 
hyperplasia, hyperprolactinaemia and thyroid disease were excluded by biochemical 
testing, including 17-hydroxyprogesterone (17-OHP), prolactin and TFT 
measurements. Patients were aged between 18 and 45 years and were not included 
in the study if they were pregnant (pregnancy test was performed at initial visit), 
breastfeeding, or had a history of current or previous use (within 3 months) of 
glucocorticoids, lipid lowering agents, anti-hypertensives, anti-diabetics or anti-obesity 
drugs. Patients with a history of hypertension or diabetes were also excluded. Patients 
with any contraindication to an MRI scan were also excluded, including pacemakers, 
implanted hearing aids, neurostimulators, intracranial metal clips and metallic bodies 
in the eye. 
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2.2.2  Healthy volunteers 
 
The control group consisted of healthy volunteer females with regular menstrual cycles 
(menses every 27-32 days) matched for age (± 2yrs) and BMI (± 2Kg/m²). Their 
healthy state was determined by history, physical examination and hormonal 
evaluation (testosterone, androstenedione, thyroid function, prolactin). Healthy 
volunteers were excluded if they were pregnant (test performed at first visit). Control 
subjects with signs of hirsutism or with a personal history of diabetes or hypertension, 
or a family history of PCOS were excluded. Those with any contraindication to MRI 
were also excluded. Healthy volunteers were recruited by advertisement among staff 
and students at the University Hospital of Wales, Cardiff University and in the local 
press. Recruitment took place between June 2013 and May 2014. All healthy 
volunteers gave written, informed consent. 
 
2.3  ANTHROPOMETRIC MEASUREMENTS 
 
Anthropometric assessment took place at the Clinical Research Facility, University 
Hospital of Wales. Assessment included measurement of height, weight, waist 
circumference and hip circumference. Height was measured using a Seca 242 
measuring rod [Seca, Birmingham, UK] and weight with Seca sit on scales [Seca, 
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Birmingham, UK]. Waist circumference was measured at minimal respiration and 
reported to the nearest 0.5cm by positioning a tape measure parallel to the floor and 
immediately above the iliac crest. Hip circumference was measured in a similar 
manner around the widest portion of the buttocks. 
 
Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. 
The Waist-Hip Ratio (WHR) was determined by dividing the waist circumference (cm) 
by the hip circumference (cm). 
 
2.4  INSULIN SENSITIVITY MEASUREMENTS 
 
Studies were conducted between 0900 and 1200 hours in a quiet physiological lab 
maintained at 20°C in the Clinical Research Facility, University Hospital of Wales. All 
subjects attended for blood sampling in a fasted state from midnight. An intravenous 
cannula was inserted into the antecubital fossa of the non-dominant arm.  
 
A standard 75g oral glucose tolerance test (OGTT) was performed using Polycal 
Liquid© [Nutricia Ltd, Wiltshire, UK] and insulin sensitivity was assessed by means of 
insulin and glucose responses. Glucose and insulin were measured by drawing blood 
from the cannula at 0, 30, 60, 90 and 120 minutes. 
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Glucose was measured using the Aeroset chemistry system [Abbott Diagnostics, 
Berkshire, UK]. Insulin samples were centrifuged within 1 hour and aliquots stored at 
-80 °C until measurement, at a maximum of 6 months post-sampling, using an 
immunometric assay specific for human insulin [Invitron, Monmouth, UK].  
 
The area under the curve (AUC) for insulin and glucose was calculated from the values 
obtained during the OGTT using the trapezoid method. The homeostatic model 
assessment (HOMA) method was also used to estimate insulin resistance (HOMA-IR) 
[Matthews et al., 1985]. In addition, the Matsuda Index was calculated using the 
glucose and insulin values from the OGTT and the equation (10,000/square root of 
[fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]) 
[Matsuda et al, 1999]. 
 
2.5  BIOCHEMICAL MEASUREMENTS 
 
Fasting basal samples were taken pre-oral glucose tolerance test, as outlined above, 
for biochemical analysis. Serum was prepared by centrifugation of blood at 4000 rpm 
for 8 minutes. Serum total cholesterol, high density lipoprotein cholesterol (HDL) and 
triglycerides were assayed using an Aeroset automated analyser [Abbott Diagnostics, 
Berkshire, UK]; LDL cholesterol (LDL) was calculated using Friedewald’s formula. 
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Total testosterone was measured by liquid chromatography-tandem mass 
spectrometry [QuattroTM Premier XE triple quadrupole tandem mass spectrometer, 
Waters Ltd, Watford, UK]. Androstenedione was measured by tandem mass 
spectrometry using an in-house method. Thyroid function tests (TFTs) were assayed 
using the Abbott Architect platform [Abbott Laboratories, Illinois]. HbA1c 
measurements were determined using a high-performance liquid chromatography 
(HPLC) assay [TOSOH HLC-723G8, Tosoh Corporation, Tokyo, Japan].The intra- and 
inter-assay coefficients of variation were all <9%.  
 
2.6   PULSE WAVE VELOCITY ASSESSMENT 
 
Measurements were made with the patient resting supine between 0900 and 1200 
hours in a quiet physiological lab maintained at 20°C in the Clinical Research Facility, 
University Hospital of Wales. 
 
The Vicorder system [Skidmore Medical, Bristol, UK] measures simultaneous 
pressure waveforms by a volume displacement technique, using blood pressure cuffs 
placed around the sites of interest. It has the advantage over applanation tonometry 
in that it is operator-independent, does not require the subject to undress and has 
been shown to be a validated and repeatable tool for assessment of pulse wave 
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velocity and measurement of central systolic blood pressure [Hickson SS 2009, Puccci 
G 2013]. Measurements were obtained using the Vicorder device by placing a 100 mm 
wide blood pressure cuff around the upper thigh to measure the femoral pulse and a 
30 mm partial cuff around the neck at the level of the carotid artery. The cuffs were 
each inflated to 60 mm Hg, and high-quality waveforms were recorded simultaneously 
for 3 s with the subject in the supine position, using a volume displacement method. 
Path length was defined as the distance from the suprasternal notch to the top of the 
thigh cuff as indicated by the manufacturer. Figure 2.1 shows a screenshot from the 
Vicorder device. 
 
Figure 2.1 
Screenshot of Vicorder device showing recording of pulse wave velocity 
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2.7  ISOMETRIC FOREARM CONTRACTION 
 
2.7.1  Rationale 
 
Isometric forearm contraction (IFC) has been shown to generate a haemodynamic 
response, characterised by a rise in arterial blood pressure, heart rate and SNS 
activation. It is thought the increase in SNS activation is driven by (i) stimulation of 
mechanoreceptors during muscle stretch (ii) chemoreceptor stimulation from 
accumulation of metabolites in the exercising muscle (also sensitising the 
mechanoreceptors) (iii) central command, although to a lesser degree. Group III and 
IV afferent fibres, both sensitive to mechanical and chemical stimulation, are thought 
to be involved in the exercise pressor reflex [Kaufman MP 2002, McCloskey 1972]. 
The stimulation of these muscle afferents results in increased MSNA outflow, with 
subsequent vasoconstriction. Increased heart rate and cardiac output also contribute 
to the blood pressure rise. Thus there may be an interaction of the mechanoreflex and 
metaboreflex in the central nervous system, enhancing the MSNA response [Cui J, 
2007].  
 
The degree of maximum effort during IFC is also thought to be relevant in the metabo-
mechanoreflex. In lean healthy individuals, the increase in MSNA during exercise until 
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10% of maximal voluntary contraction is mediated by central 
command/mechanoreceptors located in the skeletal muscle, whereas the increase in 
sympathetic nerve activity during 30% IFC is mediated by central 
command/mechanoreceptors and metaboreceptors [Seals 1988, Rowell 1992]. 
 
Coulson and colleagues recently confirmed a pressor response to IFC in healthy male 
and female volunteers and described the influence of the SNS on this response by the 
use of selective α- (phentolamine) and β-adrenoceptor (esmolol) antagonists [Coulson 
2015]. Results from Coulson’s study showed no difference in pain perception between 
a 40% of maximum isometric grip (pain score 1.5 ± 0.7) or a <5% isometric grip (pain 
score 1.5 ± 0.8). 
 
A range of IFC strengths and durations have been used in studies. During sustained 
handgrip at 30% maximum, heart rate and blood pressure increase during the first two 
minutes of the exercise, with MSNA increasing during the second minute [Mark AL, 
1985].The approach which I adopted for my protocol is therefore based upon those 
studies performing IFC at 30% maximum grip for 3 minutes which demonstrated a 
significant haemodynamic response to 30% IFC and also evoked MSNA activation 
[Negrao 2001, Ichinose M 2006].   
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2.7.2  Protocol 
 
Maximum grip strength was determined by asking the volunteer to squeeze an 
electronic hand dynamometer (90kg capacity range) [Zhongshan Camry Electronic 
Co. Ltd, China] with their dominant hand to maximum effort on three separate 
attempts, with a 60 second period of rest between each squeeze, as previously 
recommended [Hamilton 1994, Innes 1999] (Figure 2.2). The mean maximum grip 
strength was determined and 30% IFC calculated by: 
 
30% IFC  =  0.3 x  S1 + S2 + S3    
      3 
 
(S1, S2, S3 represent three initial maximum squeeze attempts (measured in kg)). 
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Figure 2.2 
Electronic hand dynamometer used for IFC 
 
Subjects were then left to rest in a supine position for 5 minutes before the experiment 
began. The protocol followed a block design 12 minutes in total, comprising 1 minute 
rest, 3 minutes squeeze, 2.5 minutes rest, 3 minutes squeeze and 2.5 minutes rest 
(Figure 2.3). The subjects were instructed as to the rest and squeeze periods, and 
targeted to sustain 30% IFC during the squeeze periods. 
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Figure 2.3 
IFC paradigm  
 
2.7.3  Catecholamine measurement 
 
Blood was drawn from the intravenous cannula in the non-dominant arm of the subject 
in a supine position after a 10 minute rest period (pre-IFC catecholamines). Following 
3 minutes of IFC at 30% maximum handgrip strength, further blood was immediately 
drawn for post-IFC catecholamines. Samples were centrifuged at 2000rpm at 4°C 
within 10 minutes of collection and aliquots stored at -80°C until analysis. 
Measurements took place within 6 months of sampling using an Epinephrine ELISA 
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Kit [Abnova, Taoyuan County, Taiwan] and Norepinephrine ELISA Kit [Abnova, 
Taoyuan County, Taiwan]. The intra- and inter-assay coefficients of variation were 
<15.4% for the epinephrine kit and <16.1% for the norepinephrine kit. 
 
2.7.4  Blood pressure and heart rate measurement 
 
Resting blood pressure (mmHg) and heart rate (beats/min) were measured at time 
zero of the IFC paradigm (after a 10 minute rest period in the supine position) using 
an Omron HEM-907 blood pressure monitoring device [Omron Healthcare UK Ltd, 
Milton Keynes, UK]. The blood pressure cuff was inflated on the non-dominant arm for 
each subject. Measurements were then made of blood pressure and heart rate every 
30 seconds throughout the 12 minute protocol. Mean arterial blood pressure (MAP) 
was calculated using the formula: 
 
   MAP = (2 x DBP) + SBP 
     3 
 
DBP = diastolic blood pressure, SBP = systolic blood pressure. 
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2.8  MRI 
 
2.8.1  Introduction 
 
MRI is a non-invasive, non-ionising radiation modality that enables imaging of the 
anatomical structure of the central nervous system. The technique of functional 
magnetic resonance imaging (fMRI) has been developed to allow mapping of local 
physiological or metabolic changes from altered brain electrical activity. fMRI provides 
excellent spatial resolution (the ability to distinguish different locations within an image, 
a few mm) and temporal resolution (the rate at which images are acquired, 
approximately 3 seconds). For this reason fMRI represents an important technique in 
experimental neuroscience. 
 
2.8.2  Physics of MRI 
 
Atomic nuclei that have an odd number of protons possess angular momentum.  
Nuclear magnetic resonance (NMR) allows the measurement of electromagnetic 
induction from the magnetic moments of the nuclei that have undergone polarisation 
in a magnetic field [Bloch 1946]. 
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Since hydrogen atoms have a magnetic moment due to the intrinsic momentum of 
their nuclei, tissues that contain varying densities of water molecules (containing 
hydrogen) can be distinguished. When placed in a strong external magnet field, a 
small proportion of hydrogen nuclei orientate parallel to the magnet field. When an 
alternating radiofrequency (RF) pulse is applied in a different plane to the external 
magnetic field, the nuclei become aligned to the RF field. When the RF pulse stops, 
this causes the nuclei to return to their original orientation (‘relaxation’) and re-radiation 
of RF energy is detected as the MRI signal. 
 
Relaxation measured in different planes allows modification of the contrast between 
different tissue densities. T1 relaxation is the recovery of longitudinal magnetisation 
whereas T2 relaxation is the decay of transverse magnetisation. A T2 contrast image, 
which is sensitive to the presence of deoxygenated blood, can be generated by 
measuring the transverse magnetic decay that results from magnetic field variations 
in the tissue within the applied static magnetic field. 
 
2.8.3  Physiology of BOLD fMRI 
 
In 1936, Pauling and Coryell discovered that the haemoglobin molecule has magnetic 
properties depending on whether it is oxygen bound or not. Oxygenated haemoglobin 
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is diamagnetic, with no unpaired electrons and zero magnetic moment, whereas 
deoxyhaemoglobin has unpaired electrons with a significant magnetic moment and is 
thus paramagnetic [Pauling and Coryell 1936]. 
 
Since paramagnetic substances distort the surrounding magnetic field, nearby protons 
experience different field strengths and therefore change the orientation of their 
rotational axis at different frequencies, resulting in more rapid decay of transverse 
magnetisation. Therefore MR pulse sequences show more signal where high amounts 
of oxygenated haemoglobin are present compared to where blood is highly 
deoxygenated. This finding was verified in experiments in the 1980s when it was found 
that the decay of transverse magnetisation depended on the proportion of oxygenated 
haemoglobin in a test tube of blood. Deoxygenation increases the volume magnetic 
susceptibility within the erythrocytes and creates local field gradients around these 
cells and in the blood vessels containing them [Thulborn 1982]. Deoxyhaemoglobin 
has therefore since been utilised as a natural contrast agent during MRI and the 
modality is therefore known as Blood Oxygenation Level Dependent (BOLD) fMRI 
[Ogawa 1990].  
 
Under normal physiological conditions, a proportion (about 40%) of oxygenated 
haemoglobin is converted to deoxygenated haemoglobin in the capillary bed (Figure 
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2.4A). During neuronal activation in the brain (Figure 2.4B), there is an 
overcompensatory increase in bloodflow, with more oxygenated haemoglobin 
supplied than is required by those areas of the brain with metabolically active neurons. 
Consequently this results in a decrease in the amount of deoxygenated haemoglobin 
and an increased, brighter MR signal [Roy and Sherrington 1890, Huettel SA 2009].   
 
The matching of local cerebral blood flow to neuronal activity is not exact which affects 
the temporal resolution of BOLD fMRI. Following neuronal activation, in some areas 
of the brain such as the visual and primary motor cortex, there is an initial decrease in 
oxygenated haemoglobin (oxy-Hb), followed by a delivery of oxy-Hb in excess of 
demand for approximately 6 seconds. This has been interpreted as reflecting local 
deoxygenation of blood in the capillary bed preceding the onset of activation-
associated hyperaemia [Buxton 1998]. This “initial dip” may provide a more accurate 
measure of the localisation of activation. A brief, post-stimulus, undershoot is then 
seen before returning to baseline.     
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Figure 2.4 
Overview of BOLD signal generation: (A) Under normal conditions oxygenated 
haemoglobin is converted to deoxygenated haemoglobin at a constant rate 
within the capillary bed. (B) When neurons become active the vascular system 
supplies more oxygenated haemoglobin than needed by the neurons, through 
an overcompensatory increase in blood flow. This results in a decrease in the 
amount of deoxygenated haemoglobin, leading to a brighter MR image.  [from 
Huettel et al, 2009] 
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2.8.4  BOLD experimental design 
 
BOLD fMRI can be used to detect relative signal intensity changes in response to a 
change in regional neural stimulation in the brain. The means of achieving this is to 
compare brain responses during different states of the same imaging session by 
introducing a stimulus. The ‘block’ design is a relatively common method used in which 
there are relatively long alternating periods (at least 30 seconds) between a stimulus 
and rest period (Figure 2.5A) [Friston KJ 1999]. In some cases, a stimulus cannot be 
maintained for long periods and thus an ‘event’ related design can be utilised while 
discrete stimuli are repeated throughout the experiment while data are acquired 
(Figure 2.5B) [Buckner 1998]. Event related fMRI requires longer acquisition times 
compared with the block paradigm in order to achieve a sufficient signal-to-noise ratio. 
 
As the neural haemodynamic response to a stimulus is delayed and prolonged it 
requires modelling of the predicted haemodynamic response to a given stimulus 
(Figure 2.6).  
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Figure 2.5 
‘Block’ versus ‘event’ related fMRI designs: Schematic representation of a block 
design functional magnetic resonance imaging (fMRI) paradigm (A) and an event 
related fMRI paradigm (B). For the block design a relatively long (e.g. 30 second) 
stimulation period is alternated with a control period. For the event related 
design a brief stimulus period is used, which can either be periodic or 
randomised. In both cases volumes of data (indicated by the crosses) are 
collected continuously, typically with a repeat time of three to five seconds.  
[from Matthews PM 2004] 
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Figure 2.6 
The modelling of the predicted haemodynamic response to a given stimulus. 
The red haemodynamic response function (HRF) is modelled against the black 
‘block’ periods of stimuli [adapted from Jezzard 2001] 
 
Various factors can affect the BOLD signal and sufficient resolution of the BOLD signal 
needs signal intensity that can be detected above background noise. Potential sources 
of noise include physiological factors such as cerebral blood flow, respiratory patterns 
and arterial carbon dioxide concentrations, as well as noise within the electronics of 
the MRI system [Wise et al 2007]. Breath-holding can also affect the signal [Murphy 
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et al 2010]. Physiological noise can be removed by regressing from the data signals 
that correlate with the breathing and cardiac cycles.  
 
2.8.5  Scan protocol 
 
The scan protocol was designed to show how BOLD signal correlates with the IFC 
(pressor) task, using a block design. 
 
Subjects were fitted with a nasal cannula to measure end tidal CO2. Respiration 
pattern was determined by a strain-gauge band around the chest. Heart rate was 
collected from a pulse oximeter in the left hand [MedRad, USA]. Physiological data 
were collected with a computer-based data acquisition and analysis system [CED 
1401, Cambridge, UK]. 
 
An in-house MRI-compatible handgrip device was positioned in the dominant hand 
and connected to a pressure transducer. The pressure signal was collected with a 
computer-based data acquisition and analysis system [CED 1401, Cambridge, UK] 
and displayed on a screen located inside the scanner via a digital projector.  
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Participants were asked to perform a maximum voluntary contraction to determine 
their maximum grip strength on two occasions. A target of 30% of maximum grip 
strength was set for the experiment and the block paradigm followed as shown in 
Figure 2.3. Subjects followed visual instructions presented on the screen as to the rest 
and squeeze periods, with a target bar showing when 30% squeeze had been 
achieved. Psychology software in Python (PsychoPy) version 1.78 [Peirce 2007] was 
used to run the visual stimulus. Subjects performed the block paradigm on two 
occasions with time to rest between the runs. 
 
The experimental protocol included visual stimuli in the form of a flashing check-board 
(2Hz lasting 15s) that appeared twice at the end of both rest periods.  
 
2.8.6  fMRI 
 
A 3-Tesla whole body MRI scanner [General Electric, US] was used for all scans. The 
head was held immobile in an eight-channel head coil by foam pads. A continuous 
series of 232 fMRI image volumes (echo-planar images using BOLD contrast, scan 
time = 12m) were collected for each run. Voxel size was 1.5x1.5x3mm³, matrix 
128x128x40 and Field-of-view (FOV) 192x192mm² in plane. The slice thickness was 
2.2mm and slice gap 0.8mm. Each volume covered the entire brain and brainstem (TR 
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= 3.1s, TE = 25ms). Slices were tilted 10°-15° from the axial to the coronal plane to 
reduce signal loss due to dephasing in the brainstem resulting from through-slice 
susceptibility-induced gradients [Weiskopf 2006]. Parameters used were adapted to 
image the brainstem, including slice orientation and using a slightly shorter echo time. 
Structural images were collected using a T1-weighted sequence order to facilitate 
visualisation. Each T1 scan was registered to the MNI152, an average T1 brain image 
constructed from 152 normal subjects at the Montreal Neurological Institute (MNI), 
Montreal, QC, Canada, using FLIRT software and linear registration[Jenkinson 2001 
& 2003]. 
 
2.8.7  Image analysis 
 
During initial image analysis, a number of pre-processing steps are performed, 
including reduction of head movement artifact, spatial smoothing, and temporal 
smoothing by filtering out temporal variations that were slower than the experimental 
paradigm [Turner et al 1998]. 
 
The Brain Extraction Tool (BET), available in FEAT, was used to remove surrounding 
tissue around the brain, as the experiments within this study were only concerned with 
analysis of brain structures.  
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During scanning, head movement by a subject can interfere with assigning the correct 
time series to the correct voxel. McFLIRT, a motion correction algorithm, was used to 
ensure that the fMRI time series was representative of the same volume of brain tissue 
[Jenkinson M 2002]. 
 
High pass filtering allows the removal of scanner drift. To prevent the removal of 
variations related to the experimental paradigm, a filter cut-off of 330 seconds was 
used. 
 
A lack of uniformity in the magnetic field can result in signal distortion and dropout. 
This is most noticeable at the tissue-air interfaces such as the air-filled sinuses.  
Acquiring separate field maps therefore allows for the correction of any distortion at 
each voxel [Jenkinson 2003]. 
 
Physiological noise correction was applied retrospectively to the imaging data using 
in-house software developed in the Cardiff University Brain Research Imaging Centre 
[Harvey et al. 2008]. 
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Analysis of the scans was by FEAT (fMRI Expert Analysis Tool, version 6.00) software 
(available on-line at www.fmrib.ox.ac.uk/fsl). FMRI images were un-warped, motion 
corrected, spatially smoothed and spatially normalised to the MNI template. A high-
pass filter of 330 seconds was used. To generate contrast images, task-related BOLD 
activation was estimated with a design matrix specifying a general linear model (GLM) 
that included a waveform based on each person’s IFC during the scan protocol. The 
visual stimulus shown in the scan session was also included in this analysis. 
 
BOLD signal changes for blood pressure condition were modelled with a waveform 
derived from the blood pressure recordings made out of scanner during the 12-minute 
paradigm.  
 
Z statistic images were thresholded using clusters determined by z > 2.3 and a cluster 
significance threshold of P = 0.05 [Worsley 2001]. Significant BOLD signal intensity 
changes were colour coded and rendered onto an individual’s T1-weighted anatomic 
image set. The resulting statistical parametric maps were used in higher level analysis 
to determine differences between PCOS and control groups. 
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2.8.8  Statistical analysis 
 
Statistical analysis is required to determine which voxels are activated by a stimulus. 
The Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB) 
expert analysis tool (FEAT) software was used for both the individual and group (lower 
and higher) level analysis to correlate the change in BOLD signal with the modelled 
neural haemodynamic response to IFC. This software uses univariate analysis to 
analyse the time series of each voxel independently through general linear modeling 
(GLM).   
 
2.8.9  General Linear Modelling 
 
GLM analyses the extent to which the timing of the measured BOLD signal correlates 
with the model of the haemodynamic response function (HRF) to a stimulus (Figure 
2.6). The stimulus function is convolved with the HRF to allow for the temporal delay 
and blurring in the HRF. A specific stimulus model is called an explanatory variable 
(EV). When the model fitting is performed, parameters are estimated that describe the 
amplitude of the signal component in the data that is represented in each EV. The 
parameter estimates a conversion to T-scores and Z statistics. 
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The equation for GLM is given by the equation: 
 
y = Xb + e 
 
Where y = the observed fMRI time course in a specific voxel 
 X = EV 
 b = parameter estimate (intensity of the signal response for a voxel) 
 e = error in the model 
 
2.8.10  Multiple comparison problems 
 
Running the statistical analysis separately for each voxel creates a massive multiple 
comparisons problem.  To correct for multiple comparisons, Gaussian Random Field 
(GRF) is used as a statistical map based on the notion that neighbouring voxels are 
not activated independently from each other but are more likely to activate together in 
clusters. Application of this GRF correction method, however, requires that the fMRI 
data are spatially smoothed which substantially reduces its high spatial resolution. 
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2.8.11  Registration 
 
Image alignment to a standard space brain template is essential in fMRI studies with 
multiple participants to allow comparisons of spatial locations. FEAT contains the 
software FLIRT (FMRIB's Linear Image Registration Tool) that allows the linear 
transformation of imaging data [Jenkinson et al. 2001 & 2002].  This registration from 
functional space to standard space is a two-step process, using a mid-point reference 
of a structural T1 image – the functional low resolution image is aligned to a T1 high-
resolution image, which is then registered to a standard space template. 
 
2.8.12  Group analysis 
 
FEAT is able to compare the BOLD response from several subjects during higher level 
analysis. This also improves the signal-to-noise ratio and allows easier identification 
true BOLD activation areas by comparing the intra- and inter-subject variability. 
 
As the paradigm was run twice, an intermediate level FEAT analysis was run for each 
subject by combining their two lower-level FEAT outputs, to produce an average for 
each subject. These were then used in the higher-level Feat analysis that could be 
used in the group analyses. 
78 
 
2.9  MUSCLE SYMPATHETIC NERVE ACTIVITY (MSNA) 
 
A pilot sub-study was undertaken in PCOS subjects and healthy volunteers who 
agreed to undergo microneurography in order to record a more direct measure of 
sympathetic activity. 
 
Microneurography studies were conducted between 0830 and 1530 hours in a quiet 
physiological lab maintained at 20°C in the Clinical Research Facility, University 
Hospital of Wales. These measurements were undertaken by Dr Yrsa Sverrisdóttir, 
Oxford University, who has many years’ experience in undertaking microneurography.   
 
Direct recordings of multiunit efferent postganglionic muscle sympathetic nerve activity 
(MSNA) were obtained with a tungsten microelectrode with a tip diameter of a few 
micrometres inserted into a muscle fascicle of the peroneal nerve, posterior to the 
ﬁbular head. A low-impedance reference electrode was inserted subcutaneously a few 
centimetres from the ﬁbular head (Figure 2.7).  
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Figure 2.7 
 
Positioned microelectrodes for MSNA recordings 
 
When a muscle nerve fascicle had been identiﬁed, small electrode adjustments were 
made until a site was found in which spontaneous, pulse-synchronous bursts of neural 
activity could be recorded. Details of the nerve recording technique and criteria for 
MSNA have been reported previously [Vallibo 1979]. Bursts identiﬁed by inspection of 
the mean voltage neurogram were expressed as burst frequency (number of pulse 
synchronic sympathetic bursts per minute) [bursts/ min (BF)] and burst incidence 
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(number of pulse synchronic sympathetic bursts per 100 heart beats) [bursts/100 
heartbeats (BI)]. During the microneurographic recording, heart rate was monitored 
via ECG chest electrodes (Figure 2.8).  
 
The nerve recordings were assigned a code and analysed blinded. MSNA data were 
analysed a) over 300 seconds and b) over the last 60 sec before the 30% IFC, which 
were the values used to compare to the last 60 seconds of the IFC. As well as burst 
frequency and burst incidence, Total MSNA activity was measured to take into account 
both the frequency and size of a sympathetic burst (the product of burst per minute 
and mean burst amplitude), expressed in arbitrary units. The total MSNA during the 
last 60 seconds of a rest period was used as a baseline to see the percentage change 
in MSNA during the last 60 seconds of the 30% IFC. 
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Figure 2.8 
 
MSNA recordings on a subject while IFC being performed. 
 
2.10  SLEEP STUDIES 
 
Home sleep studies were undertaken from 2300-0700h, in subjects who agreed to 
this. The Embletta™ X100 PDS (Portable Device System) [ResMed (UK) Ltd, 
Abingdon, Oxfordshire] was used for limited channel sleep recordings with airflow 
monitored by a nasal cannula, chest and abdominal wall motion by belts, and oxygen 
saturations and heart rate using pulse oximeter. Snoring was derived from the nasal 
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cannula. Sleep recordings were stored and analysed by standard software, RemLogic-
E [Embla, Stowood Scientific Instruments, Oxford, UK] and a sleep report produced 
for each subject. The apnoea-hypopnoea index (AHI) was calculated as the total 
number of obstructive respiratory events per hour of sleep, with OSA diagnosed 
if/when AHI is equal to or greater than 5 events per hour. The severity was then 
subdivided into mild, moderate or severe depending on the AHI score, according to 
standard criteria.  
 
2.11  SAMPLE SIZE AND STATISTICAL ANALYSIS 
 
Given its central role in my investigation, I focused my statistical considerations on 
powering the BOLD fMRI study to examine brain responses to the isometric forearm 
contraction task. Power calculations are hard to perform for all comparisons in the 
study given that such work is novel so I focused on detecting basic, task-related 
changes. My estimates are based on the study at Cardiff University Brain Research 
Imaging Centre performed in which brain activity changes were detected in the 
brainstem in a pilot cohort of 12 volunteers [Coulson 2015]. I focused on the brainstem 
as a primary region of interest for the present study which indexes the brain’s response 
to the task and which is likely to related to SNS output. Coulson et al detected a mean 
IFC (40% of maximum grip) related BOLD signal change in the brainstem (medulla) of 
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0.3 (arb. units) with a standard deviation of 0.2 (arb. units). This was in healthy 
volunteers. In the present study I aim to compare a cohort of patients with matched 
controls. Assuming a similar variance of task-related signal changes in the proposed 
cohorts, to detect a 50% greater increase in the medullary BOLD signal in response 
to IFC in patients with p<0.05 as the required statistical threshold to reject the null 
hypothesis and 70% detection power I would need to scan 20 volunteers in the patient 
group and 20 in the matched control group. I would also expect this cohort size to be 
sufficient to yield significant differences in microneurography measures.  
 
Statistical analysis for the data was performed using SPSS version 20.0 [IBM, New 
York]. Independent-Samples t Test was used to compare the statistical difference 
between the mean of the PCOS and control groups, and p<0.05 was considered 
statistically significant.   
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CHAPTER 3 
 
CLINICAL, 
CARDIOMETABOLIC AND 
SYMPATHETIC NEURAL 
CHARACTERISTICS OF 
THE STUDY POPULATION 
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Polycystic ovary syndrome (PCOS) is an established metabolic disorder associated 
with insulin resistance, dyslipidaemia and hypertension, as has been outlined in 
chapter 1 [Dunaif 1997, Talbott 1995, Kim 2013, Joham 2015]. Furthermore, the 
increasing evidence that insulin resistance, obesity, hypertension and PCOS per se 
are all associated with increased sympathetic tone has been discussed [Masuo 2003, 
Alvarez 2002, Grassi and Mancia 2004, Sverrisdottir 2008].  
 
The aims of this chapter are therefore to report: (1) the metabolic and anthropometric 
correlates of SNS activity in my study population of young women with PCOS and the 
age- and BMI-matched controls, and (2) to determine whether blood pressure and 
SNS responses to IFC are increased in PCOS compared with controls. 
 
To this end, the clinical, cardiometabolic and sympathetic neural characteristics of my 
study population will be presented and discussed. The baseline anthropometric and 
metabolic features measured (as detailed in chapter 2, sections 2.3-2.5) will be 
reported alongside the results of arterial stiffness and sleep studies (chapter 2, 
sections 2.6 and 2.10). Furthermore, the SNS response to IFC in the PCOS and 
control groups are reported (as described in chapter 2, sections 2.7 and 2.9) and the 
potential mediators that correlate with these responses. 
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3.1  BASELINE ANTHROPOMETRIC AND METABOLIC 
CHARACTERISTICS 
 
A total of 40 subjects were recruited, 20 with PCOS and 20 healthy volunteers (as 
described in Chapter 2.2), matched for age and BMI. The baseline anthropometric and 
metabolic characteristics of the two groups are summarised in Table 3.1. 
 
Mean age for the PCOS group was 29.8yrs and in controls 29.7yrs (p=0.92), with no 
significant difference in BMI between groups (mean 26.1 Kg/m² both groups), p=0.97. 
The waist-hip ratio (WHR) was calculated for both groups and was greater in the 
PCOS group (0.88) compared to controls (0.84), p=0.04. However, neither waist 
(mean 85.9cm PCOS, 85.1cm, p=0.86) nor hip circumference (mean 97.2cm PCOS, 
101.4cm controls, p=0.24) was different between groups. Although serum 
testosterone was higher in the PCOS group (1.41nmol/L versus 0.84nmol/L), the 
difference between groups did not reach statistical significance (p=0.09). Total 
cholesterol was 5.2mmol/L in the PCOS group and 4.8mmol/L in controls (p=0.12) with 
serum triglycerides significantly higher in PCOS subjects as compared to controls 
(1.34mmol/L, 0.90mmol/L), p=0.02. Baseline heart rate (HR) and mean arterial 
pressure (MAP) were measured in both groups, with mean HR 71 beats/min in both 
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groups (p=0.94), and mean MAP 81.6mmHg in the PCOS group, and 83.8mmHg in 
the control group (p=0.54). 
 
Table 3.1  
Baseline characteristics of the study population. Results are expressed as 
mean ± SD. P<0.05 is considered statistically significant 
 PCOS (n=20) Control (n=20) P value 
Age (yrs) 29.80 ± 4.78 29.65 ± 4.96 0.92 
BMI (Kg/m²) 26.05 ± 4.90 26.11 ± 4.83 0.97 
WHR 0.88 ± 0.07 0.84 ± 0.04 0.04 
Waist 
circumference 
(cm) 
85.9 ± 13.7 85.1 ± 11.1 0.86 
Hip circumference 
(cm) 
97.2 ± 10.4 101.4 ± 11.8 0.24 
Testosterone 
(nmol/L) 
1.41 ± 0.77 1.03 ± 0.53 0.09 
Androstenedione 
(nmol/L) 
4.51 ± 2.99 3.64 ± 1.28 0.25 
HbA1c (mmol/mol) 34.15 ± 2.76 34.21 ± 2.64 0.95 
Total cholesterol 
(mmol/L) 
5.22 ± 1.05 4.79 ± 0.55 0.12 
Triglycerides 
(mmol/L) 
1.34 ± 0.68 0.90 ± 0.36 0.02 
Resting HR 
(beats/min) 
71.05 ± 8.59 71.26 ± 7.65 0.94 
Resting SBP 
(mmHg) 
114.53 ± 9.33 117.58 ± 12.62 0.40 
Resting DBP 
(mmHg) 
65.16 ± 13.33 65.47 ± 14.31 0.94 
Resting MAP 
(mmHg) 
81.63 ± 11.26 83.84 ± 10.54 0.54 
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3.2  PCOS CHARACTERISTICS AND PHENOTYPES 
 
Of the 20 patients with PCOS recruited, Figure 3.1 outlines the proportion of each with 
hyperandrogenism (clinical or biochemical), ovulatory dysfunction and polycystic 
ovaries on ultrasound scan. 
 
Figure 3.1 
Proportion of PCOS subjects with various phenotypes. PCO = polycystic 
ovaries on ultrasound scan, H = clinical or biochemical hyperandrogenism, CA 
= chronic anovulation 
 
 
10% 
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Out of the 20 patients, those with biochemical evidence of hyperandrogenism (defined 
by serum testosterone >1.7nmol/L) were 5/20 (25%).  
 
11/20 (55%) had a normal BMI and 5/20 (25%) were overweight and 4/20 (20%) 
obese. The range of BMI was 20-38 Kg/m².  
 
Only 2/20 (10%) patients were both biochemically hyperandrogenic and 
overweight/obese.  
 
2/20 patients had been taking metformin therapy when recruited but had a 3-month 
washout period before any data was collected. In addition, 4 patients were on the oral 
contraceptive pill. 
 
3.3   INSULIN SENSITIVITY MEASUREMENTS 
 
39 study participants (20 PCOS, 19 controls) underwent an oral glucose tolerance test, 
as outlined in chapter 2, with 0, 30, 60, 90 and 120 minute glucose and insulin 
measured. HOMA-IR, Matsuda index, insulin AUC and glucose AUC were calculated 
for both groups, as described in chapter 2. Results are shown in Table 3.2.  
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Table 3.2  
Insulin sensitivity indices for PCOS and control groups.  
Results are expressed as mean ± SD. P<0.05 is considered statistically 
significant 
 PCOS (n=20) Control (n=19) P value 
Fasting plasma 
glucose (mmol/L) 
4.38 ± 1.08 4.55 ± 0.35 0.50 
2-hour glucose 
(mmol/L) 
5.96 ± 2.35 5.22 ± 2.15 0.31 
Glucose AUC 
(mmol min/L) 
764.85 ± 239.02 661.89 ± 0.17 
Fasting insulin 
(pmol/L) 
 47.98 ± 39.64  29.89 ± 19.71 0.09 
Insulin AUC (pmol 
min/L) 
55519.50 ± 
41547.67 
35320.26 ± 
21008.31 
0.07 
HOMA-IR 1.41 ± 1.10 0.88 ± 0.65 0.08 
Matsuda index 9.11 ± 6.52 13.39 ± 9.55 0.12 
 
As anticipated, all indices of insulin resistance were higher in the PCOS group 
although none of these reached statistical significance. The HOMA-IR was 1.41 
compared to 0.88 in controls, Matsuda index 9.11 compared to 13.39 in controls, 
insulin AUC 55520 pmol min/L compared to 35320 pmol min/L in controls and fasting 
insulin 47.98 pmol/L versus 29.89 pmol/L in controls. In addition, 2-hour glucose was 
greater in the PCOS group compared with controls (6.0 mmol/L, 5.2mmol/L), as was 
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the glucose AUC (765 mmol min/L in the PCOS group compared to 662 mmol min/L 
in controls), but these were not significantly different. 
  
 
 
 
 
 
 
 
 
Figure 3.2 
Line graphs showing the mean glucose (A) and insulin (B) responses for both 
PCOS (blue) and controls (green) during the oral glucose tolerance test. 
Values represent the mean values and error bars represent +/- 2 standard 
errors of the mean 
 
Figure 3.2 shows the glucose and insulin responses for the PCOS and control groups 
throughout the OGTT. 
 
A B 
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As anticipated, when all subjects were grouped together, there was a positive 
correlation between WHR and insulin resistance (Figure 3.3), with a Pearson 
correlation of 0.40 between WHR and insulin AUC (p=0.01). There was also a positive 
correlation between BMI and insulin AUC across all subjects, r = 0.47 (p=0.002). In 
the PCOS group alone, there was a positive Pearson correlation between BMI and 
insulin AUC, r = 0.45, p=0.04, but not a statistically significant correlation between 
WHR and insulin AUC, r = 0.37, p=0.11, likely due to the comparatively small sample 
size. Pearson’s correlation between BMI and insulin AUC for controls was 0.67 
(p=0.002), but it was not significant between WHR and insulin AUC in this group either, 
r = 0.20, p=0.41. 
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Figure 3.3 
 Relationship between WHR and insulin AUC (pmol min/L) for all subjects (n = 
39), r = 0.40, p = 0.01 
 
 
3.4  ARTERIAL STIFFNESS 
 
Arterial stiffness was assessed using the Vicorder device, as described in chapter 2. 
Table 3.3 shows the augmentation pressure, augmentation index and aortic pulse 
wave velocity (aPWV) for the PCOS and control groups. For all three measurements, 
the mean values were greater in the PCOS group compared to controls, but no 
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statistically significant differences between the groups were found. However, the study 
was not powered to reveal differences in vascular function.  
 
Table 3.3  
Arterial measurements for PCOS and control groups 
Results are expressed as mean ± SD. P<0.05 is considered statistically 
significant 
 PCOS Control P value 
Augmentation 
pressure (mmHg) 
6.94 ± 3.90 5.78 ± 2.90 0.32 
Augmentation 
index (%) 
13.63 ± 6.16 12.17 ± 6.00 0.47 
Aortic Pulse Wave 
Velocity (m/s) 
6.19 ± 0.63 5.83 ± 0.73 0.13 
  
3.5   SLEEP STUDIES 
 
A subgroup of 19 subjects (6 PCOS and 13 controls) underwent home sleep studies 
between 23.00h-07.00h, as outlined in section 2.10. The remaining subjects did not 
wish to undertake these. The apnoea-hypopnoea index (AHI) was calculated for both 
groups. The mean AHI for the PCOS group was 0.62 ± 0.60 /hr, compared to 0.56 ± 
1.21 /hr in the control group (p=0.92). Figure 3.4 shows the difference in AHI between 
PCOS and controls. No subjects in either group met the criteria for OSA, as defined 
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by ≥5 events /hr. I conducted exploratory analyses to study the association of apnoea-
hypopnoea index with anthropometric and indices in the combined group, and each of 
PCOS and controls separately. I felt justified in combining data from the two groups 
because no differences were noted in AHI between PCOS and controls. There was a 
positive correlation, r = 0.53, of WHR with AHI across all subjects (p = 0.02). Similarly 
this was noted between BMI and AHI, r = 0.54 (p = 0.02).  
 
Figure 3.4 
AHI differences between PCOS (n=6) and control groups (n=13) 
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When analysed by PCOS and control groups separately, there was no significant 
correlation between WHR and AHI in the PCOS group, r = 0.45, p = 0.37, but a strongly 
positive correlation between BMI and AHI, r = 0.83, p = 0.04. For controls, there was 
a statistically significant positive correlation between AHI and WHR, r = 0.66, p= 0.01, 
but not between AHI and BMI, r = 0.51, p = 0.07.  
 
3.6  SNS RESPONSE TO IFC 
 
3.6.1  Catecholamines 
 
The plasma catecholamine response to IFC was assessed in 39 subjects (20 PCOS, 
19 controls) before and following 3 minutes of 30% sustained IFC, as outlined in 
section 2.7.3. The mean resting baseline plasma adrenaline concentration in the 
PCOS group was 0.68 ± 0.53ng/mL and 0.77 ± 0.59ng/mL in controls (p=0.64). 
Similarly, the baseline noradrenaline concentration was not statistically different 
between groups (p=0.22), 18.11 ± 11.18ng/mL in PCOS and 22.99 ± 13.33ng/mL in 
controls. 
 
Following IFC, for all subjects (n=39), there was a significant rise in plasma adrenaline 
from 0.72 ± 0.55 ng/mL to 1.11 ± 0.67 ng/mL (p<0.001) but no change in noradrenaline 
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concentrations (baseline 20.48 ± 12.36 ng/mL to post-IFC 18.82 ± 11.15 ng/mL 
(p=0.14)). When analysed for each group separately, there was a significant rise in 
adrenaline concentrations following IFC from 0.68 ± 0.53 ng/mL to 1.23 ± 0.71 ng/mL 
in the PCOS group (p<0.001) but no change in noradrenaline concentrations from 
18.11 ± 11.18 ng/mL to 16.77 ± 10.01ng/mL (p=0.38) (Figure 3.5). For the controls, 
adrenaline levels did not significantly change following IFC (0.77 ± 0.59 ng/mL to 0.99 
± 0.61 ng/mL (p=0.14)) nor did noradrenaline concentrations (22.99 ± 13.33 ng/mL to 
20.99 ± 12.12 ng/mL (p=0.25)).  
 
When expressed as percentage change from the resting state, the proportional rise in 
adrenaline concentrations following IFC was greater in the PCOS group compared to 
controls (313.8% vs 105.9%) but this was not significantly different (p =0.32).  
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Figure 3.5 
Change in adrenaline concentrations (ng/mL) pre- and post-IFC in PCOS group 
(p<0.001) and control group (p=0.38). Adrpre = plasma adrenaline 
concentration pre-IFC; Adrpost = plasma adrenaline concentration post-IFC. 
The solid black line within each box represents the median concentration, the 
ends of the boxes the upper and lower quartiles, and the extremes of the 
whiskers the minimum and maximum concentrations. Black dots show the 
outlier values. 
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3.6.2  Pressor response 
 
38 subjects (19 PCOS, 19 controls) had measurements of heart rate and blood 
pressure in the resting state and following 3 minutes of sustained 30% IFC, as 
described in the methods section 2.7.4. Table 3.1 shows the baseline resting HR, SBP, 
DBP and MAP for both groups, with no significant differences between the PCOS and 
control groups. Following IFC, taking all subjects as one group, as expected there 
were significant rises in HR, DBP, SBP and MAP, as shown in table 3.4 
Table 3.4 
Haemodynamic measurements for all subjects (n=38) pre- and post-IFC. 
Results are expressed as mean ± SD. P<0.05 is considered statistically 
significant 
 
 
Mean ± SD 
Pre-IFC 
Mean ± SD 
Post-IFC  
Mean 
difference 
(95% CI) 
P value 
HR (beats/min) 71.2 ± 8.0 75.9 ± 8.2 4.7 (3.3-6.2) <0.001 
SBP (mmHg) 116.1 ± 11.1 126.5 ± 12.4 
10.4 (8.0-
12.8) 
<0.001 
DBP (mmHg) 65.3 ± 13.6  74.5 ± 13.3 
9.2 (7.1-
11.4) 
<0.001 
MAP (mmHg) 82.7 ± 10.8 91.8 ± 11.7 
9.1 (7.4-
10.8) 
<0.001 
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For the PCOS group, following IFC, there was a mean increase in HR of 5.6 (3.0-8.3) 
beats/min (p<0.001), SBP 12.6 (9.1-16.0) mmHg (p<0.001), DBP 9.7 (7.3-12.1) mmHg 
(p<0.001) and MAP 10.7 (8.2-13.3) mmHg. Similarly, for controls, the mean rise in HR 
was 3.8 (2.4-5.3) beats/min (p<0.001), SBP 8.3 (4.9-11.6) mmHg (p<0.001), DBP 8.7 
(4.9-12.5) mmHg (p<0.001) and MAP 7.5 (5.2-9.7) mmHg (p<0.001).  
 
The percentage increase in HR, SBP, DBP and MAP for each group was calculated, 
with the results shown in table 3.5. 
 
Table 3.5 
Mean percentage increase (±SD) in HR, DBP, SBP and MAP for PCOS and 
control groups (%). P<0.05 is considered statistically significant 
 PCOS (n=19) Controls (n=19) P value 
Percentage HR 
increase (%) 
8.5 ± 8.4 5.4 ± 4.4 0.155 
Percentage SBP 
increase (%) 
11.0 ± 5.9 7.4 ± 6.7 0.090 
Percentage DBP 
increase (%) 
15.0 ± 7.4 11.3 ± 8.0 0.157 
Percentage MAP 
increase (%) 
13.5 ± 6.5 9.3 ±  6.8 0.058 
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The percentage rises in all measures of the pressor response to IFC were greater in 
the PCOS group compared with controls, but these did not reach statistical 
significance. 
 
3.6.3  MSNA 
 
A subset of participants underwent microneurography (MSNA) recordings on a 
separate occasion, as outlined in section 2.9. Resting data were obtained from a total 
of 16 subjects (8 PCOS, 8 controls). Only 14 of these subjects (7 PCOS, 7 controls) 
were able to proceed with full MSNA recordings post-IFC due to technical difficulties, 
including inability to locate the peroneal nerve for recordings (n=1) and a participant 
who was unable to keep their leg in position (n=1). The baseline characteristics of 
these two groups are shown in table 3.6. Both groups were matched by age and BMI. 
The only significant difference between the two groups was that insulin AUC was 
greater in the PCOS group compared to controls (p = 0.03). 
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Table 3.6 
Baseline characteristics of the subjects undergoing MSNA recordings.  
Results are expressed as mean ± SD. P<0.05 is considered statistically 
significant 
 PCOS (n=7) Controls (n=7) P value 
Age (yrs) 29.57 ± 6.37 30.14 ± 6.23 0.87 
BMI (Kg/m²) 27.29 ± 4.89 27.14 ± 6.20 0.96 
WHR 0.92 ± 0.10 0.84 ± 0.04 0.08 
Testosterone 
(nmol/L) 
1.56 ± 0.82 1.20 ± 0.32 0.30 
Insulin AUC (pmol 
min/L) 
80599.29 ± 
29766.85 
46367.14 ± 
23083.73 
0.03 
HOMA-IR 1.53 ± 0.92 1.03 ± 0.98 0.34 
Matsuda 5.58 ± 4.46 11.71 ± 8.26 0.13 
Resting HR 
(beats/min) 
69.83 ± 9.70 68.67 ± 7.87 0.82 
Resting MAP 
(mmHg) 
83.00 ± 10.58 85.00 ± 8.27 0.72 
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The resting MSNA data for both groups are shown in table 3.7. Resting Burst 
frequency (BF) and Burst Incidence (BI) was not significantly different between the 
PCOS group and controls.  
 
As anticipated, IFC induced an increase in MSNA activity in both groups, as shown in 
table 3.8. However, this only reached statistical significance with respect to BF and BI 
in the PCOS group. In the controls (n=7), the increase in BF or BI post-IFC was not 
statistically significant, but the total MSNA rise was (p=0.048). 
 
Table 3.7 
Resting MSNA in PCOS and control groups, including burst frequency (BF), 
burst incidence (BI) and total MSNA activity. Results are expressed as mean ± 
SD. P<0.05 is considered statistically significant 
 PCOS (n=8) Controls (n=8) P value 
Burst frequency 
(BF) 
(bursts/min) 
26.5 ± 4.4 31.6 ± 8.8 0.16 
Burst incidence 
(BI) 
(bursts/100 heart 
beats) 
37.0 ± 9.4 44.1 ± 11.3 0.19 
Total MSNA 
activity 
2.6 ± 1.3 2.6 ± 0.7 0.97 
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Table 3.8 
Mean changes in BF, BI and total MSNA following IFC in PCOS (n=7) and 
controls (n=7). Results are expressed as mean ± SD. P<0.05 is considered 
statistically significant 
  Pre-IFC Post-IFC Difference P value 
BF 
(bursts/min) 
PCOS 25.9 ± 4.4 42.9 ± 8.2 17.0 (10.0-
24.0) 
0.001 
Control 29.6 ± 7.1 34.9 ± 4.5 5.3 (2.5-13.1) 0.149 
BI 
(bursts/100 
heartbeats) 
PCOS 36.3 ± 9.9 54.4 ± 12.1 18.1 (8.4-
27.9) 
0.004 
Control 42.0 ± 10.3 47.9 ± 7.1 5.9 (4.1-15.8) 0.199 
Total MSNA 
 
PCOS 2.4 ± 1.3 5.5 ± 3.1 3.1 (1.4-4.8) 0.004 
Control 2.6 ± 0.7 4.4 ± 1.7 1.8 (0.0-3.6) 0.048 
 
The percentage increase in BF, BI and total MSNA from pre- to post-IFC was 
calculated for each group. Figure 3.6 shows the percentage increase in BF and BI for 
the PCOS and control groups.  
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Figure 3.6 
Mean percentage increase in BI and BF for PCOS and control groups post-IFC. 
Black bars represent the percentage BI change for each group post-IFC and 
light grey bars represent percentage BF change post-IFC. Error bars represent 
95% confidence intervals. 
 
 
 
 
 
 
 
 
 
 
 
 
BF increased by 68.0% in the PCOS group compared to 11.9% in controls (p=0.002) 
and BI increased by 55.4% and 20.5% in PCOS and controls respectively (p=0.133). 
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The total MSNA increase (PCOS: 124.1%, controls: 86.4%) was not statistically 
significantly different between groups (p=0.420). 
 
3.7  POTENTIAL MEDIATORS OF SNS ACTIVATION 
 
When exploring potential mediators of SNS activation, as differences were found 
between PCOS and controls with respect to post-IFC BI and BF, I did not consider it 
valid to combine all subject data for MSNA, BI and BF and have therefore undertaken 
subsequent analyses of these separately.  
 
3.7.1  BMI 
 
Simple correlation showed that for the PCOS group, BMI was associated with resting 
adrenaline levels and percentage rise in MAP. In the control group, resting MSNA 
burst incidence (BI) and resting burst frequency (BF) correlated positively with BMI 
(Table 3.9). There was no significant association between BMI and any other 
parameters associated with sympathetic activation, although I recognise that the 
sample size for microneurography measurement was small. 
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Table 3.9 
Correlation between BMI and measures of SNS activity 
 
 
 
3.7.2  Waist circumference 
 
For the PCOS group, WHR correlated significantly with percentage rise in MAP, r = 
0.46, p = 0.045 and with percentage rise in plasma adrenaline, r = 0.79, p<0.001. 
Parameter: 
BMI 
Group Correlation 
 
R² P value 
Resting MAP 
(mmHg) 
All 0.05 0.002 0.78 
PCOS 0.05 0.002 0.84 
Control 0.06 0.003 0.81 
Percentage 
MAP rise 
All 0.41 0.16 0.01 
PCOS 0.66 0.44 0.002 
Control 0.10 0.01 0.69 
Resting 
adrenaline 
levels (ng/mL) 
All 0.21 0.04 0.21 
PCOS 0.47 0.22 0.04 
Control 0.01 0.00 0.95 
Percentage 
adrenaline rise 
All 0.20 0.04 0.23 
PCOS 0.27 0.08 0.24 
Control 0.25 0.06 0.31 
Resting BI 
(bursts/100 
heartbeats) 
PCOS 
 
0.18 0.03 0.67 
Control 0.72 0.51 0.05 
Resting BF 
(bursts/min) 
PCOS 0.52 0.27 0.19 
Control 0.83 0.69 0.01 
Resting total 
MSNA 
PCOS 0.14 0.02 0.74 
Control 0.24 0.06 0.60 
Percentage BI 
rise 
PCOS 0.09 0.01 0.86 
Control 0.24 0.06 0.61 
Percentage 
BF rise 
PCOS 0.57 0.32 0.18 
Control 0.64 0.41 0.12 
Percentage 
total MSNA 
rise 
PCOS 
 
0.58 0.33 0.18 
Control 0.39 0.15 0.39 
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Similarly, for the control group, WHR correlated with rise in MAP, r = 0.53, p=0.03, and 
with adrenaline rise, r = 0.55, p = 0.02. For all subjects analysed together, Pearson’s 
correlation between WHR and percentage MAP rise was 0.51, p=0.002, and 0.7 
(p<0.001) between WHR and percentage rise in plasma adrenaline. There was no 
significant correlation between WHR and any MSNA measurement of sympathetic 
activity for the PCOS group or control group. 
 
3.7.3  Insulin resistance 
 
Although the PCOS MSNA group was more insulin resistant, there were no 
correlations found between MSNA and HOMA-IR. For the control group, there was a 
positive correlation between resting MSNA BF and insulin AUC, 0.804, p=0.02, but no 
relationship between MSNA and insulin AUC in the PCOS group. Overall, for all 
subjects, there was no association between HOMA-IR and blood pressure 
measurements. However, by group, for the control group, there was a negative 
correlation between HOMA-IR and resting MAP, r = -0.58, p=0.01, and a strongly 
positive association (r = 0.69, p = 0.001) between HOMA-IR and percentage change 
in MAP. This was not present for the PCOS group. There was an overall positive 
correlation between insulin AUC and percentage rise in MAP for all subjects (r = 0.44, 
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p=0.01) (Figure 3.7) but this was not present when analysed by group. There were no 
significant associations between insulin sensitivity and any catecholamine measure. 
 
 
 
 
Figure 3.7 
Correlation between insulin AUC (pmol min/L) and percentage rise in MAP for 
all subjects, p = 0.01 
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3.7.4  Testosterone 
 
For the PCOS group, there was no significant correlation between serum testosterone 
and any MSNA measures. For the controls, there was a strongly positive correlation 
between testosterone and percentage rise after IFC in burst incidence (BI), r = 0.92, 
p=0.004 and testosterone and total MSNA rise, r = 0.81, p=0.03. There was also a 
negative correlation in the control group between testosterone and resting MSNA BI 
(r= -0.70, p=0.05) and resting MSNA BF (r = -0.73, p =0.04).  
 
3.7.5  Obstructive sleep apnoea 
 
For all subjects, a positive correlation was found between the apnoea-hypopnoea 
index (AHI) and resting MSNA BF, r = 0.66, p = 0.05. There were no significant 
associations between MSNA and AHI in each of the PCOS and control groups. For 
the PCOS group, there was a positive correlation between percentage rise in MAP 
and AHI, 0.94, p=0.02, but this was not present for the control group. 
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3.8  INFLUENCE OF PCOS PHENOTYPE 
 
Amongst the PCOS group, although numbers were small (n=20), analysis was 
performed to see if there was a difference between insulin sensitivity and SNS 
response to IFC between the 5 hyperandrogenic (H) patients (serum testosterone 
>1.7nmol/L) and the non-hyperandrogenic (non-H) patients. As only two patients were 
both hyperandrogenic and overweight-obese, given the very small number, it wasn’t 
thought statistically valid to compare these with the 18 non-hyperandrogenic normal 
BMI patients. 
 
In the H patients, Matsuda Index was 16.81 ± 2.70 compared to 7.53 ± 5.94 in non-H 
(p=0.004), insulin AUC 34623.00 ± 18344.31 pmol min/L in H group, compared to 
62485.00 ± 45151.20 pmol min/L in the non-H (p=0.07) and HOMA-IR 0.74 ± 0.80 in 
H group, compared to 1.63 ± 1.12 in the non-H group (p=0.08). 
 
Resting heart rate was 70.40 ± 8.20 beats /min in the H-group, compared to 71.29 ± 
9.00 beats /min in the non-H group (p=0.85). Percentage change in heart rate following 
IFC was 5.80 ± 7.98 % in the H-group and 9.50 ± 8.64 % in the non-H group (p=0.41). 
Resting MAP was 80.60 ± 13.48 mmHg in the H-group and 82.00 ± 10.91 mmHg in 
the non-H group (p=0.84). The percentage change in MAP following IFC was 11.60 ± 
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4.56 % in the H-group and 14.14 ± 7.04 % in the non-H group (p=0.38). The 
percentage change in noradrenaline post-IFC was -20.00 ± 33.13 % in the H-group 
and 22.53 ± 98.31 % in the non-H group (p=0.17), and the percentage change in 
adrenaline post-IFC was 93.40 ± 50.41 % in the H-group and 3359.73 ± 11533.75 % 
in the non-H group (p=0.29). 
 
For the PCOS subjects undergoing full MSNA recordings, 2/7 were biochemically 
hyperandrogenic (H) and 5 were non-hyperandrogenic (non-H). There was no 
statistical difference in any of the resting MSNA recordings or post-IFC recordings 
between the H and non-H groups. 
 
3.9  DISCUSSION 
 
3.9.1  Clinical and cardiometabolic findings 
 
3.9.1.1 Anthropometric findings 
 
In this study, 20 PCOS subjects were matched by both age and BMI with 20 healthy 
volunteers although the waist-hip ratio (WHR) was greater in the PCOS group 
compared to controls. This supports some previous studies which have explored body 
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fat percentage and distribution in women with PCOS, showing that compared to BMI-
matched controls, PCOS women show significantly greater visceral adipose tissue 
[Cosar E 2008, Karabulut 2012, Godoy-Matos 2009, Arpaci D 2015], although data is 
not consistent [Barber 2008]. My study would suggest that, at least by WHR 
measurements, visceral adiposity is greater in PCOS subjects compared to controls, 
even when matched by BMI.  
 
3.9.1.2 Hyperandrogenism 
 
Total testosterone and, to a lesser extent, androstenedione levels were greater in the 
PCOS group compared to controls but these levels did not reach statistical 
significance. Clinical signs of hyperandrogenism were noted for each patient but the 
use of validated assessment tools, such as the Ferriman-Gallwey scale to evaluate 
hirsutism, were not employed. This highlights the heterogeneity of PCOS and the wide 
range of phenotypes as encompassed by current diagnostic criteria. In my study I used 
the Rotterdam criteria to diagnose PCOS, and according to these criteria, androgen 
excess may be defined by clinical symptoms of hyperandrogenism and /or elevated 
testosterone/androstenedione levels [Rotterdam Group 2004]. This could explain why 
the testosterone and androstenedione levels were not significantly higher in my patient 
group. In addition, a lack of difference in testosterone levels may have been due to 
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inadequate statistical power since my sample size calculations were powered for the 
primary outcome measure (BOLD fMRI signal change in the brainstem). 
 
3.9.1.3 Dyslipidaemia 
 
The findings from my study cohort are in keeping with previous reports, in that the 
PCOS group had higher serum triglyceride levels compared with controls [Ollila 2015], 
The findings from my small group of patients with PCOS concur with this lipid pattern 
which may be an effect of central adiposity rather than the syndrome per se. 
 
3.9.1.4 Insulin sensitivity 
 
In the PCOS group markers of insulin resistance (fasting insulin, insulin AUC, HOMA-
IR and Matsuda index) tended to be more than controls, although none of these were 
statistically significant. Again, this may be a reflection of how PCOS was defined, 
whereby the Rotterdam criteria (which embrace a less severe metabolic phenotype) 
were used to establish the diagnosis. A recent cross-sectional multicentre study of 
over 2000 women with PCOS showed that those with hyperandrogenic PCOS (53% 
of total) presented with a worse cardiometabolic profile and a higher prevalence of 
cardiovascular risk factors, such as obesity and overweight, insulin resistance, and 
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metabolic syndrome, compared with women with non-hyperandrogenic PCOS. [Daan 
2014]. In my study, the PCOS patients recruited had relatively mild biochemical 
hyperandrogenism which may have been one reason why the measures of insulin 
sensitivity were not significantly different between groups. 
 
Another important reason why no significant difference in insulin sensitivity was noted 
between groups may be related to the way insulin resistance was measured. Fasting 
glucose, 2-hour glucose, HOMA-IR, insulin AUC and glucose AUC calculated and 
these parameters measure whole body insulin sensitivity rather than specifically 
peripheral insulin sensitivity. The insulin resistance in PCOS has been shown to be 
more of a defect in insulin signal transduction in peripheral muscular tissue [Courbold 
2005] which is more accurately detected using the euglycaemic hyperinsulinaemic 
clamp technique.  
 
I also noted a strong correlation between WHR and insulin resistance (as defined by 
insulin AUC) across all subjects, which would suggest that greater visceral adiposity 
is associated with increased insulin resistance. Similarly, in PCOS, it has been shown 
that central obesity is associated with higher fasting insulin levels [Lim 2013]. Indeed, 
the risk of type 2 diabetes steadily increases with BMI and is particularly high for BMI 
over 30kg/m² [Moran 2010, Morgan 2012, Pasquali 2013]. 
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3.9.1.5 Arterial Stiffness 
 
Using the Vicorder device, augmentation pressure, augmentation index and aortic 
pulse wave velocity were not different between the PCOS group and controls. 
Augmentation Index (AI) and aortic pulse wave velocity (aPWV) are both measures of 
arterial stiffness and previous studies in young women with PCOS have been 
discordant. A number of studies have supported increased arterial stiffness in PCOS 
[Meyer 2005, Soares 2008, Trakakis 2008] while others have shown no difference to 
controls [Muneyyirci-Delale O 2007, Ketel 2010, Rees E 2014]. Our group have 
recently shown that central obesity and insulin resistance are independently 
associated with arterial stiffness, but not PCOS per se [Rees 2014].  
 
It is noteworthy that arterial stiffness in this study was similar in both groups at 
baseline, although it should be remembered that the study was not powered to reveal 
differences in vascular function and this was not a major outcome measure for the 
study population. 
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3.9.1.6 Obstructive sleep apnoea 
 
The prevalence of obstructive sleep apnoea (OSA) may be increased in PCOS 
compared to controls, and associated with insulin resistance, glucose intolerance and 
increased sympathetic activation [Fogel 2001, Tasali 2008, Grassi 2005b]. The sleep 
studies in the 19 subjects showed no difference in apnoea-hypopnoea index (AHI) 
between groups and no subject had evidence of sleep apnoea (as defined by ≥5 
events /hr). However, these studies were only in a subgroup of the total study 
population, with small numbers especially in the PCOS group so it is therefore difficult 
to make any meaningful interpretations. It does confirm, however, that there were no 
subjects of the 19 who had sleep apnoea, which may have been a confounding factor 
when measuring sympathetic activation.  
 
It is interesting that there was an association with increasing WHR and AHI across this 
subgroup. This is as would be expected, with previous studies showing that WHR is 
the most reliable correlate of OSA in both sexes [Sharma 2004, Lim 2014]. 
Unfortunately neck circumference was not measured in my study, which correlates 
well with the risk of sleep apnoea, and this may have been a simple alternative to 
employing formal sleep study techniques [Kapur VK 2010]. 
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3.9.2  SNS Activation in PCOS 
 
3.9.2.1 Haemodynamic response to IFC 
 
Baseline blood pressure and heart rate was measured for both PCOS (n=19) and 
controls (n=19). No difference was found between the groups, and all participants were 
confirmed to be normotensive. This was expected as any subject with a personal 
history of hypertension was excluded from the study, with only normotensive 
participants enrolled. 
 
Following 30% IFC sustained for 3 minutes, a significant increase in HR and MAP was 
seen for all participants (p<0.001). The percentage increase in HR, SBP, DBP and 
MAP was greater in the PCOS group compared to controls but this did not reach 
statistical significance.  
 
These results contrast with Saranya et al, who found that the baseline heart rate, 
diastolic and systolic blood pressures of the PCOS cases were significantly higher 
than controls, and that there was a significantly greater rise in diastolic blood pressure 
following IFC in the PCOS group. However, in their study the two groups were not 
matched by BMI and the PCOS group had a significantly higher BMI compared to 
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controls. Fasting plasma glucose and testosterone levels were also significantly higher 
in the PCOS group and might also explain why differences in cardiovascular 
parameters were seen in their study and not in mine [Saranya 2014]. 
 
In addition blood pressure rise is a crude end-point measurement of physiological 
pathways and does not directly measure sympathoexcitation.   
 
3.9.2.2 Catecholamines 
 
Plasma catecholamines (adrenaline and noradrenaline) were measured at baseline in 
both groups and no difference was found. Following IFC there was a significant rise in 
plasma adrenaline concentrations for both groups, but no change in noradrenaline 
concentrations. The plasma adrenaline level rise following IFC was significant in the 
PCOS group (p<0.001) but not in the control group (p=0.14). When expressed as a 
percentage increase in adrenaline levels from baseline to post-IFC, there was no 
difference between the groups. 
 
There are a number of points that merit consideration here. First, the plasma 
catecholamine assay is not considered a ‘gold-standard’ measure of sympathetic 
activation, hence results should be interpreted with caution. Plasma noradrenaline 
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concentrations offer limited sensitivity, are not reproducible and are unable to 
distinguish between increased central catecholamine production and decreased 
clearance [Grassi 1999]. Also the noradrenaline concentrations in our study were 
derived from antecubital fossa sampling, reflecting venous drainage from the forearm 
alone.  
 
Second, it is interesting that there was a significant rise in plasma adrenaline 
concentrations for the whole group following IFC but not in noradrenaline. A rise in 
plasma noradrenaline levels, rather than adrenaline levels, may therefore have been 
expected, but this was not seen. It is difficult to explain why this was so, although one 
reason may be the ELISA kits used for analysis which were initially stored under 
suboptimal conditions, which may have affected the accuracy of the results obtained.  
 
Our results do concur, however, with Garcia-Rudaz et al, who  found that in the resting 
state, plasma adrenaline and noradrenaline levels were similar in patients with PCOS 
and controls  [Garcia-Rudaz 1998]. 
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3.9.2.3 MSNA 
 
Resting MSNA 
 
MSNA was recorded in a subgroup of 14 subjects (7 PCOS and 7 controls); baseline 
burst frequency (BF) and burst incidence (BI) were not different between the two 
groups. Only two other studies have compared MSNA at rest in PCOS versus controls 
and both have demonstrated elevated MSNA compared to controls [Sverisdottir 2008, 
Lambert 2015]. Sverrisdόttir et al showed that resting BF and BI was significantly  
higher in PCOS compared to controls [Sverisdottir 2008] and Lambert et al found a 
significantly higher resting BI in PCOS versus controls [Lambert 2015]. In my study, 
resting BF was 26.5 bursts/min in PCOS and 31.6 bursts/min in controls (p=0.16), and 
BI 37.0 bursts /100 heartbeats in PCOS and 44.1 bursts /100 heartbeats in controls 
(p=0.19). It is noteworthy that the resting MSNA BF and BI in our study were higher in 
the control group than in these two previous studies. 
 
There may be several reasons for these observations. First, it may relate to the case 
and volunteer selection. In Sverrisdόttir’s study PCOS women were defined by the 
Rotterdam criteria, as with our study, but had significant evidence of 
hyperandrogenism and insulin resistance compared to their control group. In 
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Lambert’s study, the PCOS population was similarly recruited according to the 
Rotterdam criteria and showed evidence of significant biochemical hyperandrogenism 
compared to controls, although there was no difference in measures of insulin 
sensitivity between groups. In my study population, the PCOS group were defined by 
the Rotterdam criteria but were not strongly hyperandrogenic, although the subgroup 
that underwent MSNA were significantly more insulin resistant than age and BMI-
matched controls.  
 
In contrast to the other two studies mentioned, my observations were made only in a 
small subgroup, compared with much larger numbers in their studies. It is therefore 
potentially difficult to draw any firm conclusions from these data. Furthermore, there 
are a number of other factors that affect resting MSNA in individuals which may have 
confounded results, including age, gender and BMI [Ng 1993, Scherrer 1994]. In 
addition, timing of the menstrual cycle is important as has been observed that SNS 
activity is highest during the mid-luteal phase of the ovulatory cycle, during which 
oestrogen and progesterone levels are high, and SNS activity falls during the early 
follicular phase at which time oestrogen and progesterone levels have fallen [Minson 
2000]. This was not taken into account when recordings were made. 
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Post-exercise MSNA 
 
Our subgroup underwent sustained IFC at 30% for 3 minutes and it was observed that 
BF and BI increased significantly in the PCOS group but not in controls. Comparing 
groups, there was a greater percentage increase in BF in the PCOS group of 68.0% 
from baseline as compared to an 11.9% increase in controls (p=0.002). The 
percentage increase in BI in PCOS group was 55.4% compared to 20.5% in controls 
but this was not significantly different. 
 
These findings suggest that there was an augmented sympathetic response to static 
exercise in PCOS compared to controls. To my knowledge, mine is the first study to 
observe the effect of static exercise on MSNA response in subjects with PCOS. 
 
Previous studies have sought to examine the autonomic neural control of the 
cardiovascular system in response to exercise in PCOS [Teikin 2008]. Giallauria et al 
compared heart rate recovery [HRR] after a cardiopulmonary exercise test in 75 young 
overweight women with PCOS with 75 age and BMI-matched healthy volunteers 
[Giallauria 2008]. Women with PCOS showed reduced HRR compared to healthy 
controls, which correlated inversely with BMI and insulin sensitivity but not with 
testosterone. 
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More specifically, IFC has been used in women with PCOS as a static SNS exercise 
stimulus but never with the MSNA response measured. In the study by Sarayna et al 
findings similarly suggested an exaggerated sympathetic response in patients with 
PCOS in response to IFC [Saranya 2014]. Other studies have also used IFC as an 
SNS stimulus and recorded the MSNA response. From those studies, an augmented 
blood pressure and MSNA response has also been seen in subjects with type 2 
diabetes [Petrofsky 2005, Holwerda 2016] and hypertension [Sausen 2009, Delaney 
2010] but not in the metabolic syndrome [Limberg 2014] or obesity [Negrao 2001].  
 
It is interesting that there was a significant rise in BF in response to IFC but not in BI 
in the PCOS as compared to controls in my study. This may reflect an increase in 
heart rate in the PCOS group that was greater than the controls, meaning the rise in 
bursts per 100 heartbeats (‘burst incidence’) was not as significant in the PCOS group 
compared to controls.  
 
Unlike some other studies using IFC, we did not have a post-exercise ischaemia (PEI) 
aspect to our IFC experiment, so it is not possible to infer any mechanisms 
underpinning the increased MSNA seen in our PCOS group. There is no way of 
delineating if the mechanoreflex or metaboreflex (or indeed both) were increased in 
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the PCOS group compared to controls, only to conclude that there was a difference 
seen post-static exercise. 
 
3.9.2.4 Potential mediators 
 
Having observed that there was a significant increase in MSNA burst frequency in the 
PCOS group compared to controls (p=0.002), it is of interest to consider any potential 
mediators contributing to this difference. 
 
In the PCOS group, there was no correlation between the increase in burst frequency 
and either BMI, WHR, insulin sensitivity measures, testosterone levels or AHI levels. 
There are only two other published MSNA studies of PCOS subjects versus controls 
to-date, as I have discussed earlier, neither of which used a SNS-stimulus task but 
both measured resting activity alone. Sverrisdόttir’s study showed a positive 
correlation of MSNA with total and free testosterone and suggested that the degree of 
sympathoexcitation relates to the degree of biochemical hyperandrogenism 
[Sverrisdottir 2008]. In contrast, Lambert’s study described an absence of a 
relationship between MSNA and testosterone, not supporting the hypothesis that 
hyperandrogenism is related to the elevated sympathetic tone. However, there was a 
strong relationship between MSNA and insulin concentration as well as with HOMA-
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IR, which remained after controlling for the presence of PCOS, which suggested that 
the degree of sympathetic activation may not be explained by obesity or insulin 
resistance alone [Lambert 2015]. In my study, the sample size was much smaller and, 
as discussed, there was no baseline difference between the two groups in terms of 
testosterone levels but there was a difference in terms of insulin AUC in the MSNA 
subgroups, although this did not correlate with BF.   
 
When considering the other measures of SNS activation that showed no difference 
between groups (catecholamines, HR and BP changes), there was a correlation noted 
between percentage MAP rise and BMI (p=0.012) and WHR (p=0.002) across all 
subjects. This contrasts with Negrão’s study, which compared the MSNA response to 
IFC in 40 young normotensive obese women and 15 age-matched normotensive lean 
women. They found that the MSNA response was blunted in the obese women 
[Negrao 2001]. Although it is known that increased adiposity correlates with 
sympathetic overactivity at rest [Alvarez 2002, Grassi 2004, Sivenius 2003], my data 
suggest that during IFC there is also a strong correlation between the MAP pressor 
response and the degree of obesity. 
 
Furthermore, when considering all subjects, there was a positive correlation between 
insulin AUC and percentage rise in MAP (r=0.439, p=0.007) which agrees with the 
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work of Holwerda et al. Although they studied patients with established type 2 diabetes 
and IFC, they noted an augmented pressor response that significantly correlated with 
fasting glucose, HbA1c and HOMA-IR [Holwerda 2016].  
 
Finally there was a positive correlation for all subjects between the apnoea-hypopnoea 
index (AHI) and resting MSNA BF, r = 0.66, p = 0.05. Again this finding stands with 
previous evidence, that OSA may be associated with increased MSNA, independently 
of body weight [Grassi 2005b] 
 
To summarise, for the difference seen in BF increase post-exercise, no potential 
mediators were identified to explain this difference. For rise in MAP, there was a 
positive correlation with BMI, WHR and insulin AUC for all subjects, suggesting they 
may play a role in the pressor response. Finally, for all subjects, the established 
correlation between resting MSNA and AHI was noted in my study, strengthening the 
link between OSA and SNS activation. 
 
3.9.3  Influence of PCOS phenotype 
 
Although evidence has suggested that the classic hyperandrogenic PCOS phenotype 
has an increased risk of cardiometabolic dysfunction compared to the non-
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hyperandrogenic group [Daan 2014, Moran 2015, Fauser BC 2012, Ehrmann D 2005] 
the current study did not find this. The only significant difference was the Matsuda 
index was actually significantly higher in the hyperandrogenic group compared with 
the non-hyperandrogenic group. There were no differences in the haemodynamic or 
sympathetic changes between these groups.  It is difficult to draw any meaningful 
conclusions from these findings as the study was not powered to look at such 
differences and only 5 out of 20 subjects had biochemical evidence of 
hyperandrogenism. This, in turn, relates back to the weakness in how PCOS was 
defined in the study and the lack of classic phenotypic PCOS patients recruited.  
 
3.9.4  Strengths and limitations 
 
Strengths of the current study were that both groups were well-matched for age and 
BMI. Also a wide range of measures used to assess sympathetic tone and activation 
in the study population. Although no ‘gold-standard’ is available, a combination of 
haemodynamic, catecholamine and microneurography techniques were used to 
capture SNS activation. This study was also the first to study the MSNA response to 
IFC in women with PCOS. 
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Several limitations have been highlighted. The current cohort recruited for the PCOS 
group was based upon the Rotterdam criteria. As has been discussed, this 
encompasses a broader phenotype, including a less androgenic and less insulin 
resistant group of patients, as seen in our study population. Therefore, the NIH 1990 
or AE-PCOS 2009 criteria for diagnosing PCOS could have been used to better define 
a more hyperandrogenic, insulin-resistant group of patients for inclusion in the study. 
In addition, the way body composition and visceral adiposity were measured using 
WHR and BMI alone was a potential weakness. The value of WHR as a reflection of 
visceral adiposity has been debated, with some evidence suggesting it is inaccurate 
[Busetto 1992, Joy 2009] More objective measures, such as single-slice CT abdomen, 
MR abdomen, or dual energy x-ray absorptiometry (DEXA) may therefore have 
potentially been more accurate ways to record visceral adiposity [Kvist 1988, Kullberg 
2007, Yoon DY 2008, Kaul 2012]. Alternatively, Bioelectrical impedance analysis (BIA) 
could have been used as a simple tool to assess body composition [Lee SY 2008]. 
Another limitation was the way insulin sensitivity was assessed in the study population. 
We assessed total body insulin sensitivity using a standard 75-g OGTT but the ‘gold-
standard’ test to more accurately assess peripheral insulin resistance, as seen in 
PCOS, would have been using a euglycaemic hyperinsulinaemic clamp technique to 
calculate the ISI. 
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Furthermore, there were confounders, including cigarette smoking, alcohol 
consumption and menstrual cycle phase not accounted for when measuring 
sympathetic activity. Also, although the total sample size was reasonable, the group 
that underwent microneurography was small (n=14) and therefore the findings from 
this subgroup, although of interest, may lack power. Furthermore, circulating 
catecholamines were measured but these offer limited sensitivity. In addition the 
haemodynamic changes were measured using an automatic, non-invasive, oscillatory 
sphygmomanometer and a device to measure continuous heart rate and blood 
pressure changes throughout the paradigm could have been used to more accurately 
monitor the haemodynamic changes.  
 
3.10  CONCLUSION 
 
In conclusion, my study has shown that women with PCOS had increased central 
adiposity and hypertriglyceridaemia compared to age- and BMI-matched controls. 
However, I was unable to show a statistically significant increase in insulin resistance 
or biochemical hyperandrogenism. Vascular function and AHI were also similar in both 
groups, and no subjects (of those screened) had evidence of OSA.  
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When studying SNS responses, there was no significant difference in resting or post-
excitatory haemodynamic or catecholamine responses in PCOS subjects compared 
to the control group (with the exception of a post-IFC rise in adrenaline). In the 
subgroups that underwent microneurography, there was no difference in resting 
sympathetic tone between groups. However, after IFC there was a significantly greater 
increase in burst frequency in the PCOS group compared to controls. Of note, the 
PCOS subgroup that was studied was more insulin resistant than the controls, with a 
higher insulin AUC (p = 0.03).  
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CHAPTER 4 
 
IDENTIFICATION OF 
HIGHER BRAIN CENTRES 
ASSOCIATED WITH SNS 
ACTIVATION 
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The higher regional brain centres involved in sympathoexcitation in PCOS are 
unknown. Imaging studies in humans without PCOS have highlighted higher cortical 
centres associated with sympathetic activation and blood pressure control, including 
the dominant anterior cingulate, postcentral gyrus, cerebellum, insular cortex and 
orbitofrontal cortex [Critchley et al 2000, Kramer 2014]. In addition, fMRI work by 
Coulson et al has identified BOLD signal change in the ventrolateral medulla 
associated with blood pressure rise induced by IFC [Coulson JM 2015].  
 
The main aim of this chapter is to report any BOLD fMRI signal activity in the brainstem 
and higher brain structures associated with SNS activation in women with PCOS 
compared with age- and BMI-matched controls. 
 
First the BOLD signal change associated with blood pressure variation will be 
presented, followed by the changes associated with both IFC motor activation and the 
visual stimulus. The influence of other factors (testosterone, insulin sensitivity and 
BMI) will then be reported, followed by a final discussion of the findings.  
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4.1  BASELINE ANTHROPOMETRIC AND METABOLIC 
CHARACTERISTICS 
 
40 subjects (20 PCOS, 20 controls) underwent fMRI scanning according to the 
protocol as outlined in chapter 2, section 2.8.5. All subjects completed the 12-minute 
block paradigm as shown in Figure 2.3, chapter 2. The analysis for the motor activation 
(section 4.3) and visual activation (section 4.4) was based upon 40 fMRI scans and 
the group differences between 20 PCOS fMRI scans and 20 control fMRI scans.  
 
The baseline anthropometric and metabolic characteristics of the 40 subjects recruited 
(20 PCOS and 20 healthy volunteers) are outlined and described in chapter 3, section 
3.1. 
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4.2  HAEMODYNAMIC RESPONSE 
 
4.2.1  Subgroup baseline characteristics 
 
In a subgroup of 30 subjects (15 PCOS and 15 controls), the 12-minute IFC paradigm 
(Figure 2.3) was performed out-of-scanner with BP and HR recordings made every 30 
seconds. In the remaining 10 subjects, either due to equipment failure, time constraints 
or subject intolerance, these data were not collected. 
 
The baseline characteristics of the subgroup of 15 PCOS and 15 controls are shown 
in table 4. 
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Table 4.1 
Baseline characteristics of the haemodynamic response study population. 
Results are expressed as mean ± SD. P<0.05 is considered statistically 
significant 
 PCOS (n=15) Control(n=15) P value 
Age (yrs) 30.7 ± 4.9 29.1 ± 4.8 0.37 
BMI (Kg/m²) 24.7 ± 3.8 25.7 ± 4.4 0.98 
WHR 0.86 ± 0.05 0.85 ± 0.04 0.35 
Testosterone 
(nmol/L) 
1.5 ± 0.9 1.1 ± 0.5 0.11 
Androstenedione 
(nmol/L) 
4.8 ± 3.3 3.7 ± 1.4 0.24 
HOMA-IR 1.2 ± 0.8 0.9 ± 0.4 0.21 
Matsuda index 9.8 ± 6.0 11.9 ± 6.2 0.39 
Insulin AUC 
(pmol min/L) 
47627.00 ± 
31127.28 
32948.57 ± 
19214.23 
0.14 
Glucose AUC 
(mmol min/L) 
743.90 ± 
250.44 
689.89 ± 
243.27 
0.56 
Resting HR 
(beats/min) 
71.9 ± 9.7 71.4 ± 7.7 0.89 
Resting SBP 
(mmHg) 
113.4 ± 8.9 116.9 ± 13.7 0.43 
Resting DBP 
(mmHg) 
62.6 ± 13.6 63.7 ± 14.7 0.85 
Resting MAP 
(mmHg) 
79.6 ± 11.1 82.7 ± 10.7 0.45 
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4.2.2  Subgroup pressor and catecholamine responses 
 
The HR, BP and plasma catecholamine responses to IFC for the subset of 15 PCOS 
and 15 controls are shown in table 4.2. There was no statistically significant difference 
in the HR, MAP or plasma catecholamine change pre- and post-IFC between the 
PCOS and control groups. 
 
In the PCOS group, 5/15 had biochemical evidence of hyperandrogenism but there 
were no differences in their HR, BP or plasma catecholamine responses to IFC. 
Table 4.2 
Changes in HR, MAP and plasma catecholamines pre- and post-IFC for the 
PCOS and control groups. Results are expressed as mean ± SD. P<0.05 is 
considered statistically significant 
 
Parameter Group Pre-IFC Post-IFC P value 
HR 
(beats/min) 
PCOS 71.9 ± 9.7 76.9 ± 9.0 <0.05 
Control 71.4 ± 7.7 75.3 ± 7.5 <0.05 
MAP (mmHg) PCOS 79.6 ± 11.1 89.3 ± 13.1 <0.05 
Control 82.7 ± 10.7 90.8 ± 9.8 <0.05 
Adrenaline 
(ng/mL) 
PCOS 0.8 ± 0.5 1.4 ± 0.7 0.001 
Control 0.6 ± 0.6 0.9 ± 0.5 0.295 
Noradrenaline 
(ng/mL) 
PCOS 21.2 ± 10.4 19.1 ± 9.6 0.29 
Control 23.3 ± 14.1 20.9 ± 12.7 0.235 
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4.2.3  Blood Pressure Model 
 
Using the blood pressure recordings from every 30 seconds during the paradigm, 
haemodynamic BP response curves were produced in Matlab (MathWorks, Natick, 
USA) for the 12-minute period based upon the mean arterial pressure (MAP). An 
example is shown in Figure 4.1. The text file for each individual subject was used as 
a blood pressure regressor in their individual Feat analyses using a Double-Gamma 
HRF convolution.  
Figure 4.1 
Mean blood pressure plots for PCOS and controls during 12-minute paradigm  
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4.2.4  BOLD response 
 
The change in BOLD signal intensity that fitted the modelled blood pressure responses 
showed activation in the PCOS group in the right cerebral cortex, right pallidum, right 
thalamus and right parietal operculum cortex (p<0.0001) and control group in the 
intracalcarine cortex and  lingual gyrus (p=0.003). BOLD signal activation was greater 
in the PCOS group versus controls in the right orbitofrontal cortex (p<0.0001), left 
angular gyrus and lateral occipital cortex (p=0.04) (Figure 4.2(a) and (b)). The MNI co-
ordinates of the peak responses for each of these are shown in table 4.3. 
 
Table 4.3 
MNI co-ordinates of the peak responses for the BOLD activation greater in the 
PCOS group versus controls 
 
Cluster 
region 
X (mm) Y (mm) Z (mm) p-value 
Right 
orbitofrontal 
cortex 
16 8 -24 <0.0001 
Left angular 
gyrus /Lateral 
occipital 
cortex 
-48 -60 20 0.04 
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Figure 4.2 (a) 
BOLD signal activation (modelled for blood pressure) greater in PCOS (n=15) 
versus controls (n=15) in the right orbitofrontal cortex. The significant region 
is displayed with a threshold of Z>2.3, with a cluster probability threshold of 
p<0.05 
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Figure 4.2 (b) 
BOLD signal activation (modelled for blood pressure) greater in PCOS (n=15) 
versus controls (n=15) in left angular gyrus and lateral occipital cortex. The 
significant region is displayed with a threshold of Z>2.3, with a cluster 
probability threshold of p<0.05 
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4.3  MOTOR ACTIVATION 
 
The scan was undertaken as outlined in chapter 2, section 2.8.5. An in-house 
pneumatic handgrip device was positioned in the dominant hand and connected to a 
pressure transducer. Subjects followed visual instructions presented on the screen as 
to the rest and squeeze periods, with a target bar showing when 30% IFC squeeze 
had been achieved. Subjects performed the block paradigm (chapter 2, Figure 2.3) on 
two occasions with time to rest between the runs. The ‘squeeze’ pattern for each 
individual was saved as a text file and used in each of the Feat analyses for each 
individual. 
 
The significant area of BOLD signal change occurred in the left cerebral white matter 
in the PCOS group (p<0.0005), and left cerebral white matter in the control group 
(lingual gyrus, temporal fusiform cortex posterior division) (p<0.0005) (Figure 4.3 (a) 
and (b)). There was no statistically significant difference in the areas of BOLD signal 
in motor activation when comparing groups. 
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Figure 4.3(a)  
BOLD activation in the PCOS group (n=20) in left cerebral white matter during 
IFC. Significant region displayed with a threshold of Z>2.3, with a cluster 
probability threshold of p<0.05 
 
 
 
 
 
 
 
 
 
144 
 
Figure 4.3(b)  
BOLD activation in the control group (n=20) in left cerebral white matter during 
IFC. Significant region displayed with a threshold of Z>2.3, with a cluster 
probability threshold of p<0.05 
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4.4  VISUAL ACTIVATION 
 
The experimental protocol included visual stimuli in the form of a flashing check-board 
(2Hz lasting 15s) that appeared twice at the end of both rest periods shown in Figure 
2.3, chapter 2, i.e. at 6 minutes 15 seconds and  11 minutes 45 seconds. A text file 
was used for each subject in the Feat analysis with these two 15 second visual stimuli 
as a regressor. 
 
The visual stimulus increased BOLD signal in the occipital cortex in both groups. In 
the PCOS group, the BOLD signal peak was in the lateral occipital cortex (cluster 
p<0.0005) and in the control group, the occipital pole (cluster p<0.0005) (Figure 4.4(a) 
and (b)). There was no significant difference in areas of BOLD signal activation during 
visual stimulus when I compared the two groups. 
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Figure 4.4(a)  
BOLD activation during visual stimulus in the PCOS group (n=20). Significant 
region displayed in lateral occipital cortex with a threshold of Z>2.3, with a 
cluster probability threshold of p<0.05 
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Figure 4.4(b)  
BOLD activation during visual stimulus in the control group (n=20). Significant 
region displayed in occipital cortex pole with a threshold of Z>2.3, with a 
cluster probability threshold of p<0.05 
 
 
 
4.5  INFLUENCE OF METABOLIC PARAMETERS 
 
4.5.1  Testosterone and Insulin Sensitivity 
 
The BOLD signal change modelled for haemodynamic response was accounted for 
variance associated with testosterone, using testosterone as a covariate at the group 
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level. BOLD activation in the right orbitofrontal cortex was still greater in the PCOS 
group as compared to controls (p<0.0001) (as shown in Figure 4.2(a)). 
 
When the BOLD signal was separately corrected for insulin sensitivity using HOMA-
IR, the BOLD signal in the right orbitofrontal cortex in the PCOS compared to the 
control group was no longer significant but the left angular gyrus and lateral occipital 
cortex remained significant. 
 
4.5.2  BMI  
 
In order to examine the effect of BMI alone on the BOLD signal change for the 
haemodynamic response, I combined the PCOS and controls into one group. These 
30 subjects with data available for the haemodynamic response model were 
subdivided into a normal BMI group (BMI ≤25Kg/m²) or overweight-obese group 
(BMI>25Kg/m²). 13 subjects were in the overweight-obese group and 17 in the normal 
BMI group. The mean BMI in the normal group was 22.5 ± 1.3Kg/² versus 29.1 ± 3.5 
Kg/m² in the overweight-obese group (p<0.005), with mean ages of 29.7 ± 3.8 yrs and 
30.1 ± 6.1 yrs (p=0.84) respectively. Insulin AUC and HOMA-IR were greater in the 
overweight-obese group compared to normal BMI group, but the difference was not 
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significant (47707.50 ± 34599.11 vs 35482.06 ± 18882.62pmol min/L, p=0.23 and 1.14 
± 0.71 vs 0.94 ± 0.59, p=0.40). 
 
BOLD signal activation was greater in the brainstem in the normal BMI group as 
compared to controls (p=0.009), shown in Figure 4.5. When this was corrected for 
HOMA-IR, this difference between groups did not persist.  
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Figure 4.5 
BOLD activation (modelled for blood pressure) greater in normal BMI group 
(n=17) compared to overweight-obese group (n=13) in the brainstem. The 
significant region is displayed with a threshold of Z>2.3, with a cluster 
probability threshold of p<0.05 
 
 
 
 
4.6  INFLUENCE OF PCOS PHENOTYPE 
 
As there were no differences in the blood pressure responses to IFC between the 
hyperandrogenic (H) and non-hyperandrogenic (non-H) groups, it did not seem valid 
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to analyse the BOLD fMRI responses to IFC and modelled blood pressure responses 
according to these subgroups. 
 
4.7  DISCUSSION 
 
4.7.1  Brain activity correlating with blood pressure variation 
 
For a subset of 30 subjects (15 PCOS and 15 controls), matched by age and BMI, the 
key finding was that in response to the modelled blood pressure changes, BOLD signal 
activity was observed in the right cerebral cortex, right pallidum, right thalamus and 
right parietal operculum cortex in the PCOS group (p<0.0001), and in the control group 
in the intracalcarine cortex and lingual gyrus (p=0.003). Furthermore, BOLD signal 
activation was greater in the PCOS group versus controls in the right orbitofrontal 
cortex (p<0.0001), left angular gyrus and lateral occipital cortex (p=0.04). 
 
This is the first study to use BOLD fMRI to identify any higher brain structures or 
brainstem correlating with modelled blood pressure responses to an IFC task in 
PCOS. Although other studies have examined the pressor response to IFC in PCOS 
[Saranya 2014], no reported studies have sought to locate areas of central command 
associated with this reflex in PCOS. 
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The role of central command in the pressor response to muscle contraction, and the 
metaboreflex, has been of increasing interest. The insular cortex and anterior cingulate 
cortex are two such regions that have been strongly implicated in this from a number 
of studies [Williamson 2003, Williamson 1997, Critchley 2000(b)]. Williamson et al. 
used single-photon emission computed tomography (SPECT) to demonstrate that 
during 3 minutes of IFC, followed by 100 seconds of PEI, that there was a marked 
increase in blood flow in the sensorimotor cortex, left anterior insular cortex, and 
anterior cingulate cortex during the contraction phase, and in the sensorimotor and 
right anterior insular cortex during the period of post-exercise ischaemia (PEI). There 
were no changes noted within the brain stem [Williamson 2003].  
 
Other studies have suggested a role of the brainstem and areas of the cerebral cortex 
in blood pressure control. Critchley et al used PET scanning to correlate the rise in 
MAP from mental stressor tasks and physical exercise to areas of localised increased 
cerebral blood flow. They found that these areas included the dominant anterior 
cingulate, postcentral gyrus, cerebellum, insular cortex and orbitofrontal cortex 
[Critchley et al 2000].  
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My study strengthens these findings, and highlights areas of the cerebral cortex 
involved in the pressor response to IFC. In particular, it shows areas of differential 
activation in PCOS versus healthy volunteers.  
 
Our findings suggest activation of the right cerebral cortex, right pallidum, right 
thalamus and right parietal operculum cortex in the PCOS group. It is not known why 
there was activation in the ipsilateral cerebral cortex during the IFC task, but these 
BOLD signal changes concur with changes seen in previous studies in the 
sensorimotor cortex [Wong SW 2007a, Wong SW 2007b, Sander 2010] and thalamus 
[Gianaros 2005]. In addition, the parietal operculum cortex covers the insular and lies 
proximal to the insular cortex which, as has been mentioned, has significant evidence 
to support its central role in the pressor response to IFC [Williamson 2003, Williamson 
1997, Critchley 2000(b), Wong SW 2007a, Wong SW 2007b, Sander 2010, Nagai 
2010].  
 
In the control group the intracalcarine cortex and lingual gyrus showed significant 
increase in BOLD signal during the pressor response to IFC. These regions are in the 
visual cortex and have a role in vision and word processing. Neither of these regions 
have been directly implicated in the pressor response previously. One possible reason 
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may be that participants were doing a visual task with the squeeze, i.e. looking at the 
target bar on the screen to see when 30% IFC had been achieved. 
 
When both groups in my study were compared, there was significantly greater BOLD 
signal activation in the PCOS group compared to controls in the right orbitofrontal 
cortex, left angular gyrus and lateral occipital cortex. The left angular gyrus and lateral 
occipital cortex have not been reported previously as having a central role in the 
pressor response to IFC. The angular gyrus is usually associated with complex 
language functions and the lateral occipital cortex with human object recognition. It 
could be that these findings are false positives. The orbitofrontal cortex, however, has 
been identified as an area of significance. 
 
In a previous fMRI study of 16 participants that used a behavioural stressor to induce 
systolic blood pressure rises, the orbitofrontal cortex was a region activated during 
these changes, along with the anterior cingulate, insula, posterior parietal, and the 
dorsolateral prefrontal regions of the cortex, the thalamus, and the cerebellum 
[Gianaros 2005]. Furthermore Harper et al used fMRI in healthy volunteers to report 
increased activity of the orbitofrontal cortex, amygdalo-hippocampal complex, 
hypothalamus and cerebellum during hypertension elicited by cold pressor stimuli and 
performance of the Valsalva manoeuvre [Harper 1998], also suggesting a central role 
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of the orbitofrontal cortex in SNS activation and blood pressure regulation. More 
recently Krāmer et al investigated the central regions involved in baroreflex regulation 
using MSNA in 15 healthy men in PET experiments. MSNA was measured at rest and 
baroreflex unloading, induced by lower body negative pressure (LBNP). As compared 
with the control condition, LBNP was associated with increased PET regional glucose 
metabolism bilaterally in the orbitofrontal cortex. Related to the rise of MSNA burst 
frequency there was increased activation of the left orbitofrontal cortex and related to 
the rise of burst incidence there was increased activation of the brainstem 
corresponding to the rostral ventrolateral medulla. This led to their reasoning that there 
is a role for the ventrolateral medulla and the orbitofrontal cortex in baroreflex-
mediated control of MSNA in humans [Kramer 2014]. 
 
It is important to question why no brainstem activation was noted in the PCOS or 
control group during the IFC task. In Coulson’s study 12 young adults underwent 
BOLD fMRI, performing IFC at 40% of maximum grip, showing a significnat increase 
in MAP and a correlating brainstem BOLD signal change localised to the ventrolateral 
medulla [Coulson 2015]. Similarly other studies discussed have shown areas of BOLD 
signal activation localised to the brainstem and specifically the rostral ventrolateral 
medulla [Sander 2010, Macefield 2009, Wong SW 2007a, Wong SW 2007b]. These 
findings sit with the known role of the RVLM in cardiovascular regulation and control. 
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There may be several reasons why no brainstem activity was found in our cohort. First, 
the scans were corrected for physiological noise (heart rate and respiratory volume 
per time) in only a proportion of cases, as the physiological data collected during 
scanning was only recorded for 5 of the 30 participants. Therefore, physiological 
factors (respiration, cardiac output, etc) may have caused more noise in the data and 
affected the brainstem analysis. In addition, the blood pressure data used as an input 
in the Feat analysis was derived from the IFC task performed out-of-scanner. 
Moreover, we could also only measure blood pressure every 30 seconds (rather than 
a continuous tracing) and therefore the blood pressure regressor may not have 
accurately reflected the actual pressor response during the scan sessions. Related to 
this, blood pressure changes were used to map BOLD signal changes, whereas 
MSNA responses (ideally ‘in-scanner’ recordings) from subjects would have better 
helped to identify brainstem areas associated with sympathetic outflow. 
 
4.7.2  Potential mediators 
 
When the BOLD signal change modelled for haemodynamic response was corrected 
using testosterone as a covariate. BOLD activation in the right orbitofrontal cortex was 
still greater in the PCOS group as compared to controls (p<0.0001). In correcting the 
BOLD signal for insulin sensitivity using HOMA-IR, BOLD signal in the right 
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orbitofrontal cortex in PCOS compared to the control group was no longer significant. 
This would suggest a potential role of insulin in regulating the BOLD signal in the 
orbitofrontal cortex.  
 
A study in 25 healthy lean and 23 overweight/obese participants performed magnetic 
resonance imaging to measure cerebral blood flow (CBF) before, 15 and 30 min after 
application of intranasal insulin or placebo. Additionally, participants explicitly rated 
pictures of high-caloric savory and sweet food 60 min after the spray for wanting and 
liking. They observed a differential response in the lean compared with the 
overweight/obese group in the prefrontal cortex, resulting in an insulin-induced CBF 
reduction in lean participants only. This prefrontal cortex response significantly 
correlated with peripheral insulin sensitivity and suggested that brain insulin action 
was selectively impaired in the prefrontal cortex in overweight and obese adults 
[Kullmann 2015]. More recently, a further fMRI study examined brain activation in 
response to a 75-g OGTT in 24 volunteers (12 lean; 12 obese) and specifically the 
effect of glucagon-like peptide-1 (GLP-1), a gut incretin peptide. They found that 
significant increase in GLP-1 levels negatively correlated with a change in the food 
cue-induced brain activity in the orbitofrontal cortex which was independent of 
simultaneous alterations in insulin and glucose concentrations. The association was 
present in lean and overweight participants. They concluded that GLP-1, released 
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after eating, may have an effect on the orbitofrontal cortex, and food intake [Henri 
2015].  
 
The orbitofrontal cortex, therefore, may be affected by insulin action, and may explain 
why in the PCOS group there was increased activation in response to IFC compared 
to controls.  
 
When I additionally subdivided the subjects into normal or overweight-obese groups, 
BOLD signal activation was greater in the brainstem in the normal BMI group as 
compared to overweight-obese (p=0.009). This difference between groups was not 
present when corrected for HOMA-IR, suggesting a role of insulin sensitivity in the 
brainstem BOLD signal changes in the normal BMI versus overweight-obese group. 
This could suggest that insulin signalling is intact in lean but not overweight individuals 
in the brainstem. 
 
It is difficult to accurately locate BOLD fMRI signal changes in the brainstem and this 
is an acknowledged problem [Beissner et al. 2011].One of the major limitations in the 
brainstem is the limited resolution which is similar to the size of nuclei of interest and 
accurate registration in this area is small. In addition, the inability of the study to define 
the location of the BOLD signal more accurately may reflect the diffuse location of 
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these structures in humans. Alternatively, the changes in BOLD signal may represent 
a high degree of background physiological “noise” [Wise et al. 2007]. However, the 
BOLD signal changes may relate to activation in the medulla. The medulla has been 
associated with an alteration in insulin sensitivity [Janetta 2010] and our findings may 
suggest a role in autonomic control in the brainstem. However, these findings need to 
be viewed carefully as the PCOS and healthy volunteer groups were ‘combined’ into 
normal versus overweight/obese groups. 
 
4.7.3  Motor activation 
 
Significant changes in BOLD fMRI signal activity were found in the left cerebral white 
matter in both the control and PCOS group (p<0.0005). There was no difference in 
areas of BOLD signal activation between groups when the motor IFC task was 
performed. The areas identified are potentially artefact in that they are not likely to be 
related to neural activation as they are deep in white matter and could even be related 
to task head motion. 
 
The motor task was used as a positive control in the experiment to show that the IFC 
task was associated with an expected BOLD response in the cerebral cortex. There 
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are no known neuroanatomical reasons why any difference in brain regions in motor 
tasks should be different between young women with PCOS and healthy controls. 
 
4.7.4  Visual activation 
 
The visual stimulus (flashing chequer board) was also used during the BOLD fMRI 
experiment as a positive control to show that there was expected BOLD activation in 
the visual cortex corresponding with the visual stimulus. It is a common positive control 
in BOLD fMRI experiments [Matthews 2004]. It was noted that in both groups there 
was increased BOLD signal in the occipital (visual) cortex, as would be expected. 
There are no obvious reasons why there would have been any significant differences 
between the two groups in terms of the area of the visual cortex showing BOLD 
activation during the task. No neuroanatomical differences in the visual pathways are 
known between PCOS and controls.  
 
4.7.5  Strengths and limitations 
 
My study has a number of strengths and limitations with respect to the central 
command BOLD fMRI aspects. A good number of PCOS and controls were recruited 
and scanned to note any changes in higher centres in response to IFC. In addition, 
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the experimental IFC protocol was run twice in the scan session, and the final results 
derived from an average of these 2 scans.  
 
However, several limitations are also present. As has been mentioned previously, the 
PCOS group were not significantly more androgenised or insulin resistant compared 
to the control group so interpretation of the results depends heavily on the original 
definition of the study population. Any subjects who were unable to undergo an MRI 
scan were excluded from the study, which may introduce bias. Furthermore, a 
significant limitation was that the blood pressure responses were recorded out-of-
scanner and not in a continuous manner, thus the actual model used in the Feat 
analysis may not be accurate. As has been mentioned, not all scans were corrected 
for physiological noise, due to an error in saving all the physiological data in the scan 
sessions. This, in turn, may have affected the results obtained, particularly the lack of 
BOLD signal change seen in the brainstem. A final area of weakness is that the MSNA 
was only recorded in a subgroup of participants. In a study that aimed to look at the 
role of higher centres in SNS activation in PCOS versus controls, it would have been 
ideal to have recorded MSNA in all subjects during the experimental IFC protocol. 
Ideally this should have been performed during the MRI scan sessions and then used 
as an input in the Feat analysis to correlate MSNA with BOLD signal changes, as used 
in other studies [Macefield 2013]. This presents practical challenges due to the need 
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for an MRI-compatible set-up.  In addition, there are haemodynamic effects that could 
confound interpretation.  With the blood pressure changes, if the autoregulation is 
different between the patients and controls a BOLD signal difference could result that 
would not be neuronal in origin.  However this is not very likely because the blood 
pressure change is fairly gradual so autoregulation should keep up and autoregulatory 
problems have not been reported in PCOS.  
 
4.8  CONCLUSION 
 
In my study, when modelling the blood pressure response to IFC, a greater response 
in BOLD activation in the right orbitofrontal cortex, left angular gyrus and lateral 
occipital cortex was noted in PCOS subjects compared with controls. The right 
orbitofrontal cortex activation persisted when corrected for testosterone but not when 
the data were adjusted for HOMA-IR. 
 
The IFC task in right-handed subjects is associated with BOLD activation in the left 
cerebral cortex. There was no difference between PCOS and control groups in any 
areas of the cerebral cortex activated. 
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The visual task evoked a BOLD response in the occipital cortex for both PCOS and 
control groups, with no difference in areas of the cerebral cortex activated between 
groups. 
 
Finally when subjects were subdivided in normal and overweight-obese BMI groups, 
greater BOLD activation was noted in the brainstem during IFC in the normal BMI 
compared to overweight-obese group, and this difference was no longer significant 
when corrected for HOMA-IR. 
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CHAPTER 5 
 
CONCLUSION AND 
FUTURE DIRECTIONS 
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5.1  RELEVANCE OF RESEARCH UNDERTAKEN 
 
Polycystic ovary syndrome (PCOS) is an established metabolic disorder associated 
with insulin resistance, dyslipidaemia and hypertension [Dunaif 1997, Talbott 1995, 
Kim 2013, Joham 2015]. Longitudinal studies have shown that there is a risk intrinsic 
to PCOS in developing Type 2 Diabetes Mellitus which increases with BMI [Moran 
2010, Morgan 2012, Pasquali 2013]. Furthermore, there is increasing evidence that 
insulin resistance, obesity, hypertension and PCOS per se are all associated with 
increased sympathetic tone [Masuo 2003, Alvarez 2002, Grassi and Mancia 2004, 
Sverrisdottir 2008].  
 
Higher centres have been identified from imaging studies looking at regions of central 
sympathetic activation and blood pressure control, including the dominant anterior 
cingulate, postcentral gyrus, cerebellum, insular cortex and orbitofrontal cortex 
[Critchley et al 2000, Kramer 2014]. Higher centres have therefore emerged as playing 
a key part in sympathetic drive and blood pressure control in humans. The higher 
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regional brain centres involved in such sympathoexcitation in PCOS are unknown. As 
fMRI has the potential to reveal some of these regions, the present study sought to 
identify higher centres involved in blood pressure control in PCOS and how these may 
be influenced by obesity, hyperandrogenism and insulin resistance. 
 
5.2  CONTRIBUTION OF MY FINDINGS TO THE FIELD OF PCOS 
 
5.2.1  PCOS and SNS activation 
 
PCOS is associated with increased SNS activation as demonstrated by augmented 
MSNA burst frequency to static exercise compared to controls. To my knowledge, 
mine is the first study to observe the effect of static exercise on MSNA response in 
PCOS. 
 
Previous studies have sought to examine the autonomic neural control of the 
cardiovascular system in response to exercise in PCOS. Tekin et al compared 26 
young women with PCOS and 24 matched healthy volunteers who were matched 
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according to age, BMI and physical activity. Their blood pressure, heart rate and heart 
rate recovery (HRR) responses to an exercise tolerance test were studied. It was 
noted that following exercise there was an augmented rise in systolic blood pressure 
during exercise in the PCOS group, which remained significantly elevated in recovery 
as compared to controls and there was also an attenuated HRR. This led them to 
conclude that after the onset of exercise in PCOS, there is an initial increase in heart 
rate that results from a decline in parasympathetic tone and an increase in sympathetic 
activity that results in an increase in systolic blood pressure and contributes to the 
increase in heart rate [Tekin 2008]. This study did not employ MSNA to measure SNS 
activity and indeed no such previous study in the field of PCOS has used MSNA to 
monitor the acute response to an exercise stimulus.  
 
5.2.2  Blood pressure changes in PCOS and BOLD signal activation  
 
Blood pressure changes associated with static exercise in PCOS correlate with 
significant BOLD signal activation in the ipsilateral orbitofrontal cortex as compared to 
controls. This could suggest that different neural pathways are involved in the blood 
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pressure response to static exercise in PCOS compared with healthy volunteers, or 
alternatively there may be circuit upregulation involving the orbitofrontal cortex in 
PCOS compared to controls. This is the first study to use BOLD fMRI to identify any 
areas of the higher brain structures or brainstem correlating with the IFC task in PCOS. 
Although other studies have examined the pressor response to IFC in PCOS [Saranya 
2014], no reported studies have sought to locate areas of central command involved 
in this reflex in PCOS. 
 
Previous fMRI studies have demonstrated activation of the oribitofrontal cortex in 
association with blood pressure rises [Gianaros 2005, Harper 1998]. In addition, 
Critchley and colleagues studied cerebral blood flow during 40% IFC in 6 young 
healthy men using positron emission tomography (PET). IFC was associated with a 
significant rise in blood pressure, and led to increased regional cerebral blood flow 
(rCBF) activity in the right anterior cingulate, left postcentral gyrus, bilateral cerebellum 
and cerebellar vermis, right posterior insula and adjacent transverse temporal gyrus, 
and right orbitofrontal cortex. Conversely, there was significant negative covariation 
between rCBF and HR evident in the right middle frontal gyrus, right anterior and 
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posterior cingulate, bilateral insula, bilateral orbitofrontal cortex, left cerebellum and 
left amygdala [Critchley 2000(a)].  
 
Furthermore it is of interest that the orbitofrontal cortex has been shown to have 
neuronal connections in monkey models to the insular cortex, which is one of the key 
areas in the higher pressor response to exercise [Cavada 2000]. There may therefore 
be significant connections between the orbitofrontal cortex, insular and ventrolateral 
medulla that are key in regulating the sympathetic and blood pressure response to 
exercise in PCOS. 
 
5.2.3  Insulin resistance and orbitofrontal cortex BOLD signal change  
 
Potential mediators of the BOLD signal change in the orbitofrontal cortex in PCOS 
may include insulin resistance and hyperandrogenism, the two key metabolic findings 
characteristic of this condition. Whilst I found no evidence of an association of 
hyperandrogenism with this activation, in correcting the BOLD signal for insulin 
sensitivity (by HOMA-IR), the BOLD signal difference in the right orbitofrontal cortex 
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between the PCOS group and controls became no longer significant. This would 
suggest a potential role of insulin sensitivity in regulating the BOLD signal in the 
orbitofrontal cortex, although causation cannot ascertained from these findings. 
 
A previous fMRI study performed resting-state scans in 17 healthy lean female 
subjects to assess intrinsic brain activity by fractional amplitude of low-frequency 
fluctuations before, 30 and 90 min after application of intranasal insulin. They showed 
that insulin decreases intrinsic brain activity in the hypothalamus and left orbitofrontal 
cortex, suggesting insulin may reduce food intake by modifying the reward and 
prefrontal circuitry of the human brain [Kullmann S 2013]. Although their study focused 
on the potential acute effect of insulin on food intake behaviour, the change in activity 
in the orbitofrontal cortex in response to insulin fits with our current findings. The 
orbitofrontal cortex, therefore, may be affected by insulin action, and may explain why 
in the PCOS group there was increased activation in response to IFC compared to 
controls. It may be that PCOS subjects retain insulin sensitivity in the neurons in the 
orbitofrontal cortex, in contrast to systemic insulin resistance in this condition, and the 
neurons there respond normally to insulin. The task-induced signal change here could 
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be greater in the PCOS group because they are hyperinsulinaemic (secondary to the 
systemic insulin resistance) compared to controls. It has been shown that insulin 
resistance in PCOS is selective, with reduced sensitivity in skeletal muscle and 
adipose tissue, but preserved insulin signalling in the ovary, resulting in 
hyperandorgenic anovulation [Ciaraldi TP 2009, Dunaif 1992, Wu 2014]. A hypothesis 
is that part of this selective insulin sensitivity in PCOS may include preserved insulin 
sensitivity in neuronal circuits in the brain, as suggested by my findings in relation to 
the orbitofrontal cortex. 
 
5.3  SUGGESTIONS FOR FUTURE RESEARCH 
 
5.3.1  Future research on SNS activation in PCOS 
 
The research can be developed in a number of ways. First, it would be interesting to 
compare a significantly hyperandrogenised, insulin-resistant group of women with 
PCOS with controls. As has been discussed, neither group differed significantly in this 
respect, so it would be useful to repeat the study in several PCOS phenotypes to see 
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if my findings are observed in all subjects with the condition or only in certain subtypes. 
Along with this, more accurately measuring visceral adiposity by MR or CT imaging, 
and performing a euglycaemic hyperinsulinaemic clamp study in the subjects would 
better characterise the cohort. 
 
Second, methods of measuring the pressor response to IFC could be modified. The 
blood pressure and heart rate responses were measured using measurements at 
intervals throughout the experiment, whereas continuous monitoring of cardiovascular 
parameters may be useful. In addition, measurement of the catecholamine response 
by the isotope dilution method would be a possibility, although difficult to undertake 
outside specialised lab environments. Future studies might also include 
microneurography in all subjects, ideally undertaken simultaneously with the fMRI 
scanning. Again, this presents practical challenges due to the invasive nature of this 
work, and the need for an MRI-compatible set-up. To examine underlying mechanisms 
of SNS activation in PCOS during the IFC task, a PEI period could also be built into 
the experiments. 
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5.3.2  Future research on higher centres in SNS activation in PCOS 
 
Finally, a key task should be to try and explore the mediators of higher centre SNS 
activation in PCOS. My data suggest that insulin resistance may be potentially 
mechanistically relevant in this regard. An interventional study aimed at clarifying the 
role of insulin in this response might incorporate (a) the use of a hyperinsulinaemic 
euglycaemic clamp in an MRI scanner to artificially induce high insulin levels, then 
undertaking the study IFC protocol pre- and post-insulin infusion to see if the signal 
changes in either group are altered in response to insulin, and (b) the use of a mixed 
meal challenge to physiologically elevate insulin levels (although this would also 
elevate glucose hence an adjustment would have to be made for this).  
 
Furthermore, using an intervention, such as weight loss, insulin-sensitisers 
(e.g.metformin) or centrally acting sympatholytics (e.g.moxonidine) to note changes in 
BOLD signal to IFC pre- and post-intervention could be an interesting component of 
future studies. Such interventions may be helpful in identifying mechanisms driving 
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central neural SNS pathways in PCOS, notably insulin resistance, and how their 
activation may be modified. 
 
Additionally, brain tissue and neurons from animal models with induced-PCOS could 
be studied in acute and chronic hyperinsulinaemic states, to see if any signalling 
pathways are altered in these states. This in turn may help to identify any underlying 
mechanisms which could explain the current findings. 
 
Finally, with respect to improving image quality in future studies, fMRI could be 
performed at 7T with enhanced signal and spatial resolution. This could help to better 
identify specific higher centres associated with blood pressure changes and SNS 
activation in PCOS, especially in the brainstem [Deistung 2013]. 
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SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN POLYCYSTIC OVARIAN 
SYNDROME 
 
PATIENT INFORMATION SHEET 
(Version 3, October 2012) 
 
Title of Study: Anthropometric and metabolic correlates of Sympathetic Nervous 
system activation in women with Polycystic Ovary Syndrome 
 
We would like to invite you to take part in our research study. Before you decide 
we would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through the information sheet with 
you and answer any questions you have. We‘d suggest this should take about 
15 minutes  
 
Talk to others about the study if you wish.  
 
Part 1 tells you the purpose of this study and what will happen to you if you take 
part.  
 
Part 2 gives you more detailed information about the conduct of the study. 
  
Ask us if there is anything that is not clear. Take time to consider whether or not 
you would wish to take part. 
 
Thank you for reading this. 
 
 
 
PART 1 
 
 
1. What is the purpose of this study? 
 
Polycystic ovary syndrome (PCOS) is the commonest hormone condition in 
women of reproductive age, affecting up to 10% of the premenopausal population. 
In addition to its well-recognised effects on weight gain, excessive hair growth and 
infertility, it is becoming increasingly clear that PCOS is associated with long-term 
health risks including diabetes and arterial (blood vessel) disease. The reasons for 
this are not entirely clear but we believe that a part of the nervous system that 
affects blood pressure and energy balance, called the sympathetic nervous 
system, may be involved.  
 
We aim to measure sympathetic nervous system activity in women with PCOS 
and relate this to body composition and changes in blood pressure. This may help 
in developing future treatments in PCOS. 
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This study will involve two visits to the Clinical Research Facility at the Heath 
hospital (each lasting 2-3 hours) and one visit to the Cardiff University Brain 
Research Imaging Centre (CUBRIC) (lasting about 1-2 hours).  
 
2. Why have I been invited? 
 
You have been invited to take part in this study as your doctor has identified you 
as having PCOS. A total of 25 patients and 25 healthy volunteers will be studied. 
  
3. Do I have to take part? 
 
It is up to you to decide to join the study. If you decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. You are still 
free to withdraw at any time and without giving a reason. A decision to withdraw 
at any time, or a decision not to take part, will not affect the standard of care you 
receive.   
 
4. What will happen to me if I take part? 
 
The study will take place at the Clinical Research Facility at the University Hospital 
of Wales and the Cardiff University Brain Research Imaging Centre (CUBRIC).  
       
      Visit 1 
On this visit you will be asked to attend in the morning having only had water to 
drink. We will require you to have a pregnancy test before carrying out any 
measurements. 
 
 
 
 
Body composition measurements 
We will measure your weight, height, blood pressure, waist circumference, hip 
circumference and take a brief clinical history. We will measure the amount of fat 
in your body by two techniques: DEXA and CT scanning. The DEXA scan is a 
simple, rapid and non-invasive technique which is used routinely in clinical 
practice. This scan does involve a very small dose of radiation, equivalent to what 
you would be exposed to simply by living in Cardiff for 1 day. A CT scan will then 
be performed. Unlike CT scans used in medical practice this will be a single image 
(or ‘slice’) only, taken at the level of your lower spine. This will give us enough 
information to measure the amount of fat present, while minimising your exposure 
to radiation. The amount of radiation you will receive is very small and similar to 
what you would be exposed to simply by living in Cardiff for 1 week.  
 
Blood tests 
We will place a plastic needle (cannula) in a vein in your elbow and take blood 
samples (approximately four teaspoons) to check levels of your hormones 
(testosterone, thyroid function and prolactin), ‘fat’ proteins (called adiponectin, 
leptin and resistin), and to measure cholesterol, insulin, glucose and CRP (a 
marker of inflammation in the body). We will then ask you to take a drink containing 
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a measured amount of glucose (an oral glucose tolerance test [OGTT]) which 
assesses how good your body is at handling sugar (termed ‘insulin sensitivity’). 
Further blood samples (at 30, 60 and 90 minutes) will be taken during the test and 
a final test is taken at two hours, equating to about a further four teaspoons.  
 
Sleep tests 
Before leaving the facility, you will be asked to complete a questionnaire about 
your sleep, provided with simple equipment to measure your sleeping pattern at 
home once overnight and shown how to set this up. Breathing (airflow through the 
nose and mouth) is measured by a thermister (measures airflow by the 
temperature change as you breathe in and out) and bands around your chest and 
abdomen will measure your breathing effort.  An oximeter probe measures oxygen 
levels in your blood. You may find them a bit strange at first, but most people do 
not find them uncomfortable or an obstacle to falling asleep.  We will make every 
effort to make sure that you are as comfortable as possible. You will be offered a 
demonstration of how to use the equipment to ensure you are happy using it and 
able to record the information required. 
 
The picture below shows the type of device that you will use for this part of the 
study. 
 
 
 
      Visit 2 
Nerve and blood pressure tests 
On this visit you will be asked to attend in the morning having only had water to 
drink. We will place a plastic needle (cannula) in a vein in your elbow. We will place 
some leads on your chest initially to record an electrocardiogram (ECG) (‘a heart 
tracing’) as shown in the diagram below. 
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We will ask you to rest on a bed and will place a small needle just under the skin 
on your leg in order to measure nerve activity. A thin wire will be placed at the 
nerve. The wires are like acupuncture needles, but the tip is very fine (it is the width 
of a human hair). Once a good nerve recording is found, the electrodes will stay in 
your leg for approximately 30-60 minutes. You will be asked to keep your leg as 
still as possible for this duration. You will be asked to squeeze a ball at different 
intensities while we measure your nerve activity, for 5-minute periods at different 
grip intensities. A blood sample (about one teaspoon) will be drawn from the 
cannula in your arm both before and after squeezing the ball. Just before you finish 
squeezing the ball on one occasion, a blood pressure cuff will be inflated around 
your upper arm to stop the blood flow to your hand for 2 minutes whilst nerve 
recordings are made, before being deflated. Your blood pressure and heart rate 
will be measured at regular intervals throughout. You will also be asked to place 
your hand in cold water for 2 minutes while nerve recordings are measured. 
 
Finally, while you are resting quietly, a medical doctor will infuse study drugs 
(called nitroprusside and phenylephrine) through the catheter in your arm to lower 
and raise your blood pressure (by approximately 10 mmHg in either direction). 
These small changes in blood pressure are brief (approximately 60 seconds) and 
reverse quickly; they are no larger than the changes seen during daily life (e.g. 
standing up, exercising, or urinating). 
 
Visit 3 
      Brain scan 
On a third day, we will ask you to attend the Cardiff University Brain Research 
Imaging Centre (CUBRIC) for a functional Magnetic Resonance Imaging (fMRI) 
scan. MRI is a method for producing images of the brain. It does not involve any 
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radiation. MRI can be used to determine which parts of the brain are active during 
different tasks – this is known as functional MRI or fMRI.  
 
Because the scanner magnet is very powerful, you will be asked to remove metal 
from your pockets (coins, keys) and also be asked to remove articles of clothing 
(in a dedicated changing room) that have metal fasteners (belts, bras, etc), as well 
as most jewellery. Please bring suitable clothing with you for the scan. Sweatshirts 
and jogging trousers are ideal.  
 
To be scanned, you will lie on your back on a bed on runners, on which you will 
be moved until your head or the specific region of your body to be scanned is 
inside the magnet (which is like a long tube). The scanning process itself creates 
intermittent loud noises, and you must wear ear-plugs or sound-reducing 
headphones. We are able to talk to you while you are in the scanner through an 
intercom. It is important that you keep your head as still as possible during the 
scan, and to help you with this, your head will be partially restrained with padded 
headrests. We shall ask you to relax your head and keep it still. You will be asked 
to squeeze a ball again (like previously) at different intensities while we measure 
your brain activity, for 5-minute periods at different grip intensities. Detailed 
instructions will be given just before the scan, and will appear on a screen during 
the scan. 
 
The picture below shows a person having an MRI scan. 
 
 
 
The whole procedure will typically take about 1 hour, plus another 15 minutes to 
discuss with you the purposes of the study and answer any questions about it 
which you may raise. This is not a diagnostic scan and therefore your scan will not 
be examined for abnormalities. 
 
Very occasionally, however, when we look at MRI data from subjects, unexpected 
potential abnormalities are discovered. Once we have looked at the data in some 
detail, we may ask a Consultant to examine the data, and if appropriate a report 
can be forwarded to your GP. You should not regard this Research scan as a 
Medical screening procedure. 
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If you wish we will be able to reimburse any travelling expenses / car parking fees 
incurred while attending for the study visits. We will also give you a single payment 
of £50 to reimburse you for your inconvenience. 
 
5. What do I have to do? 
 
It is important that you take your regular medication in the normal way without 
altering the dose or timing of these, except for prior to the nerve and brain test 
visits when we would also ask that no ‘over the counter’ medications (e.g. 
paracetamol) are taken on the morning of these visits. We also request that you 
have no alcohol on the day before these visits and the day of the visit and no 
exercise after 7:00pm the evening before these visits and no exercise on the day 
of the visit. We ask also that you consume no caffeine (e.g. coffee, coke, red bull) 
from the evening before these visits. If you are a smoker we request that you avoid 
smoking on each morning. We request that you report any illnesses to us as they 
may influence the timing of your test visit. You should inform us of any dose 
adjustments in any regular medications made during the study. If you are taking 
any heart or blood pressure medications you should not take part in the study. If 
unsure please check with the researchers. 
 
You should inform us if there is any possibility of you being pregnant and this will 
be tested for in all participants. If you are pregnant you will not be able to participate 
in this study.  
 
6.  What are the possible disadvantages and risks of taking part? 
 
Studies are carried out by trained researchers who are experienced with all the 
procedures described, thus reducing possible disadvantages and risks. Potential 
disadvantages and risks related to the experimental measurements and 
procedures we are studying include:  
Placement of a thin tube in a vein for blood samples: Collection of blood may cause 
possible discomfort (temporary pain, swelling, bruising and rarely infection). 
 
Placement of the nerve electrode: The nerve recording procedure occasionally 
may result in the leg muscles feeling tired. Also, you may have a pins-and-needles 
feeling or a greater sensitivity to touch in the leg. However, these side effects are 
rare, affecting approximately 1 in 10 participants, and if they occurred, would only 
be temporary lasting for a day or two at the most.  
 
Drugs used to change blood pressure: The drugs used on the second visit to 
change blood pressure are nitroprusside and phenylephrine. These are commonly 
used and safe drugs. Very occasionally nitroprusside can cause you to experience 
low blood pressure, excessive increase in heart rate, flushing, dizziness, and 
headache. Similarly phenylephrine can very occasionally cause high blood 
pressure, excessive increase or decrease in heart rate, dizziness, headache, and 
rarely abnormal heart beats. The small changes in blood pressure that occurs with 
these drugs are brief (approximately 60 seconds) and reverse quickly; they are no 
longer than the changes seen during daily life (e.g. standing up, exercising). A 
medical doctor will be present to supervise as these drugs are administered. 
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CT scan: A ‘single slice’ CT scan and DEXA scan do involve exposure to a small 
amount of radiation. In addition the CT scan could by chance pick up an 
unsuspected abnormality in your abdomen, in which case you will be given an 
opportunity to discuss these findings further with Dr Aled Rees.  
 
MRI scan: The fMRI scan involves lying in a relatively confined space so if you are 
likely to become very uneasy in this situation (suffer from claustrophobia), you 
should NOT take part in the study. If you do take part and this happens, you will 
be able to alert the staff by activating an alarm and will then be removed from the 
scanner quickly. Likewise the scanning process itself creates intermittent loud 
noises but you will be provided with ear-plugs or sound-reducing headphones to 
wear. 
 
Sleep studies: Sometimes there may be a sensation of warmth where the oximeter 
probe is attached to your finger.  However, this does not generally cause any 
significant or lasting discomfort.   
 
The MRI, blood and sleep studies may also pick up unsuspected abnormalities in 
which case you will be given an opportunity to discuss these findings with Dr Rees. 
 
 
7. What are the potential benefits of taking part? 
 
There are unlikely to be any direct benefits for you but the study may provide us 
with important information in determining whether sympathetic nervous system 
activity could be important in women with PCOS. It may therefore be possible in 
future to design new treatments for blood pressure and similar complications of 
PCOS. 
 
8. What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this 
is given in Part 2. 
 
9. Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
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PART 2 
 
 
1. What happens if new information becomes available? 
 
If this happens, your research doctor might consider you should withdraw from the 
study. He will explain the reasons and arrange for your care to continue. 
 
2. What will happen if I don’t want to carry on with the study? 
 
If you withdraw from the study, we will destroy all your identifiable samples, but we 
will need to use the data collected up until your withdrawal. A decision to withdraw 
at any time will not affect the standard of care you receive. 
 
3. What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions (Dr Aled Rees 
02920 7445002 reesda@cf.ac.uk or Dr Andrew Lansdown 
lansdownaj1@cf.ac.uk). This study is being indemnified by Cardiff University. If 
you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any concerns about any aspect 
of the way you have been approached or treated during the course of this study, 
the normal National Health Service complaints mechanisms will be available to 
you.  
 
4. Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the hospital 
will have your name and address removed so that you cannot be recognised from 
it. With your permission your GP will be informed of your participation in this study. 
With your permission we may also look at sections of your medical notes which 
are relevant to the research study.  
 
5. What will happen to any samples I give? 
The blood samples will be collected and stored securely for later analysis in the 
Centre for Endocrine and Diabetes Sciences at the University Hospital of Wales. 
Only immediate members of the research team will have access to these samples. 
All identifiable information will be removed from the samples which will be 
destroyed by incineration once the tests are complete.      
 
6. What will happen to the results of the research study? 
 
The results of the research study will be prepared for publication in appropriate 
medical journals together with presentation at medical conferences. Patients 
participating in the study will be able to obtain a copy of the results after they have 
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been published in the relevant journal(s). Patients will not be identified in any 
report/publication.  
 
7.  Will I be able to have the results of my tests? 
 
We will contact you if there are any unsuspected abnormalities in your test results 
and you will be given an opportunity to discuss these findings with Dr Aled Rees.  
If you wish to have all your test results (including normal results), we will be able 
to provide these for you on your request. 
 
8. Who is organising and funding the research? 
 
The study is being organised by Dr Aled Rees (the Principal Investigator) and Dr 
Andrew Lansdown (Research Registrar) from the Centre for Endocrine and 
Diabetes Sciences at the University Hospital of Wales. Funding for the study is 
provided from funds within the Centre for Endocrine and Diabetes Sciences at the 
University Hospital of Wales. The doctors conducting the research are not being 
paid for including and looking after patients in the study. 
 
9. Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. The study has been 
reviewed by the Cardiff and Vale NHS Trust Research and Development Office 
and by the South Wales Research Ethics Committee. 
 
10. Contact for further information 
 
Should you have any further queries regarding this research study, then please do 
not hesitate to contact me on 02920 7445002 or 07746 780566. You can also 
contact me via e-mail on reesda@cf.ac.uk or Dr Andrew Lansdown by email 
lansdownaj1@cf.ac.uk 
 
 
Thank you for considering taking part in this study. 
 
 
 
 
 
Dr Aled Rees 
Senior Lecturer in Endocrinology 
 
 
You will be given a copy of this Patient Information Sheet and a signed consent 
form to keep. 
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SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN POLYCYSTIC OVARY 
SYNDROME  
Patient Identification Number for this study: 
 
PATIENT CONSENT FORM 
(Version 3 October 2012) 
 
Title of Study: Anthropometric and metabolic correlates of Sympathetic Nervous system 
activation in women with Polycystic Ovary Syndrome 
  
Name of Researchers:  Dr Aled Rees, Dr Andrew Lansdown                      
     Please initial box 
 
1. I confirm that I have read and understood the information sheet dated 
October 2012 (version 3) for the above study and have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that sections of my medical notes may be looked at by the 
sponsor and responsible individuals from regulatory authorities where it 
is relevant to my taking part in research. I give permission for these 
individuals to have access to my records. 
 
4. I consent to my GP being informed of my participation in the Study. 
 
 
5. I consent to a pregnancy test.                               
 
 
6. I agree to take part in the above study. 
 
Name of patient    Date    Signature 
 
Researcher     Date    Signature 
 
Name of person taking consent  Date    Signature 
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APPENDIX 3  
 
Volunteer Information Sheet and 
Consent Form 
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SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN POLYCYSTIC OVARIAN 
SYNDROME 
 
HEALTHY VOLUNTEER INFORMATION SHEET 
(Version 3, October 2012) 
 
Title of Study: Anthropometric and metabolic correlates of Sympathetic Nervous 
system activation in women with Polycystic Ovary Syndrome 
 
We would like to invite you to take part in our research study. Before you decide 
we would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through the information sheet with 
you and answer any questions you have. We‘d suggest this should take about 
15 minutes  
 
Talk to others about the study if you wish.  
 
Part 1 tells you the purpose of this study and what will happen to you if you take 
part.  
 
Part 2 gives you more detailed information about the conduct of the study. 
  
Ask us if there is anything that is not clear. Take time to consider whether or not 
you would wish to take part. 
 
Thank you for reading this. 
 
 
 
PART 1 
 
 
2. What is the purpose of this study? 
 
Polycystic ovary syndrome (PCOS) is the commonest hormone condition in 
women of reproductive age, affecting up to 10% of the premenopausal population. 
In addition to its well-recognised effects on weight gain, excessive hair growth and 
infertility, it is becoming increasingly clear that PCOS is associated with long-term 
health risks including diabetes and arterial (blood vessel) disease. The reasons for 
this are not entirely clear but we believe that a part of the nervous system that 
affects blood pressure and energy balance, called the sympathetic nervous 
system, may be involved.  
 
We aim to measure sympathetic nervous system activity in women with PCOS 
and relate this to body composition and changes in blood pressure. This may help 
in developing future treatments in PCOS. 
 
This study will involve two visits to the Clinical Research Facility at the Heath 
hospital (each lasting 2-3 hours) and one visit to the Cardiff University Brain 
Research Imaging Centre (CUBRIC) (lasting about 1-2 hours).  
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2. Why have I been invited? 
 
You have been invited to take part in this study as you are healthy and similar in 
terms of age to the patients with PCOS. A total of 25 patients and 25 healthy 
volunteers will be studied. 
  
3. Do I have to take part? 
 
It is up to you to decide to join the study. If you decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. You are still 
free to withdraw at any time and without giving a reason.  
 
4. What will happen to me if I take part? 
 
The study will take place at the Clinical Research Facility at the University Hospital 
of Wales and the Cardiff University Brain Research Imaging Centre (CUBRIC).  
       
      Visit 1 
On this visit you will be asked to attend in the morning having only had water to 
drink. We will require you to have a pregnancy test before carrying out any 
measurements. 
 
 
Body composition measurements 
We will measure your weight, height, blood pressure, waist circumference, hip 
circumference and take a brief clinical history. We will measure the amount of fat 
in your body by two techniques: DEXA and CT scanning. The DEXA scan is a 
simple, rapid and non-invasive technique which is used routinely in clinical 
practice. This scan does involve a very small dose of radiation, equivalent to what 
you would be exposed to simply by living in Cardiff for 1 day. A CT scan will then 
be performed. Unlike CT scans used in medical practice this will be a single image 
(or ‘slice’) only, taken at the level of your lower spine. This will give us enough 
information to measure the amount of fat present, while minimising your exposure 
to radiation. The amount of radiation you will receive is very small and similar to 
what you would be exposed to simply by living in Cardiff for 1 week.  
 
Blood tests 
We will place a plastic needle (cannula) in a vein in your elbow and take blood 
samples (approximately four teaspoons) to check levels of your hormones 
(testosterone, thyroid function and prolactin), ‘fat’ proteins (called adiponectin, 
leptin and resistin), and to measure cholesterol, insulin, glucose and CRP (a 
marker of inflammation in the body). We will then ask you to take a drink containing 
a measured amount of glucose (an oral glucose tolerance test [OGTT]) which 
assesses how good your body is at handling sugar (termed ‘insulin sensitivity’). 
Further blood samples (at 30, 60 and 90 minutes) will be taken during the test and 
a final test is taken at two hours, equating to about a further four teaspoons. 
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Sleep tests 
Before leaving the facility, you will be asked to complete a questionnaire about 
your sleep, provided with simple equipment to measure your sleeping pattern at 
home once overnight and shown how to set this up. Breathing (airflow through the 
nose and mouth) is measured by a thermister (measures airflow by the 
temperature change as you breathe in and out) and bands around your chest and 
abdomen will measure your breathing effort.  An oximeter probe measures oxygen 
levels in your blood. You may find them a bit strange at first, but most people do 
not find them uncomfortable or an obstacle to falling asleep.  We will make every 
effort to make sure that you are as comfortable as possible. You will be offered a 
demonstration of how to use the equipment to ensure you are happy using it and 
able to record the information required. 
 
The picture below shows the type of device that you will use for this part of the 
study. 
 
 
 
      Visit 2 
Nerve and blood pressure tests 
On this visit you will be asked to attend in the morning having only had water to 
drink. We will place a plastic needle (cannula) in a vein in your elbow. We will place 
some leads on your chest initially to record an electrocardiogram (ECG) (‘a heart 
tracing’) as shown in the diagram below.  
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We will ask you to rest on a bed and will place a small needle just under the skin 
on your leg in order to measure nerve activity. A thin wire will be placed at the 
nerve. The wires are like acupuncture needles, but the tip is very fine (it is the width 
of a human hair). Once a good nerve recording is found, the electrodes will stay in 
your leg for approximately 30-60 minutes. You will be asked to keep your leg as 
still as possible for this duration. You will be asked to squeeze a ball at different 
intensities while we measure your nerve activity, for 5-minute periods at different 
grip intensities. A blood sample (about one teaspoon) will be drawn from the 
cannula in your arm both before and after squeezing the ball. Just before you finish 
squeezing the ball on one occasion, a blood pressure cuff will be inflated around 
your upper arm to stop the blood flow to your hand for 2 minutes whilst nerve 
recordings are made, before being deflated. Your blood pressure and heart rate 
will be measured at regular intervals throughout. You will also be asked to place 
your hand in cold water for 2 minutes while nerve recordings are measured. 
 
Finally, while you are resting quietly, a medical doctor will infuse study drugs 
(called nitroprusside and phenylephrine) through the catheter in your arm to lower 
and raise your blood pressure (by approximately 10 mmHg in either direction). 
These small changes in blood pressure are brief (approximately 60 seconds) and 
reverse quickly; they are no larger than the changes seen during daily life (e.g. 
standing up, exercising, or urinating). 
 
Visit 3 
      Brain scan 
On a third day, we will ask you to attend the Cardiff University Brain Research 
Imaging Centre (CUBRIC) for a functional Magnetic Resonance Imaging (fMRI) 
scan. MRI is a method for producing images of the brain. It does not involve any 
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radiation. MRI can be used to determine which parts of the brain are active during 
different tasks – this is known as functional MRI or fMRI.  
 
Because the scanner magnet is very powerful, you will be asked to remove metal 
from your pockets (coins, keys) and also be asked to remove articles of clothing 
(in a dedicated changing room) that have metal fasteners (belts, bras, etc), as well 
as most jewellery. Please bring suitable clothing with you for the scan. Sweatshirts 
and jogging trousers are ideal.  
 
To be scanned, you will lie on your back on a bed on runners, on which you will 
be moved until your head or the specific region of your body to be scanned is 
inside the magnet (which is like a long tube). The scanning process itself creates 
intermittent loud noises, and you must wear ear-plugs or sound-reducing 
headphones. We are able to talk to you while you are in the scanner through an 
intercom. It is important that you keep your head as still as possible during the 
scan, and to help you with this, your head will be partially restrained with padded 
headrests. We shall ask you to relax your head and keep it still. You will be asked 
to squeeze a ball again (like previously) at different intensities while we measure 
your brain activity, for 5-minute periods at different grip intensities. Detailed 
instructions will be given just before the scan, and will appear on a screen during 
the scan. 
 
The picture below shows a person having an MRI scan. 
 
 
The whole procedure will typically take about 1 hour, plus another 15 minutes to 
discuss with you the purposes of the study and answer any questions about it 
which you may raise. This is not a diagnostic scan and therefore your scan will not 
be examined for abnormalities. 
 
Very occasionally, however, when we look at MRI data from healthy subjects, 
unexpected potential abnormalities are discovered. Once we have looked at the 
data in some detail, we may ask a Consultant to examine the data, and if 
appropriate a report can be forwarded to your GP. You should not regard this 
Research scan as a Medical screening procedure. 
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If you wish we will be able to reimburse any travelling expenses / car parking fees 
incurred while attending for the study visits. We will also give you a single payment 
of £50 to reimburse you for your inconvenience. 
 
5. What do I have to do? 
 
It is important that you take your regular medication in the normal way without 
altering the dose or timing of these, except for prior to the nerve and brain test 
visits when we would also ask that no ‘over the counter’ medications (e.g. 
paracetamol) are taken on the morning of these visits. We also request that you 
have no alcohol on the day before these visits and the day of the visit and no 
exercise after 7:00pm the evening before these visits and no exercise on the day 
of the visit. We would ask also that you consume no caffeine (e.g. coffee, coke, 
red bull) from the evening before these visits. If you are a smoker we request that 
you avoid smoking on each morning. We request that you report any illnesses to 
us as they may influence the timing of your test visit. You should inform us of any 
dose adjustments in any regular medications made during the study. If you are 
taking any heart or blood pressure medications you should not take part in the 
study. If unsure please check with the researchers. 
 
You should inform us if there is any possibility of you being pregnant and this will 
be tested for in all participants. If you are pregnant you will not be able to participate 
in this study.  
 
6.  What are the possible disadvantages and risks of taking part? 
 
Studies are carried out by trained researchers who are experienced with all the 
procedures described, thus reducing possible disadvantages and risks. Potential 
disadvantages and risks related to the experimental measurements and 
procedures we are studying include:  
Placement of a thin tube in a vein for blood samples: Collection of blood may cause 
possible discomfort (temporary pain, swelling, bruising and rarely infection). 
 
Placement of the nerve electrode: The nerve recording procedure occasionally 
may result in the leg muscles feeling tired. Also, you may have a pins-and-needles 
feeling or a greater sensitivity to touch in the leg. However, these side effects are 
rare, affecting approximately 1 in 10 participants, and if they occurred, would only 
be temporary lasting for a day or two at the most. 
 
Drugs used to change blood pressure: The drugs used on the second visit to 
change blood pressure are nitroprusside and phenylephrine. These are commonly 
used and safe drugs. Very occasionally nitroprusside can cause you to experience 
low blood pressure, excessive increase in heart rate, flushing, dizziness, and 
headache. Similarly phenylephrine can very occasionally cause high blood 
pressure, excessive increase or decrease in heart rate, dizziness, headache, and 
rarely abnormal heart beats. The small changes in blood pressure that occurs with 
these drugs are brief (approximately 60 seconds) and reverse quickly; they are no 
longer than the changes seen during daily life (e.g. standing up, exercising). A 
medical doctor will be present to supervise as these drugs are administered.  
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CT scan: A ‘single slice’ CT scan and DEXA scan do involve exposure to a small 
amount of radiation. In addition the CT scan could by chance pick up an 
unsuspected abnormality in your abdomen, in which case you will be given an 
opportunity to discuss these findings further with Dr Aled Rees.  
 
MRI scan: The fMRI scan involves lying in a relatively confined space so if you are 
likely to become very uneasy in this situation (suffer from claustrophobia), you 
should NOT take part in the study. If you do take part and this happens, you will 
be able to alert the staff by activating an alarm and will then be removed from the 
scanner quickly. Likewise the scanning process itself creates intermittent loud 
noises but you will be provided with ear-plugs or sound-reducing headphones to 
wear. 
 
Sleep studies: Sometimes there may be a sensation of warmth where the oximeter 
probe is attached to your finger.  However, this does not generally cause any 
significant or lasting discomfort.   
 
The MRI, blood and sleep studies may also pick up unsuspected abnormalities in 
which case you will be given an opportunity to discuss these findings with Dr Rees. 
 
 
7. What are the potential benefits of taking part? 
 
There are unlikely to be any direct benefits for you but the study may provide us 
with important information in determining whether sympathetic nervous system 
activity could be important in women with PCOS. It may therefore be possible in 
future to design new treatments for blood pressure and similar complications of 
PCOS. 
 
8. What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this 
is given in Part 2. 
 
9. Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
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PART 2 
 
 
4. What happens if new information becomes available? 
 
If this happens, your research doctor might consider you should withdraw from the 
study. He will explain the reasons and arrange for your care to continue. 
 
5. What will happen if I don’t want to carry on with the study? 
 
If you withdraw from the study, we will destroy all your identifiable samples, but we 
will need to use the data collected up until your withdrawal. A decision to withdraw 
at any time will not affect the standard of care you receive. 
 
6. What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions (Dr Aled Rees 
02920 7445002 reesda@cf.ac.uk or Dr Andrew Lansdown 
lansdownaj1@cf.ac.uk). This study is being indemnified by Cardiff University. If 
you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any concerns about any aspect 
of the way you have been approached or treated during the course of this study, 
the normal National Health Service complaints mechanisms will be available to 
you.  
 
4. Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the hospital 
will have your name and address removed so that you cannot be recognised from 
it. With your permission your GP will be informed of your participation in this study. 
With your permission we may also look at sections of your medical notes which 
are relevant to the research study.  
 
6. What will happen to any samples I give? 
The blood samples will be collected and stored securely for later analysis in the 
Centre for Endocrine and Diabetes Sciences at the University Hospital of Wales. 
Only immediate members of the research team will have access to these samples. 
All identifiable information will be removed from the samples which will be 
destroyed by incineration once the tests are complete.      
 
6. What will happen to the results of the research study? 
 
The results of the research study will be prepared for publication in appropriate 
medical journals together with presentation at medical conferences. Patients 
participating in the study will be able to obtain a copy of the results after they have 
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been published in the relevant journal(s). Patients will not be identified in any 
report/publication.  
 
7.  Will I be able to have the results of my tests? 
 
We will contact you if there are any unsuspected abnormalities in your test results 
and you will be given an opportunity to discuss these findings with Dr Aled Rees.  
If you wish to have all your test results (including normal results), we will be able 
to provide these for you on your request. 
 
8. Who is organising and funding the research? 
 
The study is being organised by Dr Aled Rees (the Principal Investigator) and Dr 
Andrew Lansdown (Research Registrar) from the Centre for Endocrine and 
Diabetes Sciences at the University Hospital of Wales. Funding for the study is 
provided from funds within the Centre for Endocrine and Diabetes Sciences at the 
University Hospital of Wales. The doctors conducting the research are not being 
paid for including and looking after patients in the study. 
 
9. Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. The study has been 
reviewed by the Cardiff and Vale NHS Trust Research and Development Office 
and by the South Wales Research Ethics Committee. 
 
10. Contact for further information 
 
Should you have any further queries regarding this research study, then please do 
not hesitate to contact me on 02920 7445002 or 07746 780566. You can also 
contact me via e-mail on reesda@cf.ac.uk or Dr Andrew Lansdown by email 
lansdownaj1@cf.ac.uk 
 
 
Thank you for considering taking part in this study. 
 
 
 
 
 
Dr Aled Rees 
Senior Lecturer in Endocrinology 
 
 
You will be given a copy of this Patient Information Sheet and a signed consent 
form to keep. 
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SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN POLYCYSTIC OVARY 
SYNDROME  
 
Patient Identification Number for this study: 
 
HEALTHY VOLUNTEER CONSENT FORM 
(Version 3 October 2012) 
 
Title of Study: Anthropometric and metabolic correlates of Sympathetic Nervous 
system activation in women with Polycystic Ovary Syndrome 
  
Name of Researchers:  Dr Aled Rees, Dr Andrew Lansdown                    
           
 Please initial box 
 
1. I confirm that I have read and understood the information sheet dated 
October 2012 (version 3) for the above study and have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that sections of any medical notes I may have may be 
looked at by the sponsor and responsible individuals from regulatory 
authorities where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. 
 
4.   I consent to my GP being informed of my participation in the Study. 
 
 
5.   I consent to a pregnancy test.                               
 
 
6.   I agree to take part in the above study. 
 
 
 
Name of patient    Date    Signature 
 
 
Researcher     Date    Signature 
 
 
Name of person taking consent  Date    Signature 
 
